<?xml version="1.0" ?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.3 20210610//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">elife</journal-id>
<journal-id journal-id-type="publisher-id">eLife</journal-id>
<journal-title-group>
<journal-title>eLife</journal-title>
</journal-title-group>
<issn publication-format="electronic" pub-type="epub">2050-084X</issn>
<publisher>
<publisher-name>eLife Sciences Publications, Ltd</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">87340</article-id>
<article-id pub-id-type="doi">10.7554/eLife.87340</article-id>
<article-id pub-id-type="doi" specific-use="version">10.7554/eLife.87340.2</article-id>
<article-version-alternatives>
<article-version article-version-type="publication-state">reviewed preprint</article-version>
<article-version article-version-type="preprint-version">1.2</article-version>
</article-version-alternatives>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Biochemistry and Chemical Biology</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Cell Biology</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Mitochondrial electron transport chain, ceramide and Coenzyme Q are linked in a pathway that drives insulin resistance in skeletal muscle</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Diaz-Vegas</surname>
<given-names>Alexis</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Madsen</surname>
<given-names>Soren</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cooke</surname>
<given-names>Kristen C.</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8600-4023</contrib-id>
<name>
<surname>Carroll</surname>
<given-names>Luke</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Khor</surname>
<given-names>Jasmine X. Y.</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Turner</surname>
<given-names>Nigel</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lim</surname>
<given-names>Xin Ying</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9896-8831</contrib-id>
<name>
<surname>Astore</surname>
<given-names>Miro A.</given-names>
</name>
<xref ref-type="aff" rid="a7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Morris</surname>
<given-names>Jonathan</given-names>
</name>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1655-1184</contrib-id>
<name>
<surname>Don</surname>
<given-names>Anthony</given-names>
</name>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Garfield</surname>
<given-names>Amanda</given-names>
</name>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zarini</surname>
<given-names>Simona</given-names>
</name>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7089-691X</contrib-id>
<name>
<surname>Zemski Berry</surname>
<given-names>Karin A.</given-names>
</name>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ryan</surname>
<given-names>Andrew</given-names>
</name>
<xref ref-type="aff" rid="a6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bergman</surname>
<given-names>Bryan C.</given-names>
</name>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7946-3432</contrib-id>
<name>
<surname>Brozinick</surname>
<given-names>Joseph T.</given-names>
</name>
<xref ref-type="aff" rid="a6">6</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5946-5257</contrib-id>
<name>
<surname>James</surname>
<given-names>David E.</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="corresp" rid="cor1">#</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6609-6151</contrib-id>
<name>
<surname>Burchfield</surname>
<given-names>James G.</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="corresp" rid="cor1">#</xref>
</contrib>
<aff id="a1"><label>1</label><institution>Charles Perkins Centre, School of life and Environmental Sciences, University of Sydney</institution>, Sydney, <country>Australia</country></aff>
<aff id="a2"><label>2</label><institution>Charles Perkins Centre and School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney</institution>, Camperdown, NSW, 2050, <country>Australia</country></aff>
<aff id="a3"><label>3</label><institution>Cellular Bioenergetics Laboratory, Victor Chang Cardiac Research Institute</institution>, Darlinghurst, NSW, <country>Australia</country></aff>
<aff id="a4"><label>4</label><institution>School of Chemistry</institution>, UNSW Sydney, Sydney, 2052, NSW, <country>Australia</country></aff>
<aff id="a5"><label>5</label><institution>Division of Endocrinology, Metabolism, and Diabetes, University of Colorado Anschutz Medical Campus</institution>, Aurora, CO 80045, <country>USA</country></aff>
<aff id="a6"><label>6</label><institution>Lilly Research Laboratories, Division of Eli Lilly and Company</institution>, Indianapolis, IN, <country>USA</country></aff>
<aff id="a7"><label>7</label><institution>Center for Computational Biology and Center for Computational Mathematics, Flatiron Institute</institution>, New York, NY 10010, <country>USA</country></aff>
</contrib-group>
<contrib-group content-type="section">
<contrib contrib-type="editor">
<name>
<surname>Czech</surname>
<given-names>Michael</given-names>
</name>
<role>Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>University of Massachusetts Medical School</institution>
</institution-wrap>
<city>Worcester</city>
<country>United States of America</country>
</aff>
</contrib>
<contrib contrib-type="senior_editor">
<name>
<surname>Kornmann</surname>
<given-names>Benoit</given-names>
</name>
<role>Senior Editor</role>
<aff>
<institution-wrap>
<institution>University of Oxford</institution>
</institution-wrap>
<city>Oxford</city>
<country>United Kingdom</country>
</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>#</label>Corresponding Author: Tel: +61 2 8627 1621; E-mail: <email>david.james@sydney.edu.au</email> (DEJ), <email>james.burchfield@sydney.edu.au</email></corresp>
</author-notes>
<pub-date date-type="original-publication" iso-8601-date="2023-05-04">
<day>04</day>
<month>05</month>
<year>2023</year>
</pub-date>
<pub-date date-type="update" iso-8601-date="2023-11-20">
<day>20</day>
<month>11</month>
<year>2023</year>
</pub-date>
<volume>12</volume>
<elocation-id>RP87340</elocation-id>
<history>
<date date-type="sent-for-review" iso-8601-date="2023-03-10">
<day>10</day>
<month>03</month>
<year>2023</year>
</date>
</history>
<pub-history>
<event>
<event-desc>Preprint posted</event-desc>
<date date-type="preprint" iso-8601-date="2023-03-12">
<day>12</day>
<month>03</month>
<year>2023</year>
</date>
<self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.03.10.532020"/>
</event>
<event>
<event-desc>Reviewed preprint v1</event-desc>
<date date-type="reviewed-preprint" iso-8601-date="2023-05-04">
<day>04</day>
<month>05</month>
<year>2023</year>
</date>
<self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.87340.1"/>
<self-uri content-type="editor-report" xlink:href="https://doi.org/10.7554/eLife.87340.1.sa2">eLife assessment</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.87340.1.sa1">Reviewer #1 (Public Review):</self-uri>
<self-uri content-type="referee-report" xlink:href="https://doi.org/10.7554/eLife.87340.1.sa0">Reviewer #2 (Public Review):</self-uri>
<self-uri content-type="author-comment" xlink:href="https://doi.org/10.7554/eLife.87340.1.sa3">Author Response:</self-uri>
</event>
</pub-history>
<permissions>
<copyright-statement>© 2023, Diaz-Vegas et al</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Diaz-Vegas et al</copyright-holder>
<ali:free_to_read/>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="elife-preprint-87340-v2.pdf"/>
<abstract>
<title>Summary</title><p>Insulin resistance (IR) is a complex metabolic disorder that underlies several human diseases, including type 2 diabetes and cardiovascular disease. Despite extensive research, the precise mechanisms underlying IR development remain poorly understood. Here, we provide new insights into the mechanistic connections between cellular alterations associated with IR, including increased ceramides, deficiency of coenzyme Q (CoQ), mitochondrial dysfunction, and oxidative stress. We demonstrate that elevated levels of ceramide in the mitochondria of skeletal muscle cells results in CoQ depletion and loss of mitochondrial respiratory chain components, leading to mitochondrial dysfunction and IR. Further, decreasing mitochondrial ceramide levels in vitro and in animal models (under chow and high fat diet) increased CoQ levels and was protective against IR. CoQ supplementation also rescued ceramide-associated IR. Examination of the mitochondrial proteome from human muscle biopsies revealed a strong correlation between the respirasome system and mitochondrial ceramide as key determinants of insulin sensitivity. Our findings highlight the mitochondrial Ceramide-CoQ-respiratory chain nexus as a potential foundation of an IR pathway that may also play a critical role in other conditions associated with ceramide accumulation and mitochondrial dysfunction, such as heart failure, cancer, and aging. These insights may have important clinical implications for the development of novel therapeutic strategies for the treatment of IR and related metabolic disorders.</p>
</abstract>

</article-meta>
<notes>
<notes notes-type="competing-interest-statement">
<title>Competing Interest Statement</title><p>The authors have declared no competing interest.</p></notes>
<fn-group content-type="summary-of-updates">
<title>Summary of Updates:</title>
<fn fn-type="update"><p>Rebutal paper that address reviewers comments from eLife.</p></fn>
</fn-group>
</notes>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Insulin is the primary hormone responsible for lowering blood glucose, in part, by stimulating glucose transport into muscle and adipose tissue. This is mediated by the phosphatidylinositol 3-kinase/Akt dependent delivery of insulin sensitive glucose transporters (GLUT4) to the plasma membrane (PM)<sup><xref ref-type="bibr" rid="c1">1</xref>,<xref ref-type="bibr" rid="c2">2</xref></sup>. This process is defective in insulin resistance, a significant risk factor for cardiometabolic diseases such as type 2 diabetes<sup><xref ref-type="bibr" rid="c3">3</xref></sup>, heart failure<sup><xref ref-type="bibr" rid="c4">4</xref></sup>, and some types of cancer<sup><xref ref-type="bibr" rid="c5">5</xref></sup> and so defective GLUT4 translocation represents one of the hallmarks of insulin resistance.</p>
<p>The development of insulin resistance in skeletal muscle and adipocytes has been associated with multiple intracellular lesions, including mitochondrial Coenzyme Q (CoQ) deficiency<sup><xref ref-type="bibr" rid="c6">6</xref></sup>, accumulation of intracellular lipids such as ceramides<sup><xref ref-type="bibr" rid="c7">7</xref></sup> and increased mitochondrial reactive oxygen species (ROS)<sup><xref ref-type="bibr" rid="c8">8</xref>–<xref ref-type="bibr" rid="c10">10</xref></sup>. However, delineating the relative contribution of these lesions to whole body insulin resistance and their interconnectivity remains a challenge.</p>
<p>Coenzyme Q (CoQ, CoQ9 in rodents and CoQ10 in humans) is a mitochondrial cofactor and antioxidant synthesised and localised in the inner mitochondrial membrane (IMM). This cofactor is essential for mitochondrial respiration<sup>1</sup><sup><xref ref-type="bibr" rid="c1">1</xref></sup>, fatty acid oxidation<sup><xref ref-type="bibr" rid="c12">12</xref></sup> and nucleotide biosynthesis<sup><xref ref-type="bibr" rid="c13">13</xref></sup>. We reported that mitochondrial, but not global, CoQ9 depletion is both necessary and sufficient to induce insulin resistance <italic>in vitro</italic> and <italic>in vivo</italic><sup><xref ref-type="bibr" rid="c6">6</xref></sup>, suggesting a causal role of CoQ9/10 depletion in insulin resistance. CoQ deficiency can result from primary mutation in the CoQ biosynthetic machinery (named Complex Q)<sup><xref ref-type="bibr" rid="c14">14</xref></sup> or secondary from other cellular defects such as deletion of the oxidative phosphorylation system (OXPHOS)<sup><xref ref-type="bibr" rid="c15">15</xref>,<xref ref-type="bibr" rid="c16">16</xref></sup>. Low levels of CoQ10 are associated with human metabolic disease, including diabetes<sup><xref ref-type="bibr" rid="c17">17</xref>,<xref ref-type="bibr" rid="c18">18</xref></sup>, cardiovascular disease<sup><xref ref-type="bibr" rid="c19">19</xref></sup> and aging<sup><xref ref-type="bibr" rid="c20">20</xref></sup>. Strikingly, many of these conditions are also associated with loss of OXPHOS and mitochondrial dysfunction<sup><xref ref-type="bibr" rid="c21">21</xref>,<xref ref-type="bibr" rid="c22">22</xref></sup>. However, it is unclear what causes these mitochondrial defects or if they are mechanistically linked.</p>
<p>Ceramides belong to the sphingolipid family, and high levels are strongly associated with insulin resistance<sup><xref ref-type="bibr" rid="c23">23</xref></sup>. Whilst it has been proposed that ceramides cause insulin resistance by inhibition of PI3K/Akt signalling<sup><xref ref-type="bibr" rid="c24">24</xref>–<xref ref-type="bibr" rid="c26">26</xref></sup>, there is now considerable evidence that does not support this<sup><xref ref-type="bibr" rid="c3">3</xref>,<xref ref-type="bibr" rid="c6">6</xref>,<xref ref-type="bibr" rid="c27">27</xref>,<xref ref-type="bibr" rid="c28">28</xref></sup>. Hence, ceramides may induce insulin resistance by a non-canonical mechanism. The rapid decline of mitochondrial oxidative phosphorylation in isolated mitochondria in the presence of N-acetylsphingosine (C2-ceramide), a synthetic ceramide analog that can penetrate cells, suggests that ceramides may be responsible for defective mitochondria<sup><xref ref-type="bibr" rid="c29">29</xref></sup>. This effect seems to be ceramide-specific as neither diacylglycerides (DAGs) nor triacylglycerides (TAGs) affect mitochondrial respiration <sup><xref ref-type="bibr" rid="c30">30</xref></sup>. Recent evidence suggests a link between mitochondrial ceramides and insulin sensitivity, with the observation that reducing mitochondrial, but not global, ceramide in the liver protects against the development of diet induced insulin resistance and obesity<sup><xref ref-type="bibr" rid="c30">30</xref>,<xref ref-type="bibr" rid="c31">31</xref></sup>. Consistent with this, mitochondrial ceramide levels are more strongly associated with insulin resistance than with whole tissue ceramide in human skeletal muscle<sup><xref ref-type="bibr" rid="c30">30</xref></sup>. Despite this association, no direct evidence exists linking mitochondrial ceramides with insulin sensitivity in skeletal muscle.</p>
<p>Here we describe the linkage between mitochondrial Ceramide, CoQ, OXPHOS and ROS in the aetiology of insulin resistance. We show that a strong inverse relationship between mitochondrial CoQ and ceramide levels is intimately linked to the control of cellular insulin sensitivity. For example, increasing mitochondrial ceramide using either chemical or genetic tools, decreased mitochondrial CoQ levels, and induced insulin resistance. Conversely, genetic or pharmacologic manipulations that lowered mitochondrial ceramide levels increased CoQ levels and protected against insulin resistance. Increased mitochondrial ceramides also led to a reduction in several OXPHOS components, hindering mitochondrial respiration and elevating mitochondrial ROS <italic>in vitro</italic>. This was further supported in human skeletal muscle, where we observed a strong association between insulin sensitivity, abundance of OXPHOS and mitochondrial ceramides. We propose that increased mitochondrial ceramides cause a depletion in various OXPHOS components, leading to mitochondrial malfunction and deficiency in CoQ, resulting in increased ROS and insulin resistance. This provides a significant advance in our understanding of how ceramide causes mitochondrial dysfunction and insulin resistance in mammals.</p>
</sec>
<sec id="s2">
<title>Results</title>
<sec id="s2a">
<title>Palmitate induces insulin resistance by increasing ceramides and lowering CoQ9 levels in L6 –myotubes</title>
<p>Lipotoxicity plays a major role in insulin resistance and Cardiometabolic disease<sup><xref ref-type="bibr" rid="c32">32</xref></sup>. Excess lipids accumulate in insulin target tissues, such as muscle, impairing insulin-stimulated GLUT4 translocation as well as other metabolic actions of insulin. For this reason, several in vitro models have been employed involving incubation of insulin sensitive cell types with lipids such as palmitate to mimic lipotoxicity in vivo<sup><xref ref-type="bibr" rid="c9">9</xref></sup>. In this study we have used cell surface GLUT4-HA abundance as the main readout of insulin response. As shown (<xref rid="fig1" ref-type="fig">Fig. 1A</xref>), incubation of L6 myotubes with palmitate (150 μM for 16 h) reduced the insulin-stimulated translocation of GLUT4 to the cell surface by ∼30 %, consistent with impaired insulin action. Despite this marked defect in GLUT4 translocation, we did not observe any defect in proximal insulin signalling as measured by phosphorylation of Akt or TBC1D4 (<xref rid="fig1" ref-type="fig">Fig. 1C</xref> &amp; <xref ref-type="fig" rid="fig1">D</xref> - 100nM insulin; 20mins). Previous studies linking ceramides to defective insulin signalling have utilised the short chain ceramide analogue (C2-ceramide)<sup><xref ref-type="bibr" rid="c24">24</xref>–<xref ref-type="bibr" rid="c26">26</xref></sup>. Intriguingly, we were able to replicate that C2-ceramide inhibited both GLUT4 translocation and Akt phosphorylation in L6 myocytes (<xref rid="fig1" ref-type="fig">Fig. 1B, C</xref> &amp; <xref ref-type="fig" rid="fig1">D</xref>). One possibility is that palmitate induces insulin resistance in L6 myotubes via a ceramide-independent pathway. However, this is unlikely as palmitate-induced insulin resistance was prevented by the ceramide biosynthesis inhibitor myriocin (<xref rid="fig1" ref-type="fig">Fig. 1A</xref>) and we observed a specific increase in C16-ceramide levels in L6 cells following incubation with palmitate, which was also prevented by myriocin (<xref rid="fig1" ref-type="fig">Fig. 1E</xref> &amp; <xref ref-type="fig" rid="fig1">F</xref>, <xref ref-type="fig" rid="figs1">Sup. Fig. 1</xref>). Based on these data we surmise that C2-ceramide does not faithfully recapitulate physiological insulin resistance, in contrast to that seen with incubation with palmitate.</p>
<fig id="fig1" position="float" orientation="portrait" fig-type="figure">
<label>Figure 1.</label>
<caption><title>Palmitate increases ceramides, decreases CoQ and induces insulin resistance in L6-myotubes.</title>
<p>A) Insulin-induced GLUT4 translocation in L6-HA-GLUT4 myotubes exposed to palmitate (150 μM for 16 h, Palm) or BSA (Control) in presence of DMSO (control), myriocin (10 μM for 16 h) or CoQ9 (10 μM for 16 h). Plasma membrane GLUT4 (PM-GLUT4) abundance was normalised to insulin-treated control cells. N = 4, mean ± S.E.M. *p&lt; 0.05 vs Control ins, # p&lt; 0.5 vs Palm ins</p><p>B) Insulin-induced GLUT4 translocation in L6-HA-GLUT4 myotubes exposed to C2-ceramide, Dihydroceramide (100 μM, DHC) or DMSO (Control) for 2 h. Plasma membrane GLUT4 (PM-GLUT4) abundance was normalised to insulin-treated control cells. N = 5, mean ± S.E.M. **p&lt; 0.01vs control ins, # p&lt; 0.5 vs 100 μM C2 Ceramide ins.</p><p>(C and D) L6-HA-GLUT4 myotubes were serum-starved after BSA (Control for 16 h), Palmitate (Palm for 16 h), C2-ceramide (100 μM for 2 h, C2) or dihydroceramide (100 μM for 2 h, DHC) treatment and acute insulin (Ins) was added where indicated. Phosphorylation status of indicated sites was assessed by immunoblot (C). Immunoblots were quantified by densitometry and normalised to insulin-treated control cells (indicated by dotted line). N = 3, mean ± S.E.M. **p&lt; 0.01, ***p&lt; 0.001</p><p>(E and F) Endogenous ceramides levels in L6-HA-GLUT4 myotubes treated for 16 h with BSA (control), palmitate (150 μM, Palm), myriocin (10 μM for 16 h) or CoQ (10 μM for 16 h) as indicated in the graph. Total (E) and specific (F) ceramide species were quantified. N = 4, mean ± S.E.M. **p&lt; 0.01, ****p&lt; 0.001vs Control, ### p &lt; 0.001 vs Palm, ρ p&lt;0.01 vs Palm.</p><p>G) CoQ9 level in mitochondrial fraction obtained from L6-HA-GLUT4 myotubes. N = 4, mean ± S.E.M. ***p&lt; 0.001 vs Control, ## p&lt;0.01 vs Palm</p><p>H) Insulin-induced GLUT4 translocation in L6-HA-GLUT4 myotubes exposed to 4-NB (2.5 mM for 16 h) or DMSO (Control) in presence of CoQ9 (10 μM for 16 h). Plasma membrane GLUT4 (PM-GLUT4) abundance was normalised to insulin-treated control cells. N = 4, mean ± S.E.M. ***p&lt; 0.001 vs Control ins, ## p&lt;0.01, ### p&lt;0.001 vs 4NB</p><p>I) CoQ9 level in mitochondrial fraction obtained from L6-HA-GLUT4 myotubes exposed to DMSO (Control) or 4NB for 16 h. N = 4, mean ± S.E.M. *p&lt; 0.05</p><p>(J and K) Total (J) and specific (K) ceramide species quantified in L6-HA-GLUT4 myotubes treated for 16 h with DMSO (control) or 4NB (2.5 mM for 16 h).. N = 4, mean ± S.E.M. **p&lt; 0.01, ****p&lt; 0.0001</p><p>L) Insulin-induced GLUT4 translocation in L6-HA-GLUT4 myotubes exposed to Saclac (10 μM for 24 h) or EtOH (Control) in presence of DMSO (control), myriocin (10 μM for 16 h) or CoQ9 (10 μM for 16 h). Plasma membrane GLUT4 (PM-GLUT4) abundance was normalised to insulin-treated control cells. N = 5, mean ± S.E.M. ***p&lt; 0.001 vs Control Ins, ### p &lt; 0.001 vs Saclac Ins.</p></caption>
<graphic xlink:href="532020v2_fig1.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>We previously demonstrated that insulin resistance was associated with CoQ depletion in muscle from high-fat diet fed mice<sup><xref ref-type="bibr" rid="c6">6</xref></sup>. To test if CoQ supplementation reversed palmitate-induced insulin resistance, L6-myotubes were co-treated with palmitate plus CoQ9. Addition of CoQ9 had no effect on control cells but overcame insulin resistance in palmitate treated cells (<xref rid="fig1" ref-type="fig">Fig. 1A</xref>). Notably, the protective effect of CoQ9 appears to be downstream of ceramide accumulation, as it had no impact on palmitate-induced ceramide accumulation (<xref rid="fig1" ref-type="fig">Fig. 1E-F</xref>). Strikingly, both myriocin and CoQ9 reversed insulin resistance, suggesting that there might be an interaction between ceramides and CoQ in the induction of insulin resistance with palmitate in these cells. Moreover, we have previously shown that mitochondrial CoQ is a key determinant of insulin resistance<sup><xref ref-type="bibr" rid="c6">6</xref></sup> suggesting that ceramides and CoQ may interact in mitochondria. To explore this link, we next examined the effect of palmitate on mitochondrial CoQ levels. As shown (<xref rid="fig1" ref-type="fig">Fig. 1G</xref>), palmitate lowered mitochondrial CoQ9 abundance by ∼40 %, and this was prevented with myriocin. To test whether CoQ depletion is downstream of ceramide accumulation, we exposed GLUT4-HA-L6 myotubes to 4-nitrobenzoic acid (4NB) to competitively inhibit 4-hydroxybenzoate:prolyprenyl transferase (Coq2), a limiting step in CoQ9 synthesis<sup><xref ref-type="bibr" rid="c33">33</xref></sup>. 4NB (2.5 mM for 16 h) decreased mitochondrial CoQ9 to a similar extent as observed in palmitate-treated myocytes (<xref rid="fig1" ref-type="fig">Fig. 1 I</xref>) and generated insulin resistance in GLUT4-HA-L6 myotubes (<xref rid="fig1" ref-type="fig">Fig. 1 H</xref>). Notably, 4NB mediated insulin resistance was prevented by provision of CoQ9, as previously described<sup><xref ref-type="bibr" rid="c6">6</xref></sup>. Interestingly, total ceramide abundance was increased in 4NB treated cells albeit to a lesser extent than observed with palmitate, without affecting other lipid species (<xref rid="fig1" ref-type="fig">Fig. 1 J</xref> &amp; <xref ref-type="fig" rid="figs1">K</xref>, <xref ref-type="fig" rid="figs1">Sup. Fig. 1</xref>). One possibility is that CoQ directly controls ceramide turnover<sup><xref ref-type="bibr" rid="c34">34</xref></sup>. An alternate possibility is that CoQ inside mitochondria is necessary for fatty acid oxidation<sup><xref ref-type="bibr" rid="c12">12</xref></sup> and CoQ depletion triggers lipid overload in the cytoplasm promoting ceramide production<sup><xref ref-type="bibr" rid="c35">35</xref></sup>. In fact, increased fatty acid oxidation is protective against insulin resistance in several model organisms <sup><xref ref-type="bibr" rid="c36">36</xref>–<xref ref-type="bibr" rid="c38">38</xref></sup>. Future studies are required to determine how CoQ depletion promotes Cer accumulation. Regardless, these data indicate that ceramide and CoQ have a central role in regulating cellular insulin sensitivity.</p>
<p>Since palmitate treatment can have a number of effects beyond ceramides, we next attempted to increase intracellular ceramides by inhibiting the ceramide degradation pathway. We exposed L6 myotubes to different concentrations of Saclac, an inhibitor of acid ceramidase (Kao et al., 2019), for 24 h. Saclac increases ceramides in L6 cells in a dose-dependent fashion, with the largest effect on C16:0 ceramides (<xref ref-type="fig" rid="figs1">Sup. Fig. 1F</xref>). Interestingly, Saclac also promoted accumulation of DAGs, sphingosine-1 phosphate (S1P) and sphingosine (SPH), demonstrating the tight interaction between these lipid species (<xref ref-type="fig" rid="figs1">Sup. Fig. 1 B, C</xref> &amp; <xref ref-type="fig" rid="figs1">E</xref>). Consistent with a role of ceramide in insulin sensitivity, Saclac (10 μM for 24 h) reduced insulin stimulated GLUT4 translocation by 40% (<xref rid="fig1" ref-type="fig">Fig. 1L</xref>, vs Control; p&lt;0.001) and this was prevented by myriocin or CoQ9 supplementation (<xref rid="fig1" ref-type="fig">Fig. 1L</xref>). Notably, no detectable defects in Akt phosphorylation were observed (<xref ref-type="fig" rid="figs1">Sup. Fig. 1G</xref> &amp; <xref ref-type="fig" rid="figs1">H</xref>).</p>
<p>To explore if ceramides promote CoQ depletion beyond skeletal muscle, human cervical cancer cells (HeLa) were exposed to Saclac, as previously described (2 μM for 24 h)<sup><xref ref-type="bibr" rid="c39">39</xref></sup>. Consistent with our observation in L6-myotubes, Saclac increased total ceramide levels (∼6 fold over basal) (<xref ref-type="fig" rid="figs2">Sup. Fig. 2 A</xref> &amp; <xref ref-type="fig" rid="figs2">B</xref>) and lowered CoQ levels inside mitochondria (<xref ref-type="fig" rid="figs2">Sup. Fig 2C</xref>). Of interest, myriocin prevented Saclac-induced-CoQ depletion demonstrating that there is a similar interaction between ceramide and CoQ levels in this human cell line as observed in L6 cells (<xref ref-type="fig" rid="figs2">Sup. Fig. 2D</xref>). Moreover, this was relatively specific to CoQ as we did not observe any change in mitochondrial mass with Saclac (<xref ref-type="fig" rid="figs2">Sup. Fig 2 E-G</xref>), cell viability (<xref ref-type="fig" rid="figs2">Sup. Fig. 2H</xref>) or DAGs abundance (<xref ref-type="fig" rid="figs2">Sup. Fig. 2 I</xref>) Regardless, these data indicate that there is a strong association between ceramide and CoQ and that this has a central role in regulating cellular insulin sensitivity.</p>
</sec>
<sec id="s2b">
<title>Mitochondrial ceramide promotes insulin resistance by lowering CoQ levels</title>
<p>Although mitochondrial ceramides have been linked with insulin resistance in human skeletal muscle<sup><xref ref-type="bibr" rid="c30">30</xref></sup>, to date, there is no direct evidence linking mitochondrial ceramides with insulin sensitivity. We wanted to determine if ceramide accumulation specifically in mitochondria is associated with altered CoQ levels and insulin resistance. To achieve this, we employed doxycycline-Tet-On inducible<sup><xref ref-type="bibr" rid="c40">40</xref></sup> overexpression of a mitochondrial-targeted Sphingomyelin Phosphodiesterase 5 (mtSMPD5) in GLUT4-HA-L6 cells (GLUT4-HA-L6-mtSMPD5) (<xref rid="fig2" ref-type="fig">Fig. 2A</xref>). SMPD5 is a murine mitochondria-associated enzyme<sup><xref ref-type="bibr" rid="c41">41</xref></sup> that hydrolyses sphingomyelin to produce ceramides<sup><xref ref-type="bibr" rid="c42">42</xref></sup>. Thus, overexpressing mtSMPD5 should specifically increase ceramides within mitochondria and avoid potential non-specific effects associated with small molecule inhibitors. As expected, doxycycline induced mitochondrial expression of mtSMPD5, as demonstrated by enrichment of SMPD5 in mitochondria isolated from L6 cells (<xref rid="fig2" ref-type="fig">Fig. 2B</xref>) and this was associated with increased total mitochondrial ceramides to the same extent as observed with palmitate treatment (<xref rid="fig2" ref-type="fig">Fig. 2C</xref>), with the largest increase in C16-ceramide (<xref rid="fig2" ref-type="fig">Fig. 2D</xref>). Importantly, mtSMPD5 overexpression did not affect ceramide abundance in the whole cell lysate nor other lipid species inside mitochondria such as cardiolipin, cholesterol and DAGs (<xref ref-type="fig" rid="figs3">Sup. Fig. 3 A, D-J</xref>). Intriguingly, mtSMD5 did not affect sphingomyelin levels in mitochondria (<xref ref-type="fig" rid="figs3">Sup. Fig. 3G</xref>), consistent with exchange between mitochondrial and extra-mitochondrial sphingomyelin pools to compensate for the degradation induced by SMPD5 overexpression<sup><xref ref-type="bibr" rid="c43">43</xref></sup>. Consistent with our hypothesis, mtSMPD5 was sufficient to promote insulin resistance in response to submaximal and maximal insulin doses (<xref rid="fig2" ref-type="fig">Fig. 2E</xref>). Furthermore, mtSMPD5 overexpression promoted insulin resistance without affecting Akt phosphorylation (<xref rid="fig2" ref-type="fig">Fig. 2F</xref> - H), and no differences in total GLUT4 levels were observed across the treatments (<xref rid="fig2" ref-type="fig">Fig. 2F</xref> &amp; <xref ref-type="fig" rid="figs3">Sup. Fig. 3B</xref>). We next explored if mitochondrial ceramide-induced insulin resistance was mediated by lowering CoQ within mitochondria. In line with our previous results, Mitochondrial CoQ levels were depleted in both palmitate-treated and mtSMPD5-overexpressing cells without any additive effects. This suggests that these strategies to increase ceramides share a common mechanism for inducing CoQ depletion in L6 myotubes (<xref rid="fig2" ref-type="fig">Fig. 2I</xref>). Importantly, CoQ9 supplementation prevented both palmitate- and mtSMPD5 induced-insulin resistance (<xref rid="fig2" ref-type="fig">Fig. 2J</xref>), suggesting that CoQ depletion is an essential mediator of insulin resistance.</p>
<fig id="fig2" position="float" orientation="portrait" fig-type="figure">
<label>Figure 2.</label>
<caption><title>Mitochondrial overexpression of SMPD5 induces insulin resistance by lowering CoQ9 in L6-myotubes.</title>
<p>A) Schematic representation of doxycycline-inducible overexpression of mitochondrial targeted sphingomyelinase 5 (SMPD5). L6-HA-GLUT4 myotubes were exposed to 1 μg/mL of Doxycycline from day 3 to day 6 of differentiation. Experiments were performed on day 7 of differentiation.</p><p>B) Determination of SMPD5 expression in mitochondrial fraction obtained from L6-HA-GLUT4. Doxycycline was added where indicated.</p><p>(C and D) Levels of endogenous ceramides in mitochondrial fraction from L6-HA-GLUT4 myotubes treated with BSA (Control) palmitate (150 μM for 16 h, palm) or doxycycline. Total (C) and specific (D) ceramide species were quantified. N = 3, mean ± S.E.M. *p&lt; 0.05, ** p&lt;0.01 and ****p&lt; 0.0001 vs Control.</p><p>E) Insulin-induced GLUT4 translocation in L6-HA-GLUT4 myotubes exposed to Doxycycline (1 μg/mL for 3 d). Plasma membrane GLUT4 (PM-GLUT4) abundance was normalised to 100 nM insulin-treated control cells. N = 6, mean ± S.E.M. *p&lt; 0.05, **p&lt;0.01, ***p&lt;0.001 vs control ins.</p><p>(F, G and H) L6-HA-GLUT4 myotubes were serum-starved after BSA (Control), Palmitate (150 μM for 16 h, palm) or Doxycycline (1 μg/mL for 3 d) treatment and acute insulin (Ins) was added where indicated. Phosphorylation status of indicated sites was assessed by immunoblot. Immunoblots were quantified by densitometry and normalised to insulin-treated control cells (indicated by dotted line). N = 3, mean ± S.E.M. * p&lt;0.05, *** p&lt;0.001 vs Basal</p><p>I) CoQ9 level in mitochondrial fraction obtained from L6-HA-GLUT4 myotubes exposed to doxycycline (1 μg/mL for 3 d) N = 4, mean ± S.E.M. **p&lt;0.001.</p><p>J) Insulin-induced GLUT4 translocation in L6-HA-GLUT4 myotubes exposed to Doxycycline (1 μg/mL for 3 d). Control or doxycycline treated cells were exposed to BSA (control), Palmitate (150 μM for 16 h, palm) or CoQ9 (10 μM for 16 h). Plasma membrane GLUT4 (PM-GLUT4) abundance was normalised to insulin-treated control cells. N = 5, mean ± S.E.M. **p&lt; 0.01 vs Control ins, ## p&lt;0.01 vs palm ins</p></caption>
<graphic xlink:href="532020v2_fig2.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<sec id="s2c">
<title>Mitochondrial ceramides are necessary for palmitate-induced CoQ depletion and insulin resistance</title>
<p>Given increased mitochondrial ceramides are sufficient to induce CoQ depletion and insulin resistance, we next asked whether increased mitochondrial ceramides are necessary to drive these phenotypes. Using the doxycycline-Tet-On inducible system<sup><xref ref-type="bibr" rid="c40">40</xref></sup> we overexpressed a mitochondrial-targeted Acid Ceramidase 1 (mtASAH1) in GLUT4-HA-L6 cells (GLUT4-HA-L6-mtASAH1) (<xref rid="fig3" ref-type="fig">Fig. 3A</xref>). ASAH1 degrades ceramides to fatty acid and sphingosine<sup><xref ref-type="bibr" rid="c44">44</xref></sup>. Hence, mitochondrial overexpression of ASAH1 was expected to selectively lower ceramides inside mitochondria. Doxycycline increased the abundance of mtASAH1 in the mitochondrial fraction, demonstrating the correct localisation of this construct (<xref rid="fig3" ref-type="fig">Fig. 3B</xref>). Furthermore, mtASAH1 induction prevented palmitate-induced mitochondrial ceramide accumulation (total levels and 18:1\16:0 ceramides) (<xref rid="fig3" ref-type="fig">Fig. 3C</xref>), indicating the enzyme was functioning as expected. Similar to our observations with mtSMD5 overexpression, mtASAH1 did not alter ceramide abundance in the whole cell lysate or mitochondrial sphingomyelin levels (<xref ref-type="fig" rid="figs4">Sup. Fig. 4 A</xref>&amp;<xref ref-type="fig" rid="figs4">F</xref>). Notably, mtASAH1 overexpression protected cells from palmitate-induced insulin resistance without affecting basal insulin sensitivity (<xref rid="fig3" ref-type="fig">Fig. 3E</xref>). Similar results were observed using insulin-induced glycogen synthesis as an orthologous technique for GLUT4 translocation. These results provide additional evidence highlighting the role of dysfunctional mitochondria in muscle cell glucose metabolism (<xref ref-type="fig" rid="figs5">Sup. Fig. 5K</xref>). Importantly, mtASAH1 overexpression did not rescue insulin sensitivity in cells depleted of CoQ (2.5 mM 4NB for 24 h) supporting the notion that mitochondrial ceramides are upstream of CoQ (<xref rid="fig3" ref-type="fig">Fig. 3E</xref>). Neither palmitate nor mtASAH1 overexpression attenuated insulin-dependent Akt phosphorylation (<xref rid="fig3" ref-type="fig">Fig. 3 F-H</xref>) nor total GLUT4 abundance (<xref rid="fig3" ref-type="fig">Fig. 3F</xref>, <xref ref-type="fig" rid="figs4">Sup. Fig. 4B</xref>). Finally, mtASAH1 overexpression increased CoQ levels. In both control and mtASAH1 cells, palmitate induced a depletion of CoQ, however the levels in palmitate treated mtASAH1 cells remained similar to control untreated cells (<xref rid="fig3" ref-type="fig">Fig. 3I</xref>). This suggests that the absolute concentration of CoQ is crucial for insulin sensitivity, rather than the relative depletion compared to basal conditions, thus supporting the causal role of mitochondrial ceramide accumulation in reducing CoQ levels in insulin resistance.</p>
<fig id="fig3" position="float" orientation="portrait" fig-type="figure">
<label>Figure 3.</label>
<caption><title>Mitochondrial overexpression of ASAH1 protects against insulin resistance and increases CoQ levels in L6-myotubes.</title>
<p>A) Schematic representation of doxycycline-inducible overexpression of mitochondrial targeted Acid Ceramidase 1 (ASAH1). L6-HA-GLUT4 myotubes were exposed to 1 μg/mL of Doxycycline from day 3 to day 6 of differentiation. Experiments were performed on day 7 of differentiation.</p><p>B) Determination of ASAH1 expression in mitochondrial fraction obtained from L6-HA-GLUT4. Doxycycline was added where indicated. (C and D) Endogenous ceramides levels in mitochondrial fraction from L6-HA-GLUT4 myotubes treated with BSA (Control) palmitate (150 μM for 16 h, palm) or doxycycline. Total (C) and specific (D) ceramide species were quantified. N = 3, mean ± S.E.M. *p&lt; 0.05 vs Control, ## p&lt;0.01 vs Palm</p><p>E) Insulin-induced GLUT4 translocation in L6-HA-GLUT4 myotubes exposed to Doxycycline (1 μg/mL for 3 d). Control or doxycycline treated cells were exposed to BSA (control), Palmitate (150 μM for 16 h, palm) or 4NB (2.5 mM for 16 h). Plasma membrane GLUT4 (PM-GLUT4) abundance was normalised to insulin-treated control cells. N = 6, mean ± S.E.M. **p&lt;0.01 vs Control ins, ### p&lt;0.001 vs Palm ins</p><p>(F, G and H) L6-HA-GLUT4 myotubes were serum-starved after BSA (Control), Palmitate (150 μM for 16 h, palm) or Doxycycline (1 μg/mL for 3 d) treatment and acute insulin (Ins) was added where indicated. Phosphorylation status of indicated sites was assessed by immunoblot. Immunoblots were quantified by densitometry and normalised to insulin-treated control cells (indicated by dotted line). N = 3, mean ± S.E.M. ***p&lt;0.001 vs Basal, # p&lt;0.05 vs Control ins.</p><p>I) CoQ9 level in mitochondrial fraction obtained from L6-HA-GLUT4 myotubes exposed to doxycycline (1 μg/mL for 3 d). Control or doxycycline treated cells were exposed to BSA (control) or palmitate (150 μM for 16 h, palm) N = 4, mean ± S.E.M. *p&lt;0.05 vs control, ## p&lt;0.01 vs Palm.</p><p>J) Levels of total ceramides in skeletal muscle of mice fed chow with vehicle or 5 mg/kg P053 for 6 wks. N = 7, Mean ± S.E.M. ***p&lt; 0.001.</p><p>K) Levels of CoQ in mitochondrial fraction isolated from skeletal muscle of mice fed chow with vehicle or 5 mg/kg P053 for 6 wks. N = 7, Mean ± S.E.M. *p&lt;0.05.</p></caption>
<graphic xlink:href="532020v2_fig3.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>In order to demonstrate the connection between ceramide and CoQ in vivo, we examined whether a reduction of ceramides in mouse skeletal muscle, using a Ceramide Synthase 1 (CerS1) inhibitor, would alter mitochondrial CoQ levels. Treatment of adult mice with the CerS1 inhibitor P053 for 6 wks selectively lowered muscle ceramides without affecting other lipid species (<xref rid="fig3" ref-type="fig">Fig 3J</xref>, <xref ref-type="fig" rid="figs5">Sup. Fig 5</xref>). Notably, CerS1 inhibition increased CoQ in mitochondrial fractions isolated from skeletal muscle (<xref rid="fig3" ref-type="fig">Fig. 3K</xref>), similar effect was observed in mice exposed to a high fat diet (HFD) for 5 wks (<xref ref-type="fig" rid="figs4">Supp. Fig. 4H-I</xref>). These animals exhibited an improvement in mitochondrial function and reduced muscle triglycerides and adiposity upon HFD (further phenotypic and metabolic characterization of these animals can be found in <sup><xref ref-type="bibr" rid="c45">45</xref></sup>) demonstrating the existence of the ceramide/CoQ relationship in muscle in vivo.</p>
</sec>
<sec id="s2d">
<title>Mitochondrial ceramides induce depletion of the electron transport chain</title>
<p>We have established that both increased mitochondrial ceramides and a loss of mitochondrial CoQ are necessary for the induction of insulin resistance. As such these changes are likely to induce other mitochondrial defects. To gain insight into how increased mitochondrial ceramides drive changes in mitochondrial function we performed MS-based proteomics on L6 cells overexpressing mtSMPD5.</p>
<p>mtSMPD5-L6 myotubes were treated with doxycycline for various time points (2, 8, 24, 48 and 72 h) and positive induction was observed after 24 h of treatment (<xref ref-type="fig" rid="figs6">Fig. Sup. 6A</xref>). Subsequently, control, 24, and 72 h time points were selected for further studies. Mitochondria were purified via gradient separation and analysed using liquid chromatography-tandem mass spectrometry (LC-MS/MS) in data-independent acquisition (DIA) mode (<xref rid="fig4" ref-type="fig">Fig. 4A</xref>). Across control and mtSMPD5 cells we quantified 2501 proteins where 555 were annotated as mitochondrial proteins (MitoCarta 3.0 and uniprot localisation)<sup><xref ref-type="bibr" rid="c46">46</xref></sup>.</p>
<fig id="fig4" position="float" orientation="portrait" fig-type="figure">
<label>Figure 4.</label>
<caption><title>Mitochondrial ceramides induce a selective depletion of supercomplexes associated proteins in L6-myotubes.</title>
<p>A) Workflow schematics.</p><p>B &amp; C) Pairwise comparisons of mitochondrial proteome between all four groups. Cut-off for -log10 adjusted p-value (-log10(p-value)) was set at 2 and Log2(FC) at 0.5 (blue).</p><p>D) Quantification of the OXPHOS protein complexes generated by the summed abundance of all subunits within a given complex.</p><p>E) Quantification of the Complex Q protein complexes generated by the summed abundance of all subunits within the complex.</p><p>F) Schematics of CoQ distribution between CI-binding and free CoQ<sup><xref ref-type="bibr" rid="c82">82</xref></sup></p><p>G) Schematics of OXPHOS subunits (top) and assembly factors (bottom) significatively up-regulated (light red), down-regulated (blue) and no change (grey) after 72 h of mtSMPD5 overexpression.</p><p>H) Subunit levels for proteins after mtSMPD5 overexpression mapped to the complex I structure<sup><xref ref-type="bibr" rid="c48">48</xref></sup>. The colours were calculated with an in-house python script and the resultant model was rendered using ChimeraX. Grey, no detected; Purple, below cut off (Log2FC = 0.4).</p></caption>
<graphic xlink:href="532020v2_fig4.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>Analysis of the proteome revealed that 9 and 19 % of mitochondrially annotated proteins were significantly changed at 24 and 72 h respectively (adj. p&lt;0.05, Absolute log2 FC &gt; 0.4) indicative of a temporal progression of changes following induction of mSMPD5 expression (<xref rid="fig4" ref-type="fig">Fig.4 B</xref> &amp; <xref ref-type="fig" rid="fig4">C</xref>). 60 proteins were decreased at 72 h and of these 47% were functionally annotated as components of oxidative phosphorylation (OXPHOS (rank 1, 28/135 proteins). Within OXPHOS, we observed a significant depletion of the electron transport chain components (ETC). The ETC is composed of several complexes (complex I-V, CI-CV). In this dataset, CI (14/15 decreased), CIII (5/6 decreased) and CIV (13/13 decreased) but not CII (0/3 decreased) or CV (3/15 decreased) were depleted after mtSMPD5 overexpression (<xref rid="fig4" ref-type="fig">Fig. 4D</xref>). Despite the bulk downregulation of CI, III and IV, the assembly machinery associated with each complex was either upregulated or unchanged after mtSMPD5 overexpression (<xref rid="fig4" ref-type="fig">Fig. 4J</xref>) suggesting that mitochondrial ceramides somehow alter ETC stability. Intriguingly, neither CII nor CV were affected by mtSMPD5 suggesting that ceramides preferentially affect those ETC complexes that are part of structures known as supercomplexes (SCs)<sup><xref ref-type="bibr" rid="c47">47</xref></sup>. Importantly, as part of CoQ is found in SCs binding CI (<xref rid="fig4" ref-type="fig">Fig. 4F</xref>) we mapped the levels of individual subunits of CI onto the recently solved structure of bovine CI<sup><xref ref-type="bibr" rid="c48">48</xref></sup>. This revealed the loss of subunits around the N-module (Ndufs1, Ndufs4, Ndufs6, Ndufv2 &amp; Ndufv3) and Q-module (Ndufa5 &amp; Ndufs2) in CI (<xref rid="fig4" ref-type="fig">Fig. 4H</xref>). Importantly, CI downregulation was not associated with reduction in gene expression as shown in <xref ref-type="fig" rid="figs6">Sup. Fig. 6J</xref>. The N-module is essential for NADH oxidation, and the Q-module is where CoQ binds CI. Hence, loss of the Q-module might trigger a stoichiometric depletion of CoQ upon ceramide accumulation.</p>
<p>Of note, we observed a heterogeneous response of the mitochondrial proteome after mtSMPD5 overexpression. For instance, proteins associated with glucose oxidation and mitochondrial translation/transcription did not change after mtSMPD5 induction (<xref ref-type="fig" rid="figs6">Fig. Sup. 6D, F</xref> &amp; <xref ref-type="fig" rid="figs6">G</xref>), proteins involved in fatty acid oxidation and OXPHOS were consistently downregulated after 24 h treatment (<xref rid="fig4" ref-type="fig">Fig. 4B, C</xref>, &amp; D and <xref ref-type="fig" rid="figs6">Sup. Fig. 6E</xref>), proteins related with the mitochondrial import machinery were consistently upregulated (<xref ref-type="fig" rid="figs6">Fig. Sup. 6C</xref>) and proteins associated with CoQ production were transiently downregulated after 24 h induction (<xref rid="fig4" ref-type="fig">Fig. 4E</xref>).</p>
</sec>
<sec id="s2e">
<title>Mitochondrial ceramides impair mitochondrial function</title>
<p>Based on the ceramide-dependent depletion of ETC members, we hypothesised that mitochondrial ceramides would impair mitochondrial function. To test this, we evaluated several aspects of mitochondrial function upon mtSMPD5 overexpression. Mitochondrial respiration is broadly considered to be the best measure for describing mitochondrial activity<sup><xref ref-type="bibr" rid="c22">22</xref>,<xref ref-type="bibr" rid="c49">49</xref></sup>. Respiration was assessed in intact mtSMPD5-L6 myotubes treated with CoQ9 by Seahorse extracellular flux analysis. mtSMPD5 overexpression decreased basal and ATP-linked mitochondrial respiration (<xref rid="fig5" ref-type="fig">Fig. 5 A, B</xref> &amp;<xref ref-type="fig" rid="fig5">C</xref>), as well as maximal, proton-leak and non-mitochondrial respiration (<xref rid="fig5" ref-type="fig">Fig. 5 A, D, E</xref> &amp; <xref ref-type="fig" rid="fig5">F</xref>) suggesting that mitochondrial ceramides induce a generalised attenuation in mitochondrial function. Notably, we did not observe evidence of energy deficiency in our model (data not shown). Interestingly, CoQ9 supplementation partially recovered basal and ATP-linked mitochondrial respiration, suggesting that part of the mitochondrial defects are induced by CoQ9 depletion. The attenuation in mitochondrial respiration is consistent with a depletion of the ETC subunits observed in our proteomic dataset (<xref rid="fig4" ref-type="fig">Fig. 4</xref>). Since mitochondrial respiratory activity is limited by several factors including nutrient supply, bioenergetic demands, among others<sup><xref ref-type="bibr" rid="c50">50</xref></sup> we tested whether the ETC generally or a specific respiratory complex was affected by mtSMPD5 overexpression. We measured the activity of the respiratory chain by providing substrates for each respiratory chain complex to permeabilized cells and analysed oxygen consumption. mtSMPD5 overexpressing cells exhibited attenuated mitochondrial respiration irrespective of the substrate provided (<xref rid="fig5" ref-type="fig">Fig. 5 G-L</xref>) supporting the notion that mitochondrial ceramides induce a generalised defect in mitochondrial respiration. In line with defective mitochondrial function, cells with mtSMPD5 overexpression also exhibited increased oxidative stress (<xref rid="fig5" ref-type="fig">Fig. 5M</xref>) measured by the redox sensitive dye MitoSOX. Interestingly, no difference in mitochondrial membrane potential was observed across conditions (<xref rid="fig5" ref-type="fig">Fig. 5N</xref>). Collectively, these data suggest that increased mitochondrial ceramides cause a loss of mitochondrial respiratory capacity and an increase in ROS production as a result of ETC depletion in L6-myotubes.</p>
<fig id="fig5" position="float" orientation="portrait" fig-type="figure">
<label>Figure 5.</label>
<caption><title>Mitochondrial ceramides impair mitochondrial function.</title>
<p>A) mtSMPD5 overexpression decreases oxygen consumption rate (<italic>J</italic>O<sub>2</sub>) (means ± SEM; n = 6 - 8 biological replicates) measured by mitochondrial stress test. After 1 h no CO<sub>2</sub> environment, cells were stimulated with oligomycin (Oligo), Carbonyl cyanide-p-trifluoromethoxyphenylhydrazon (FCCP) and antimycin A (AA) and Rotenote (Rot) at indicated time points. (means ± SEM; n = 6 - 8 biological replicates).</p><p>B - F) Quantification of <italic>J</italic>O<sub>2</sub> measured by mitochondrial stress test from <xref rid="fig6" ref-type="fig">Fig 6A</xref> as described in material and method. (means ± SEM; n = 6 - 8 biological replicates). * p&lt;0.05, ** p&lt;0.01, *** p&lt;0.001 vs control</p><p>G-L) mtSMPD5 overexpression diminishes respiratory CI (G &amp; J), CII (H &amp; K) and CIV (I &amp; L). <italic>J</italic>O<sub>2</sub> was performed in permeabilized cells supplemented with adenosine diphosphate (ADP) and CI to IV substrates (means ± SEM; n = 3 biological replicates). Mal, Malate; Glut, Glutamate; Rot, Rotenone; Succ, Succinate; TMPD, tetramethyl-phenylenediamine; Asc, Ascorbic acid; Oligo, Oligomycin. J, K and L are quantifications from graphs G, H and I respectively. * p&lt;0.05, ** p&lt;0.01 vs control.</p><p>M) mtSMPD5 overexpression increased mitochondrial oxidative stress. Cells were loaded with the redox sensitive dye MitoSOX and the mitochondrial marker mitoTracker deep Red for 30 min before imaging in a confocal microscope (see method). (means ± SEM; n = 10 biological replicates). AA, Antimycin A. ** p&lt;0.01, *** p&lt;0.001 vs control</p><p>N) mtSMPD5 overexpression does not alter mitochondrial membrane potential. Cells were loaded with the potentiometric dye Tetramethylrhodamine, Ethyl Ester, Perchlorate (TMRM<sup>+</sup>) in non quenching mode and the mitochondrial marker mitoTracker deep Red for 30 min before imaging in a confocal microscope (see method). (means ± SEM; n &gt; 10 biological replicates).</p></caption>
<graphic xlink:href="532020v2_fig5.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<sec id="s2f">
<title>Association of mitochondrial proteome with insulin sensitivity and mitochondrial ceramides in human muscle</title>
<p>To further characterise the effect of mitochondrial ceramides on ETC abundance in a more physiological context we performed a cross-sectional study assessing the mitochondrial lipid profile and protein abundance in muscle biopsies obtained from four groups of people (athletes, lean, obese and type 2 diabetics (T2D). The demographic information and detailed lipidomic analysis of these individuals was previously reported<sup><xref ref-type="bibr" rid="c30">30</xref></sup>, <xref ref-type="fig" rid="figs7">Fig. Sup. 7 A</xref>). In line with our <italic>in-vitro</italic> data, long tail ceramides (C18:0) in the mitochondria/ Endoplasmic reticulum (ER) enriched fraction, but not whole tissue, were inversely correlated with muscle insulin sensitivity<sup><xref ref-type="bibr" rid="c30">30</xref></sup>. To expand this observation, we employed proteomics analysis of the mitochondrial/ER fraction from the same subjects (<xref rid="fig6" ref-type="fig">Fig. 6A</xref>). A total of 2,058 unique protein groups were quantified in at least one sample, where 571 were annotated as mitochondrial associated proteins (Human MitoCarta 3.0)<sup><xref ref-type="bibr" rid="c46">46</xref></sup>. After filtering (proteins in &gt;50% of samples within each group), 492 mitochondrial proteins were reliably quantified across 67 samples (<xref rid="fig6" ref-type="fig">Fig. 6B</xref>). We noted that the mitochondrial fraction from athletes were enriched for mitochondrial proteins, and this could be corrected by global median normalisation (<xref ref-type="fig" rid="figs7">Fig. Sup. 7D</xref>). Pairwise comparison of the mitochondrial proteome between all groups revealed differences between groups, although relatively small in effect size (<xref rid="fig6" ref-type="fig">Fig. 6C</xref> &amp; <xref ref-type="fig" rid="fig6">D</xref>). For instance, 16% of all mitochondrial proteins were significantly different between T2D and athletes (<xref rid="fig6" ref-type="fig">Fig. 6C</xref>), however 56% (45/80) of these proteins were changed by less than 1.5-fold. This trend was even stronger when comparing the obese group to the athletes, where 18% of mitochondrial proteins were changed, but ∼80% were changed less than 1.5-fold. Gene set enrichment revealed a highly significant general trend following the difference in insulin sensitivity (measure by the rate of glucose disappearance -Rd- using a stable isotope - [6,6-<sup>2</sup>H<sub>2</sub>]glucose - during a hyperinsulinemic-euglycemic clamp <sup><xref ref-type="bibr" rid="c30">30</xref></sup>, where TCA cycle and respiratory electron transport and Complex I biogenesis were enriched as follows: Athletes &gt; Lean &gt; Obese &gt; T2D (Sup. Table 2). Of note, the T2D group had an enrichment of mitochondrial translation compared to the obese group.</p>
<fig id="fig6" position="float" orientation="portrait" fig-type="figure">
<label>Figure 6.</label>
<caption><title>Mitochondrial proteome profiling associates complex I with muscle insulin sensitivity.</title>
<p>A) Quantification of proteins across samples.</p><p>B) Number of significant deferential regulated (DR) proteins by pairwise comparison. Groups not shown have no significantly regulated proteins after correcting for multiple testing.</p><p>C) Gene set enrichment between all comparisons.</p><p>D) Relative protein abundance in isolated mitochondria from human skeletal muscle muscle cells. Comparisons are shown on top of each graph. Light blue, significatively regulated proteins (-log10(p-val) = 2).</p><p>E) Proteins rank against rate glucose disappearance during clamp (Rd) correlation. Proteins within complex I of the electron transport chain are highly significant with Rd.</p><p>F) Proteins rank against mitochondrial ceramide (Cer) 18:0 abundance. Proteins within complex I of the electron transport chain are highly significant with Cer18:0.</p><p>G) Subunit levels associated with mitochondrial ceramides mapped to the complex I structure <sup><xref ref-type="bibr" rid="c48">48</xref></sup>. The colours were calculated with an in-house python script and the resultant model was rendered using ChimeraX. Grey, no detected; Purple, below cut off (Corr. Coef. = - 0.25 to 0.25).</p><p>H) Quantification of the mitochondrial proteins generated by the summed abundance of all subunits associated with a specific function from mtSMPD5-L6 myotubes after 72 h vs summed mitochondrial proteins (function) associated with either C18:0 ceramide (left panel) or insulin sensitivity (right panel) from human samples.</p></caption>
<graphic xlink:href="532020v2_fig6.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<p>To further explore the relationship between mitochondria and insulin sensitivity, the mitochondrial proteome was correlated to the muscle insulin sensitivity measured using <sup>2</sup>H<sub>2</sub> glucose Rd. As a group, all detected proteins within CI of the ETC were highly correlated with muscle insulin sensitivity (p = 4e-15) (<xref rid="fig6" ref-type="fig">Fig. 6E</xref>), and to a lesser extent proteins within CIV (p=0.08) and CV (p= 0.09; <xref ref-type="fig" rid="figs7">Fig. Sup. 7E</xref>). The abundance of CII and CIII, together with the small and large mitochondrial ribosome subunits, were not associated with insulin sensitivity across all the samples (<xref ref-type="fig" rid="figs7">Fig. Sup. 7F</xref>). Next, we determined the association between the mitochondrial proteome and the levels of C18:0 ceramide in the mitochondria/ER fraction. In line with our previous observations, as a group, CI proteins were inversely correlated with mitochondrial ceramides (p = 8e-14) and no association was observed between CII and C18:0 ceramides across samples (<xref rid="fig6" ref-type="fig">Fig. 6F</xref>). Furthermore, components of CIV were also negatively correlated with mitochondrial ceramides although to a lesser extent (<xref ref-type="fig" rid="figs7">Sup. Fig. 7F</xref>, p = 0.026) and CV was not associated with mitochondrial ceramides (<xref ref-type="fig" rid="figs7">Sup. Fig. 7F</xref>, p = 0.737). According to these results, ETC subunits exhibit differential sensitivity to mitochondrial ceramides, with CI subunits being the most sensitive in human muscle. To uncover structural changes in CI that could correlate with increased ceramide we mapped those proteins significatively associated with mitochondrial ceramides to the bovine CI structure<sup><xref ref-type="bibr" rid="c48">48</xref></sup>. Consistent with L6-mtSMPD5 myotubes, the N and Q modules were the regions with the most negative associated subunits with mitochondria ceramides in human muscle (<xref rid="fig6" ref-type="fig">Fig. 6G</xref>). To determine the conservation in the changes in the mitochondrial proteome induced by increased ceramides, we compared the proteomes of mtSMPD5-L6-myotubes (72 h after induction) and human muscle biopsies. We observed that across the two datasets, CI and CIV subunits were downregulated after mtSMPD5 overexpression and were negatively associated with C18 ceramides in human samples (<xref rid="fig6" ref-type="fig">Fig. 6H</xref>). In turn, CI and CIV were positively associated with muscle insulin sensitivity (<xref rid="fig6" ref-type="fig">Fig. 6I</xref>), suggesting that these ETC subunits exhibited a conserved sensitivity to ceramide accumulation with a potential role in insulin sensitivity.</p>
</sec>
</sec>
<sec id="s3">
<title>Discussion</title>
<p>Insulin resistance is characterised by attenuated insulin-dependent glucose uptake in relevant target tissues, such as muscle and fat, and it plays a central role in cardiometabolic diseases<sup><xref ref-type="bibr" rid="c3">3</xref></sup>. In skeletal muscle, mitochondrial ceramides have been linked to insulin resistance<sup><xref ref-type="bibr" rid="c30">30</xref></sup>, however, to date no direct link connecting mitochondrial ceramides with insulin resistance has been established. Furthermore, CoQ depletion and defective mitochondria have also been independently associated with insulin resistance<sup><xref ref-type="bibr" rid="c6">6</xref>,<xref ref-type="bibr" rid="c7">7</xref></sup>. In the current study we present evidence suggesting that these factors are mechanistically linked inside mitochondria. Our data demonstrate that increased mitochondrial ceramides are both necessary and sufficient to induce insulin resistance in skeletal muscle. This is likely a function of increased ROS production that results from the specific depletion of the OXPHOS subunits and the concomitant loss of CoQ. Analysis of the human muscle mitochondrial proteome strongly supports mitochondrial ceramide linked changes in the OXPHOS machinery as major drivers of insulin sensitivity. In this study, we mainly utilised L6-myotubes, which share many important characteristics with primary muscle fibres. Both types of cells exhibit high sensitivity to insulin and respond similarly to maximal doses of insulin, with GLUT4 translocation stimulated between 2 to 4 times over basal levels in response to 100 nM insulin (as shown in <xref rid="fig1" ref-type="fig">Fig. 1</xref>-<xref rid="fig4" ref-type="fig">4</xref>,<sup><xref ref-type="bibr" rid="c51">51</xref>,<xref ref-type="bibr" rid="c52">52</xref></sup>). Additionally, mitochondrial respiration in L6-myotubes have a similar sensitivity to mitochondrial poisons, as observed in primary muscle fibres (as shown in <xref rid="fig5" ref-type="fig">Fig. 5</xref>,<sup><xref ref-type="bibr" rid="c53">53</xref></sup>). Finally, inhibiting ceramide production increases CoQ levels in both L6-myotubes and adult muscle tissue (as shown in <xref rid="fig2" ref-type="fig">Fig. 2</xref>-<xref rid="fig3" ref-type="fig">3</xref>). Therefore, L6-myotubes possess the necessary metabolic features to investigate the role of mitochondria in insulin resistance, and this relationship is likely applicable to primary muscle fibres.</p>
<p>Many stressors, including chronic inflammation and anticancer drugs, stimulate endogenous ceramide generation<sup><xref ref-type="bibr" rid="c54">54</xref></sup> and CoQ depletion in mitochondria<sup><xref ref-type="bibr" rid="c55">55</xref>,<xref ref-type="bibr" rid="c56">56</xref></sup>. Nevertheless, experimental evidence testing the link between these molecules has been lacking. We observed that increased mitochondrial ceramides drive a depletion of mitochondrial CoQ leading to insulin resistance (<xref rid="fig1" ref-type="fig">Fig. 1</xref> &amp; <xref ref-type="fig" rid="fig2">2</xref>), and that reducing mitochondrial ceramide protects against the loss of CoQ and IR (<xref rid="fig3" ref-type="fig">Fig. 3</xref>). These findings align with our earlier observations demonstrating that mice exposed to HFHSD exhibit mitochondrial CoQ depletion in skeletal muscle <sup><xref ref-type="bibr" rid="c6">6</xref></sup>. Given that CoQ supplementation is sufficient to overcome ceramide induced-IR (<xref rid="fig1" ref-type="fig">Fig. 1</xref> &amp; <xref ref-type="fig" rid="fig2">2</xref>), but a reduction of mitochondrial ceramide does not overcome a loss of CoQ (<xref rid="fig3" ref-type="fig">Fig. 3</xref>), our data support a pathway whereby an increase in mitochondrial ceramides precedes loss of CoQ. Interestingly, inhibition of CoQ synthesis also increased ceramides, suggesting a bidirectionality to the ceramide-CoQ nexus. That said, this effect was modest (<xref rid="fig1" ref-type="fig">Fig. 1</xref>) and we cannot exclude off target effects of the inhibitor. It is possible that CoQ directly controls ceramide turnover<sup><xref ref-type="bibr" rid="c34">34</xref></sup> or alternatively that CoQ inside mitochondria is necessary for fatty acid oxidation<sup><xref ref-type="bibr" rid="c12">12</xref></sup> and CoQ depletion triggers lipid overload in the cytoplasm promoting ceramide production<sup><xref ref-type="bibr" rid="c35">35</xref></sup>. Further studies will be needed to determine how CoQ depletion promotes ceramide accumulation.</p>
<p>Our proteomics analysis revealed that the loss of CoQ parallels a loss of mitochondrial ETC complexes CI, CIII and CIV. These are known to form supercomplexes or respirasomes where ∼25 - 35 % of CoQ is localised in mammals <sup><xref ref-type="bibr" rid="c57">57</xref>,<xref ref-type="bibr" rid="c16">16</xref></sup>. This bulk downregulation of the respirasome induced by ceramides may lead to CoQ depletion. The observation that both palmitate and SMPD5 overexpression trigger CoQ depletion without additive effects support the notion that ceramides may trigger the depletion of a specific CoQ9 pool localised within the inner mitochondrial membrane. Despite the significant impact of ceramide on mitochondrial respiration, we did not observe any indications of cell damage in any of the treatments, suggesting that our models are not explained by toxicity and increased cell death (<xref ref-type="fig" rid="figs2">Sup. Fig. 2H</xref> &amp; <xref ref-type="fig" rid="figs2">J</xref>). Whilst the physiological role of respirasomes is still a subject of discussion, it has been suggested that they may enhance energy generation by optimising electron flow while reducing production of ROS<sup><xref ref-type="bibr" rid="c58">58</xref>,<xref ref-type="bibr" rid="c59">59</xref></sup> and therefore their loss can be predicted to increase ROS generation. The 2 major mechanisms that might account for the loss of the respirasomes are decreased synthesis or increased degradation. Proteomics data suggests no deficiency in the OXPHOS biosynthetic machinery or assembly proteins and an increase in the machinery for protein import (<xref rid="fig4" ref-type="fig">Fig. 4</xref>). In addition, the absence of mRNA downregulation in mtSMPD5 overexpressing cells strongly suggests that at least a portion of the observed protein depletion within CI is attributed to diminished protein stability. It therefore seems reasonable to speculate that the loss of these mitochondrial complexes is driven by increased degradation. Interestingly, pharmacological CIII inhibition leads to respirasome degradation via oxidative stress produced by reverse electron transfer (RET)<sup><xref ref-type="bibr" rid="c60">60</xref></sup>. Since ceramides can directly inhibit CIII<sup><xref ref-type="bibr" rid="c61">61</xref></sup> it is possible that a similar mechanism mediates the effect of ceramides on the respirasome (<xref rid="fig5" ref-type="fig">Fig. 5</xref>). This suggests that defective respirasome activity (e.g. induced by ceramides) triggers ROS, which over time depletes respirasome subunits and a stoichiometric CoQ depletion, leading to further ROS production as a consequence. Another possibility is that, because of its highly hydrophobic nature, ceramides impact membrane fluidity promoting a gel/fluid phase transition<sup><xref ref-type="bibr" rid="c62">62</xref></sup>. These alterations in membrane fluidity could decrease respirasome stability. It is likely that bound lipids stabilise the interactions between the complexes in the respirasome and that this is impaired by ceramides. In fact, bound lipid molecules are observed in the structure of the porcine respirasome<sup><xref ref-type="bibr" rid="c63">63</xref></sup> and the isolated bovine CI<sup><xref ref-type="bibr" rid="c63">63</xref></sup> but none of the lipids identified thus far directly bridge different complexes. In order to understand the role of lipids in stabilising respirasomes and the role of ceramides in such stabilisation, higher-resolution structures will be required<sup><xref ref-type="bibr" rid="c64">64</xref></sup>.</p>
<p>The current studies pose a number of key unanswered questions. First, how does ceramide accumulate in mitochondria in insulin resistance? This could involve transfer from a different subcellular compartment<sup><xref ref-type="bibr" rid="c65">65</xref>,<xref ref-type="bibr" rid="c66">66</xref></sup> or <italic>in situ</italic> mitochondrial ceramide synthesis. Consistent with the latter, previous studies have suggested that various enzymes involved in ceramide metabolism are specifically found in mitochondria<sup><xref ref-type="bibr" rid="c41">41</xref>,<xref ref-type="bibr" rid="c67">67</xref>–<xref ref-type="bibr" rid="c71">71</xref></sup>. Notably, CerS1-derived ceramide induces insulin-resistance in skeletal muscle<sup><xref ref-type="bibr" rid="c72">72</xref></sup>. Although this enzyme has not been reported as a mitochondrial protein, it can be transferred from the endoplasmic reticulum surface to the mitochondria under cellular stress in metabolically active tissues such as muscle and brain<sup><xref ref-type="bibr" rid="c73">73</xref></sup>. This provides a potential mechanism where cellular stress, like nutrient overload, may induce transfer of CerS1 to mitochondria, increasing mitochondrial ceramide to trigger insulin resistance.</p>
<p>A further question is how ceramide regulates insulin sensitivity. We present evidence that mitochondrial dysfunction precedes insulin resistance. However, previous studies have failed to observe changes in mitochondrial morphology, respiration or ETC components during early stages of insulin resistance<sup><xref ref-type="bibr" rid="c22">22</xref>,<xref ref-type="bibr" rid="c74">74</xref></sup>. However, in many cases such studies fail to document changes in insulin-dependent glucose metabolism in the same tissue as was used for assessment of mitochondrial function. This is crucial because we and others do not observe impaired insulin action in all muscles from high fat fed mice for example <sup><xref ref-type="bibr" rid="c6">6</xref>,<xref ref-type="bibr" rid="c9">9</xref></sup>. In addition, surrogate measures such as insulin-stimulated Akt phosphorylation may not accurately reflect tissue specific insulin action as demonstrated in <xref rid="fig1" ref-type="fig">figure 1C</xref>. Thus, further work is required to clarify some of these inconsistencies. We observed that mitochondrial ceramides were associated with the loss of CoQ, increased production of mitochondrial ROS and impaired mitochondrial respiration<sup><xref ref-type="bibr" rid="c6">6</xref>,<xref ref-type="bibr" rid="c9">9</xref>,<xref ref-type="bibr" rid="c10">10</xref></sup>. As we discussed above, this is likely a direct result of respirasome depletion. The molecular linkage between ROS production and IR remains unknown. Early studies suggested that ceramides and ROS impaired canonical insulin signalling<sup><xref ref-type="bibr" rid="c24">24</xref>–<xref ref-type="bibr" rid="c26">26</xref></sup>, however, our current data do not support this, with the caveat that these were static signalling measures. One possibility is the release of a signalling molecule from the mitochondria that impairs insulin action<sup><xref ref-type="bibr" rid="c75">75</xref></sup>. The mitochondrial permeability transition pore (mPTP) is an attractive candidate for this release since its activity is increased by mitochondrial ROS<sup><xref ref-type="bibr" rid="c76">76</xref></sup> and ceramides<sup><xref ref-type="bibr" rid="c77">77</xref></sup>. It has been shown that mPTP inhibition protects against insulin resistance in either palmitate- or ceramide-induced L6-myotubes and mice on a high-fat diet<sup><xref ref-type="bibr" rid="c78">78</xref></sup>. Furthermore, mPTP deletion in the liver protects against liver steatosis and insulin resistance in mice<sup><xref ref-type="bibr" rid="c79">79</xref></sup>. Strikingly, CoQ is an antioxidant and also an inhibitor of mPTP suggesting that part of the protective mechanism of CoQ may involve the mPTP<sup><xref ref-type="bibr" rid="c80">80</xref></sup>. Because CoQ can accumulate in various intracellular compartments, it’s important to consider that its impact on insulin resistance might be due to its overall antioxidant properties rather than being limited to a mitochondrial effect. Excitingly, mtSMPD5 increased the abundance of mPTP associated proteins suggesting a role of this pore in ceramide induced insulin resistance (<xref ref-type="fig" rid="figs6">Sup. Fig. 6E</xref>). It is also possible that ceramides generated within mitochondria in SMPD5 cells leak out from the mitochondria into other membranes (e.g. PM and GLUT4vesicles) affecting other aspects of GLUT4 trafficking and insulin action. However, the observation that ASAH1 overexpression reversed IR without affecting whole cell ceramides argues against this possibility.</p>
<p>Ultimately, the significant challenge for the field is the discovery of the unknown factor(s) released from mitochondria that cause insulin resistance, their molecular target(s), and the transduction mechanism(s).</p>
<p>The observations described above led us to speculate on whether there is a teleological reason for why these mitochondrial perturbations occur and why they drive insulin resistance? Under conditions of stress, nutrient incorporation into the cell needs to be adjusted to keep the balance between energy supply and utilisation. In situations where the mitochondrial respirasome is depleted, the mitochondria’s ability to oxidise nutrients can be easily overwhelmed without a corresponding reduction in nutrient uptake. In this scenario, insulin resistance may be a protective mechanism to prevent mitochondrial nutrient oversupply<sup><xref ref-type="bibr" rid="c9">9</xref></sup>. Beyond nutrient uptake, the respirasome depletion could also affect the ability of the mitochondria to switch between different energy substrates depending on fuel availability, named “metabolic Inflexibility”<sup><xref ref-type="bibr" rid="c81">81</xref></sup> this mechanism may potentially play a role in the ectopic lipid accumulation seen in individuals with obesity, a condition linked with cardio-metabolic disease.</p>
<p>In summary, our results provide evidence for the existence of a mechanism inside mitochondria connecting ceramides, mitochondrial respiratory complexes, CoQ and mitochondrial dysfunction as part of a core pathway leading to insulin resistance. We identified that CoQ depletion links ceramides with insulin resistance and define the respirasome as a critical connection between ceramides and mitochondrial dysfunction. While many pieces of the puzzle remain to be solved, identifying the temporal link between ceramide, mitochondrial dysfunction and CoQ in mitochondria is an important step forward in understanding insulin resistance and other human diseases affecting mitochondrial function.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>This work was supported by National Health and Medical Research Council (NHMRC) Project Grants: GNT1120201 and GNT1061122 to D.E.J.; GNT2013621 to J.G.B, D.E.J. and A.D.V; and GNT112613 to N.T., J.M. and A.D. B.C.B received a research grant from Eli Lilly and from NIH R01DK111559. D.E.J. is an Australian Research Council (ARC) Laureate Fellow. J.G.B and A.D.V. were supported by the Diabetes Australian Research Program (Y22G-DIAA) and the Mitochondrial Foundation (Mitofoundation, G057). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NHMRC or ARC. The authors also acknowledge the facilities, and the scientific and technical assistance of Sydney Cytometry and the Sydney Mass Spectrometry Facility, at the Charles Perkins Centre, University of Sydney. The authors are extremely grateful to Scott A. Summers, William L. Holland and Navdeep S Chandel for their thoughtful discussion of the project.</p>
</ack>
<sec id="s4">
<title>Author contributions</title>
<p>Conceptualization; A.D.V., J.G.B., B.C.B, J.T.B., and D.E.J. Formal analysis; A.D.V., J.G.B., A.D., J.K. Investigation; A.D.V., K.C.C., J.G.B., J.K. Methodology; A.D.V., J.G.B., K.C.C., L.C., J.K., N.T., X.Y.L., J.M., A.D., A.G., S.Z., K.A.Z.B., A.R., B.C.B., S.M., M.A.A., and J.T.B. Writing – original draft; A.D.V, J.G.B. and D.E.J. Writing - review &amp; editing; all authors.</p>
</sec>
<sec id="s5">
<title>Declaration of interests</title>
<p>The authors declare that they have no conflict of interest.</p>
</sec>
<sec id="s11">
<title>Supplementary Figures</title>
<fig id="figs1" position="float" orientation="portrait" fig-type="figure">
<label>Figure S1</label>
<caption><p>A) Mitochondrial enriched fraction from L6-myotubes. Calnexin was used as a marker of endoplasmic reticulum. OXPHOS: oxidative phosphorylation system. Cholesterol (B), Diacylglycerol (DAGs) (C), Sphingosine-1 phosphate (S1P) (D), and Sphingosine (SPH) (E) abundance in L6 myotubes exposed to different compounds (as indicated). Lipid abundance was determined by lipidomics and normalised against protein concentration. N = 4, Mean ± S.E.M. ***p&lt; 0.001, ****p&lt; 0.0001. F) Concentration of endogenous ceramide in L6-HA-GLUT4 myotubes treated for 24 h with EtOH (control) or different concentrations of Saclac. N = 3, mean ± S.E.M. *p&lt;0.05. **p&lt; 0.01, ****p&lt; 0.0001. G-H) L6-HA-GLUT4 myotubes were serum-starved after EtOH (Control) or Saclac (10 μM) treatment (for 24 h) and acute insulin (Ins) was added where indicated. Phosphorylation status of indicated sites was assessed by immunoblot. Immunoblots were quantified by densitometry and normalised to insulin-treated control cells. N = 2, mean ± S.E.M.</p></caption>
<graphic xlink:href="532020v2_figs1.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs2" position="float" orientation="portrait" fig-type="figure">
<label>Figure S2</label>
<caption><p>(A and B) Total (A) and specific (B) ceramide species quantified in HeLa cells treated for 24 h with Saclac (2uM for 24 h) or vehicle control (EtOH, Control) as indicated. N = 4, mean ± S.E.M. **p&lt; 0.01, ****p&lt; 0.0001 vs control C) CoQ10 levels in the mitochondrial fraction obtained from HeLa cells exposed to different concentrations of Saclac or vehicle control. N = 4, mean ± S.E.M. *p&lt;0.05 D) CoQ10 levels in the mitochondrial fraction obtained from HeLa cells exposed to different concentrations of Saclac (2 μM for 24 h) or control in presence or absence of myriocin (10 μM for 16 h). N = 4, mean ± S.E.M. *p&lt;0.05. E-G) Mitochondrial abundance markers determined by Western Blot in HeLA cells exposed to 2 uM of Saclac for 24 h. F - G) Immunoblots were quantified by densitometry and normalised to control cells. N = 3, Mean ± S.E.M H) Percentage of non-viable HeLa cells determined by propidium iodide (PI) staining and microscopy, following a 24 h treatment with Saclac. N = 3, mean ± S.E.M. **p&lt;0.01. I) specific diacylglycerol species were quantified in HeLA cells exposed to Saclac vs control. Lipid abundance was determined by lipidomics and normalised against protein concentration. N = 4, Mean ± S.E.M. *p&lt; 0.001, ****p&lt; 0.0001. J) L6 myotubes were loaded with TMRE (20 nM) for 20 min in control cells, SMPD5 overexpressing cells and cells treated with Saclac (50 uM) for 24 h.</p></caption>
<graphic xlink:href="532020v2_figs2.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs3" position="float" orientation="portrait" fig-type="figure">
<label>Figure S3</label>
<caption><p>A) Total ceramide levels extracted from whole lysate of L6-myotubes exposed to different treatments (as indicated). B-C) Densitometric analysis of <xref rid="fig3" ref-type="fig">Figure 3F</xref> of selected proteins (As indicated). Mitochondrial levels of cardiolipin (D), cholesterol (E), Sphingosine (F), sphingomyelin (G), Sphingosine-1 phosphate (H) and diacylglycerol (I - J) (as indicated) were determined by lipidomics and normalised against mitochondrial protein concentration. Cells were exposed to doxycycline for 3 d for SMPD5 induction. N= 3, Mean ± S.E.M. ****p&lt; 0.0001.</p></caption>
<graphic xlink:href="532020v2_figs3.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs4" position="float" orientation="portrait" fig-type="figure">
<label>Figure S4</label>
<caption><p>A) Total ceramide levels extracted from whole lysate of L6-myotubes exposed to different treatments (as indicated). B-C) Densitometric analysis of <xref rid="fig3" ref-type="fig">Figure 3F</xref> of selected proteins (As indicated). Mitochondrial levels of cardiolipin (D), cholesterol (E), Sphingosine (F), sphingomyelin (G), Sphingosine-1 phosphate (H) and diacylglycerol (I - J) (as indicated) were determined by lipidomics and normalised against mitochondrial protein concentration. Cells were exposed to doxycycline for 3 d for ASAH1 induction. N= 3, Mean ± S.E.M. *p&lt;0.05, **p&lt;0.01, ****p&lt; 0.0001. K) Insulin-induced glycogen synthesis. L6-myotubes were exposed to different treatments (as indicated) and glycogen storage was measured by 14-C glucose (as indicated in material and method section). Data is expressed as a percentage of increased 14-glycogen after insulin stimulation relative to control cells. N = 4, mean ± S.E.M. *p&lt;0.05. H-I) Total ceramides (H) and mitochondrial CoQ levels (I) in skeletal muscle from mice exposed to a high-fat diet and exposed to either vehicle (DMSO) or the inhibitor of CerS1 P053 (5 mg/Kg) in drinking water for 6 wks as described in <sup><xref ref-type="bibr" rid="c45">45</xref></sup>. N = 6, mean ± S.E.M. *p&lt;0.05, *** p&lt;0.001 vs control.</p></caption>
<graphic xlink:href="532020v2_figs4.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs5" position="float" orientation="portrait" fig-type="figure">
<label>Figure S5</label>
<caption><p>A) Body weight of mice exposed to either vehicle (DMSO) or the inhibitor of CerS1 P053 (5 mg/Kg) in drinking water for 6 wk. B) Ceramide, C) Sphingomyelin and D) Diacylglycerol species were determined in skeletal muscle by lipidomics and normalised against mg of tissue. N= 6, Mean ± S.E.M. *p&lt;0.05, ****p&lt; 0.0001.</p></caption>
<graphic xlink:href="532020v2_figs5.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs6" position="float" orientation="portrait" fig-type="figure">
<label>Figure S6</label>
<caption><p>A) L6-myotubes were exposed to doxycycline for different times to promote mtSMPD5 overexpression. The Immunoblot of Flag is shown in A. B) Violin plot of proteomic data after median normalised. C - I) Summed intensities of protein, subunits associated with a specific process as denoted on top of each graph. N = 4 ± S.E.M. J) L6-myotubes were exposed to doxycycline to promote mtSMPD5 overexpression. The Immunoblot of Flag is shown in the left panel. mRNA levels for different complex I subunits were determined by RT-PCR and normalised against beta actin N = 4 ± S.D.</p></caption>
<graphic xlink:href="532020v2_figs6.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs7" position="float" orientation="portrait" fig-type="figure">
<label>Figure S7</label>
<caption><p>A) Box plot of all proteomics samples before (top) and after (bottom) median normalisation. B) Pairwise comparisons of mitochondrial proteome between all four groups. C) Proteins rank against rate glucose disappearance during clamp (Rd) correlation. Proteins within complex IV and V of the electron transport chain associate with Rd. D) Association of proteins within Complex II, III, small and large ribosomal subunits with Rd.</p></caption>
<graphic xlink:href="532020v2_figs7.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
<fig id="figs8" position="float" orientation="portrait" fig-type="figure">
<label>Supplementary figure 8</label>
<graphic xlink:href="532020v2_figs8.tif" mimetype="image" mime-subtype="tiff"/>
</fig>
</sec>
<sec id="s6">
<title>Lead contact</title>
<p>Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, David James (<email>David.james@sydney.edu.au</email>) or James Burchfield (<email>James.burchfield@sydney.edu.au</email>)</p>
</sec>
<sec id="s7">
<title>Materials availability</title>
<p>This study generated two new molecular tools to overexpress mitochondria targeted SMPD5 and ASAH1. The plasmids are available upon request.</p>
</sec>
<sec id="s8">
<title>Data availability</title>
<p>All Lipidomic analyses are available as supplementary information.</p>
</sec>
<sec id="s9">
<title>Experimental model</title>
<sec id="s9a">
<title>Administration of P053 to mice</title>
<p>Mice of the C57BL6/J strain were obtained from the Animal Resources Centre of Perth (WA, Australia). Mice were housed in a controlled 12:12 h light-dark cycle, and they had ad libitum access to water and food. The oral gavage administration of P053 (5 mg/kg) was performed daily, while the control animals received vehicle (2% DMSO). The experiments were approved by the UNSW animal care and ethics committee (ACEC 15/48B), and followed guidelines issued by the National Health and Medical Research Council of Australia.</p>
</sec>
<sec id="s9b">
<title>Cell lines</title>
<p>Mycoplasma-free L6 myotubes overexpressing HA-GLUT4 and HeLa cell lines were used for all in vitro experiments (detailed below each legend). HA-GLUT4 overexpression is essential for studying insulin sensitivity in vitro as we previously described<sup><xref ref-type="bibr" rid="c9">9</xref></sup>. L6-myoblast and HeLa cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) (Gibco by Life Technologies) supplemented with 10% foetal bovine serum (FBS) (v/v) (Gibco by Life Technologies) and 2 mM Glutamax (Gibco by Life Technologies) at 37 °C and 10% CO2. L6 myoblasts were differentiated in DMEM/Glutamax/2% Horse serum as previously described<sup><xref ref-type="bibr" rid="c9">9</xref></sup>. The media was replaced every 48 h for 6 d. For induction of SMPD5 or ASAH1, L6 myotubes were incubated with doxycycline from day 3 until day 6 after the initiation of differentiation. L6-myotubes were used day 7 after the initiation of differentiation. At least 90 % of the cells were differentiated prior to experiments.</p>
</sec>
</sec>
<sec id="s10">
<title>Method details</title>
<sec id="s10a">
<title>Lentiviral transduction</title>
<p>Lentivirus was made by transfecting LentiX-293T (Takara Bio) cells with Lenti-X Packaging Single Shot (Takara Bio) with one of the following plasmids pLVX-Tet3G, pLVX-TRE3G-SMPD5-Myc-DDK or pLVX-TRE3G-ASAH-Myc-DDK according to the manufacturer’s specifications. Virus containing media was collected from the LentiX-293T cells and concentrated using Lenti-X Concentrator (Takara Bio). pLVX-Tet3G virus and polybrene was added to L6-myoblast cells and cells were positively selected using neomycin to create Tet3G expressing cells. The Tet3G expressing L6 cells then were subsequently infected with polybrene and either the pLVX-TRE3G-SMPD5-Myc-DDK or pLVX-TRE3G-ASAH-Myc-DDK virus. Cells were selected using puromycin to create a Tet-inducible SMPD5-Myc-Flag-DDK or ASAH-Myc-Flag-DDK L6 cell line.</p>
</sec>
<sec id="s10b">
<title>Lipid extraction</title>
<p>Two-phase extraction of lipids from frozen tissue samples (20 mg) or cells was carried out using the methyl-tert-butyl ether (MTBE)/methanol/water (10:3:2.5, v/v/v) method(Matyash et al., 2008). Frozen tissue samples (∼20 mg) were homogenised in 0.2 mL methanol (0.01% butylated hydroxytoluene, BHT) using a Precellys 24 homogenizer and Cryolys cooling unit (Betin Technologies) with CK14 (1.4-mm ceramide) beads. HeLa cells and L6-myotubes were washed with PBS and scraped into 0.6 mL of ice-cold methanol(Turner et al., 2018). Mitochondrial pellets were washed twice to remove BSA from the fraction (see below), and 30 ug of mitochondrial protein was used for extraction. The homogenates were spiked with an internal standard mixture (2 nmole of 18:1/15:0 d5-diacylglycerol and 18:1/17:0 SM, 4 nmole 14:0/14:0/14:0/14:0 cardiolipin, 5 nmole d7-cholesterol, 500 pmole 18:1/17:0 ceramide, and 200 pmole d17:1 sphingosine and d17:1 S1P), then transferred to 10 mL screw cap glass tubes. MTBE (1.7 mL) was added and the samples were sonicated for 30 min in an ice-cold sonicating water bath (Thermoline Scientific, Australia). Phase separation was induced by adding 417 µL of mass spectrometry-grade water with vortexing (max speed for 30 sec), then centrifugation (1000 x g for 10 min). The upper organic phase was transferred into 5 mL glass tubes. The aqueous phase was re-extracted 3 times (MTBE/methanol/water 10:3:2.5), combining the organic phase in the 5 mL glass tube. The organic phase was dried under vacuum in a Savant SC210 SpeedVac (Thermo Scientific). Dried lipids were resuspended in 500 μL of 80% MeOH/ 0.2 % formic acid / 2mM ammonium formate and stored at −20°C until analysis.</p>
</sec>
<sec id="s10c">
<title>Lipid quantification</title>
<p>Lipids were quantified by selected reaction monitoring on a TSQ Altis triple quadrupole mass spectrometer coupled to a Vanquish HPLC system (ThermoFisher Scientific). Lipids were separated on a 2.1 100 mm Waters Acquity UPLC C18 column (1.7 µM pore size) using a flow rate of 0.28 mL/min. Mobile phase A was 0.1% formic acid, 10 mM ammonium formate in 60% acetonitrile/40% water. Mobile phase B was 0.1% formic acid and 10mM ammonium formate in 90% isopropanol/10% acetonitrile. Total run time was 25 min, starting at 20% B and holding for 3 min, increasing to 100% B from 3-14 min, holding at 100% from 14-20 min, returning to 20% B at 20.5 min, and holding at 20% B for a further 4.5 min. Ceramides, sphingomyelin, sphingosine, and sphingosine 1-phosphate were identified as the [M+H]+ precursor ion, with m/z 262.3 (sphinganine), 264.3 (sphingosine), or 266.3 (sphinganine) product ion, and m/z 184.1 product ion in the case of sphingomyelin. Diacylglycerols (DAGs) were identified as the [M+NH4]+ precursor ion and product ion corresponding to neutral loss of a fatty acid + NH3. Cardiolipins were identified as the [M+H]+ precursor ion and product ion corresponding to neutral loss of a DAG. Cholesterol was detected using precursor m/z 369.4 and product m/z 161.1. TraceFinder software (ThermoFisher) was used for peak alignment and integration. The amount of each lipid was determined relative to its class-specific internal standard. Lipidomic profiling of skeletal muscle tissue was performed exactly as described (Turner et al, 2018).</p>
</sec>
<sec id="s10d">
<title>Mass spectrometry sample preparation</title>
<p>Isolated mitochondria were defrosted and centrifuged at 4 °C at 4,000 x g for 15 min, and supernatant was removed. The mitochondrial pellet was resuspended in 100 uL 2 % SDC in Tris-HCl buffer (100 mM; pH 8.0) and the protein concentration determined by BCA assay. 10 ug of each sample was aliquoted and volume adjusted to 50 uL with milli-Q water, and samples were reduced and alkylated by addition of TCEP and CAA (10 and 40 mM respectively) at 60 °C for 20 minutes. Once cooled to room temperature, 0.4 ug MS grade trypsin and Lys-C were added to each sample, and proteins were digested overnight (16 h) at 37 °C. Peptides were prepared for MS analysis by SDB-RPS stage tips. 2 layers of SDB-RPS material was packed into 200 µL tips and washed by centrifugation of StageTips at 1,000 x g for 2 min in a 96-well adaptor with 50 µL acetonitrile followed by 0.2% TFA in 30% methanol and then 0.2% TFA in water. 50 µL of samples were loaded to StageTips by centrifugation at 1,000 g for 3 min. Stage tips were washed with subsequent spins at 1,000 g for 3 min with 50 uL 1% TFA in ethyl acetate, then 1% TFA in isopropanol, and 0.2% TFA in 5% ACN. Samples were eluted by addition of 60 µL 60% ACN with 5% NH4OH4. Samples were dried by vacuum centrifugation and reconstituted in 30 µL 0.1% TFA in 2% ACN.</p>
</sec>
<sec id="s10e">
<title>Mass spectrometry acquisition and analysis</title>
<p>Samples were analysed using a Dionex UltiMate™ 3000 RSLCnano LC coupled to a Exploris Orbitrap mass spectrometer. 3 µL of peptide sample was injected onto an in-house packed 75 μm × 40 cm column (1.9 μm particle size, ReproSil Pur C18-AQ) and separated using a gradient elution, with Buffer A consisting of 0.1 % formic acid in water and Buffer B consisting of 0.1% formic acid in 80% ACN. Samples were loaded to the column at a flow rate 0.5 µL min-1 at 3% B for 14 min, before dropping to 0.3 µL min-1 over 1 min and subsequent ramping to 30% B over 110 min, then to 60% B over 5 min and 98% B over 3 min and held for 6 min, before dropping to 50% and increasing flow rate to 0.5 µL min-1 over 1 min. Eluting peptides were ionised by electrospray with a spray voltage of 2.3 kV and a transfer capillary temperature of 300°C. Mass spectra were collected using a DIA method with varying isolation width windows (widths of m/z 22-589) between 350 - 1650 according to Supplementary Table 1. MS1 spectra were collected between m/z 350 - 1650 m/z at a resolution of 60,000. Ions were fragmented with an HCD collision energy at 30% and MS2 spectra collected between m/z 300-2000 at resolution of 30,000, with an AGC target of 3e5 and the maximum injection time set to automatic. Raw data files were searched using DIA-NN using library generated from a 16-fraction high pH reverse phase library<sup><xref ref-type="bibr" rid="c83">83</xref></sup>. The protease was set to Trypsin/P with 1 missed cleavage, N-term M excision, carbamidomethylation and M oxidation options on. Peptide length was set to 7-30, precursor range 350-1650, and fragment range 300-2000, and FDR set to 1%.</p>
</sec>
<sec id="s10f">
<title>Statistical Analysis of L6 mitochondrial proteome</title>
<p>Mouse MitoCarta(REF) was mapped to Rattus norvegicus proteins using OrthoDB identifiers downloaded from Uniprot. The Rat MitoCarta was used to annotate the L6 proteome. Manual scanning of the annotation revealed a number of known mitochondrial proteins not captured using this approach. Proteins were therefore classified as mitochondria if they were annotated by our mouse:rat Mitocarta (380 proteins), contained “mitochondrial” in the protein name (78 additional proteins; 231 overlap with mitocarta) or if the first entry under Uniprot “Subcellular location” was mitochondria (97 additional proteins; 374 overlap with Mitocarta or protein name). LFQ intensities were Log 2 transformed and normalised to the median of the mitochondrially annotated proteins. Identification of differentially regulated proteins was performed using moderated t-tests<sup><xref ref-type="bibr" rid="c84">84</xref></sup>. Functional enrichment was performed using the STRING web-based platform<sup><xref ref-type="bibr" rid="c85">85</xref></sup>.</p>
</sec>
<sec id="s10g">
<title>Statistical Analysis of human proteome and mito-ER lipidome</title>
<p>Analysis of the human proteome and mito-ER lipidome were performed with R (version 4.2.1). Identification of differentially regulated proteins between each group were performed using the R package limma<sup><xref ref-type="bibr" rid="c86">86</xref></sup> and p-values were corrected with p.adjust (method = “fdr”) within each comparison. Correlations were calculated with biweight midcorrelations from the R package WGCNA<sup><xref ref-type="bibr" rid="c87">87</xref></sup>. Gene set enrichment was performed with the R package clusterProfiler<sup><xref ref-type="bibr" rid="c88">88</xref></sup> utilising pathways from Reactome for differentially regulated proteins<sup><xref ref-type="bibr" rid="c89">89</xref></sup>. Custom mitochondrial genes were constructed from HGNC Database<sup><xref ref-type="bibr" rid="c90">90</xref></sup> and enrichment and enrichment figures were done with the R package fgsa (<ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/060012v3">https://www.biorxiv.org/content/10.1101/060012v3</ext-link>).</p>
</sec>
<sec id="s10h">
<title>High pH reverse phase fractionation and library generation</title>
<p>A pooled sample was made by combining 1 uL of each sample and fractionated by high pH reverse phase liquid chromatography. 50 uL of pooled sample was injected onto a Waters XBridge Peptide BEH C18 column (4.6 x 250 mm, 130 Å, 3.5 um) using a ThermoScientific UltiMate 3000 BioRS System and peptides separated using gradient elution at 1 mL min-1, with the column oven set to 30 °C. Buffer A consisted of 10 mM ammonium formate, and Buffer B consisted of 10 mM ammonium formate in 80 % acetonitrile, which both adjusted to pH 9.0 with ammonium hydroxide. Initially Buffer B was set to 10 % and ramped up to 40 % over 11 minutes, before ramping up to 100 % B over 1 minute and held for 5 min before returning to 10 % for re-equilibration. Peptides were separated into 64 fractions collected between 3.45 min to 14.5 min, and samples were concatenated into 16 final fractions. Fractions were dried using a GeneVac 2.0 vacuum centrifuge using the HPLC program, with a max temperature of 60 °C. Fractions were resuspended in 10 uL 0.1% TFA in 2% ACN and 2 uL was injected and separated as described for DIA samples above, however, MS was acquired in a DDA manner. An MS1 was collected between m/z 350-1650 with a resolution of 60,000. The top 15 most intense precursors were selected from fragmentation with an isolation window of 1.4 m/z, resolution of 15,000, HCD collision energy of 30 %, with an exclusion window of 30 s. Raw files were searched with MaxQuant against a FASTA file containing the reviewed UniProt human proteome (downloaded May 2020).</p>
</sec>
<sec id="s10i">
<title>Matrigel-coated plates</title>
<p>Matrigel diluted 1:100 v/v in ice-cold PBS was dispensed into 96-well plates (Eppendorf Cell Imaging plate, UNSPSC 41122107; and Perkin Elmer Cell Carrier Ultra, Cat# 6055300) and incubated for 2 h at room temperature. Before use, plates were washed twice in PBS at room temperature.</p>
</sec>
<sec id="s10j">
<title>HA-GLUT4 assay</title>
<p>HA-GLUT4 levels on the plasma membrane were determined as previously described<sup><xref ref-type="bibr" rid="c9">9</xref>,<xref ref-type="bibr" rid="c91">91</xref></sup>. L6-myotubes stably overexpressing HA-Glut4 were washed twice with warm PBS and serum-starved for two hours (in DMEM/0.2% BSA/GlutaMAX/with 220 mM bicarbonate (pH 7.4) at 37 °C, 10 % CO2). Cells were then stimulated with insulin for twenty minutes, after which the cells were placed on ice and washed three times with ice cold PBS. Cells were blocked with ice cold 10 % horse serum in PBS for 20 min, fixed with 4 % paraformaldehyde (PFA) for 5 min on ice and 20 min at room temperature. PFA was quenched with 50 mM glycine in PBS for 5 min at room temperature. We measured the accessibility of the HA epitope to an anti-HA antibody (Covance, 16B12) for 1 h at room temperature. Cells were then incubated with 20 mg/mL goat anti-mouse Alexa-488-conjugated secondary antibody (Thermo Fisher Scientific) for 45 min at room temperature. The determination of total HA-GLUT4 was performed in a separate set of cells following permeabilization with 0.01% saponin (w/v) and anti-HA staining (as above). Each experimental treatment group had its own total HA-GLUT4. A FLuostar Galaxy microplate reader (BMG LABTECH) was used to measure fluorescence (excitation 485 nm/emission 520 nm). Surface HA-GLUT4 was expressed as a fold over control insulin condition.</p>
</sec>
<sec id="s10k">
<title>Induction of insulin resistance</title>
<p>To promote insulin resistance, cells were stimulated for 16 h with 150 μM palmitate-BSA or EtOH-BSA as control. The palmitate was complexed with BSA as previously described<sup><xref ref-type="bibr" rid="c9">9</xref></sup>. Briefly, fatty acid was dissolved in 50% ethanol and then diluted 25 times in 10.5 % fatty acid free BSA solution. These stock solutions were further diluted in culture media to reach a final concentration of 150 μM (Final lipid:BSA ratio 4:1).</p>
</sec>
<sec id="s10l">
<title>Glycogen synthesis assay</title>
<p>L6 myotubes overexpressing ASAH were grown and differentiated in 12-well plates, as described in the Cell lines section, and stimulated for 16 h with palmitate-BSA or EtOH-BSA, as detailed in the Induction of insulin resistance section.</p>
<p>On day seven of differentiation, myotubes were serum starved in plain DMEM for 3 and a half hours. After incubation for 1 hour at 37 °C with 2 µCi/ml D-[U-14C]-glucose in the presence or absence of 100 nM insulin, glycogen synthesis assay was performed, as previously described <sup><xref ref-type="bibr" rid="c92">92</xref></sup></p>
</sec>
<sec id="s10m">
<title>Coenzyme Q determination</title>
<p>CoQ9 and CoQ10 content in cell lysates and mitochondrial fractions were determined as described previously(Burger et al., 2020). Aliquots of 15 µg mitochondrial protein as prepared below were adjusted to a volume of 100 µL with water and subsequently mixed with 250 μL ice-cold methanol containing 0.1% HCl, 20 µL internal standard (CoQ8, 200 pmol in hexane, Avanti Polar Lipids) and 300 μL of hexane. The mixture was vortexed for 30 sec, centrifuged (9,000 g x 5 min) and the supernatant was transferred into deepwell plate 96/1000 uL (Cat. numb. 951032905). Samples were dried using a rotary evaporator (GeneVac, low BP at 45 °C for 40 min). The resulting dried lipids were re-dissolved in 100 uL of 100 % EtOH (HPLC grade), transferred into HPLC vials and stored at −20 °C until analysis by LC/MS.</p>
<p>LC-MS/MS was performed on a Vanquish LC (ThermoFisher) coupled to a TSQ Altis triple quadrupole mass spectrometer (Thermo Fisher Scientific). Samples were kept at in the autosampler at 4 °C and 15 µL was injected on onto column (50 x 2.1 mm, Kinetex 2.6 μm XB-X18 100 A) at 45 °C, and CoQ8, CoQ9 and CoQ10 were separated by gradient elution using mobile phase A (2.5 mM ammonium formate in 95:5 methanol:isopropanol) and mobile phase B (2.5 mM ammonium formate in 100% isopropanol) at 0.8 mL/min. An initial concentration of 0 % B was held for 1 min before increasing to 45 % B over 1 min and held for 1 min, before decreasing back to 0 % B over 0.5 min and column re-equilibrated over 1.5 min. Under these conditions, CoQ8 eluted at 1.0 min, CoQ9 at 1.6 min and CoQ10 at 2.0 min. Eluent was then directed into the QqQ with a source voltage of 3.5 kV, sheath gas set to 2, auxiliary gas set to 2, and a transfer capillary temperature of 350 °C Ammonium adducts of each of the analytes were detected by SRM with Q1 and Q3 resolution set to 0.7 FWHM with the following parameters: [CoQ8+NH4]+, m/z 744.9 ® 197.1 with collision energy 32.76; [CoQ9+NH4]+, m/z 812.9®197.1 with collision energy 32.76; [CoQ9H2+NH4]+, m/z 814.9®197.1 with collision energy 36.4; and [CoQ10+NH4]+, m/z 880.9 ®197.1 with collision energy 32.76. CoQ9 and CoQ10 areas were normalised to the internal standard CoQ8 levels (20 ng/mL). CoQ9 and CoQ10 were quantified against external standard curves generated from authentic commercial standards obtained from Sigma Aldrich (USA).</p>
</sec>
<sec id="s10n">
<title>Mitochondrial isolation</title>
<p>Mitochondrial isolation from cultured L6-myotubes and was performed as described elsewhere<sup><xref ref-type="bibr" rid="c93">93</xref>,<xref ref-type="bibr" rid="c94">94</xref></sup>. Briefly, cells were homogenised in an ice-cold mitochondrial isolation buffer (5 mM HEPES, 0.5 mM EGTA, 200 mM mannitol and 0.1 % BSA, pH 7.4 containing protease inhibitors) using a Cell Homogenizer with 18-micron ball. Cells were passed through the Cell Homogenizer 10 times using 1 mL syringe. Cell Homogenizer was equilibrated with 1 mL of ice-cold isolation buffer prior to the experiment. Homogenates were centrifuged at 700 g for 10 min and the supernatant centrifuged at 10,300 g for 10 min to generate the crude mitochondrial pellet. The 10,300 g pellet was resuspended in 1 mL of isolation buffer and transferred into a polycarbonate tube containing 7.9 mL of 18% Percoll in the homogenization buffer and centrifuged at 95,000 g at 4 °C for 30 min. The mitochondrial pellet was collected and diluted in a homogenization buffer (1 mL) and centrifuged at 10,000 g for 10 min at 4 °C. The supernatant was discarded, and the pellet was washed with a homogenization buffer without BSA followed by protein quantification with BCA protein assay.</p>
<p>Mitochondria from adult skeletal muscle (from mixed hindlimb muscle) were isolated by differential centrifugation as described previously<sup><xref ref-type="bibr" rid="c95">95</xref></sup>. Briefly, muscle was diced in CP-1 medium (100 mM KCl, 50 mM Tris/HCl, pH 7.4, and 2 mM EGTA), digested on ice for 3 min in CP-2 medium [CP-1, to which was added 0.5% (w/v) BSA, 5 mM MgCl2, 1 mM ATP and 2.45 units ml–1 Protease Type VIII (Sigma P 5380)] and homogenised using an ultra-turrax homogenizer. The homogenate was spun for 5 min at 500 g and 4°C. The resulting supernatant was subjected to a high-speed spin (10,600 g, 10 min, 4°C) and the mitochondrial pellet was resuspended in CP-1. The 10,600 g spin cycle was repeated, the supernatant removed and the mitochondrial pellet snapped frozen.</p>
</sec>
<sec id="s10o">
<title>Western Blotting</title>
<p>After insulin stimulation or mitochondrial isolation, samples were tip sonicated in 2% SDS-RIPA. Insoluble material was removed by centrifugation at 21,000 g x 10 min. Protein concentration was determined by bicinchoninic acid method (Thermo Scientific). 10 μg of protein was resolved by SDS-PAGE and transferred to PDVF membranes. Membranes were blocked in Tris-buffered saline (TBS) 4 % skim milk for 30 min at room temperature, followed by primary antibody incubation (detailed antibody is provided in “Key Resource Table”). Membranes were washed in TBS 0.1% tween (TBS-T) and incubated with appropriate secondary antibodies (IRDye700- or IRDye800-conjugated) in TBS-T 2% skim milk for 45 min at room temperature. Images were obtained by using 700- or 800-nm channels using Odyssey IR imager. Densitometry analysis of immunoblots was performed using Image Studio Lite (version 5.2). Uncropped Western blots are provided in Supplementary Material.</p>
</sec>
<sec id="s10p">
<title>Seahorse extracellular flux analyses</title>
<p>Mitochondrial respiration (<italic>J</italic>O<sub>2</sub>) of intact cells were measured using an XF HS mini Analyser Extracellular Flux Analyzer (Seahorse Bioscience, Copenhagen, Denmark). L6 myoblasts were seeded and differentiated in Seahorse XFp culture plates coated with matrigel and assayed after incubation at 37°C without CO<sub>2</sub> for 1 hour. Prior to the assay, cells were washed 3 times with PBS, once with bicarbonate-free DMEM buffered with 30 mM Na-HEPES, pH 7.4 (DMEM/HEPES), and then incubated in DMEM/HEPES supplemented with 0.2% (w/v) BSA, 25 mM glucose, 1 mM GlutaMAX and 1 mM glutamine (Media B), for 1.5 h in a non-CO2 incubator at 37 °C. During the assay, respiration was assayed with mix/wait/read cycles of 2/0/2 min for L6 myotubes. Following assessment of basal respiration, the following compounds (final concentrations in parentheses) were injected sequentially: oligoymcin (10 μg/ml), BAM15 (10 mM), rotenone/antimycin A (5 μM / 10 μM). All of these reagents were obtained from Sigma-Aldrich. basal (baseline - Ant./Rot), ATP-linked respiration (determined by basal – oligomycin), maximal respiration (calculated by FCCP – AntA/Rot) and non-mitochondrial respiration (equal to AntA/Rot) was determined as previously described<sup><xref ref-type="bibr" rid="c96">96</xref></sup>. Protein concentration was determined immediately after the assy and data are presented as O2/min. Complex specific activity in permeabilized cells were performed according to<sup><xref ref-type="bibr" rid="c97">97</xref></sup>. The cells were seeded and the media was changed to a buffer consisting of 70 mM sucrose, 220 mM Mannitol, 10 mM KH2PO4, 5 mM MgCl2, 2 mM Hepes (pH 7.2), 1 mM EGTA, and 0.4% BSA. Then, flux measurements began after taking three baseline measurements. The cells were permeabilized by adding digitonin (1 nM) and 1 mM ADP, followed by injecting respiratory complex substrates or ADP only (complex I, glutamate/malate (5 mM/2.5 mM); complex II, succinate/rotenone (10 mM/1 μM); complex III, and complex IV, N,N,N,N-tetramethyl-p-phenylenediamine/ascorbate (0.5 mM/2 mM)). Subsequently, oligomycin (1 μg/ml) and respective complex inhibitors were added (complex I, 1 μM rotenone; complexes II and III, 20 μM antimycin A; complex IV, 20 mM sodium azide). Wells where cells detached from the plate during the assay were excluded from the analysis.</p>
</sec>
<sec id="s10q">
<title>Mitochondrial membrane potential</title>
<p>Mitochondrial membrane potential was measured by loading cells with 20nM tetramethylrhodamine, ethyl ester (TMRM+, Life Technologies) for 30 min at 37◦C plus mitotracker deep Red (MTDR). MTDR was used to normalize the fluorescence among the different mitochondrial populations as previously reported<sup><xref ref-type="bibr" rid="c96">96</xref></sup>. TMRM+ fluorescence was detected using the excitation-emission λ545–580/590 nm and MTDR was detected using an ex/em ~644/665 nm using confocal microscopy. The mitochondrial membrane potential was evaluated as raw fluorescence intensity of background-corrected images.</p>
</sec>
<sec id="s10r">
<title>Mitochondrial oxidative stress</title>
<p>MitoSOX Red was administered as described by the manufacturer (Molecular Probes); At the end of the induction period cells were washed twice with PBS and incubated with 0.5 μM MitoSOX Red for 30 min plus mitotracker deep Red (MTDR). MTDR was used to normalize the fluorescence among the different mitochondrial populations as previously reported. Cells were cultured in low-absorbance, black-walled 96-well plates. After MitoSOX treatment cells were quickly washed with PBS and fluorescence was detected on a confocal microscope. MitoSOX fluorescence was detected using the excitation-emission λ396/610 nm and MTDR was detected using an ex/em ~644/665 nm using confocal microscopy.</p>
</sec>
<sec id="s10s">
<title>RT-PCR</title>
<p>RNA was extracted by addition of TRIzol (Thermo-fisher) followed by addition of 0.1x volume of 1-bromo-3-chloropropane. Samples were centrifuged at 13,000xg for 15 minutes for phase separation. The clear phase was transferred to a fresh tube and an equal volume of isopropanol was added. Samples were centrifuged at 13,000xg for 10 minutes to precipitate RNA. RNA was washed three times in 70% ethanol with centrifugation. RNA was resuspended in DEPC treated water and quantified on a NanoDrop 2000 (Thermo Scientific). RNA was reverse transcribed to cDNA using PrimeScript Reverse Transcriptase(Takara) as per the manufacturer’s instructions. qPCR was performed using FastStart SYBR Green MasterMix (2x) (Biorad) as per the manufacturer’s instructions. All primers sequence van be found in <xref ref-type="fig" rid="figs8">sup. Fig. 8</xref></p>
</sec>
<sec id="s10t">
<title>Statistical analysis</title>
<p>Data are presented as mean ± S.E.M. Statistical tests were performed using GraphPad Prism version 9. HA-GLUT4 and Western blot assay was analysed by using Kruskal-Wallis with Dunn’s multiple comparisons test. CoQ and ceramide abundance were analysed with ordinary one-Way ANOVA and Dunnett’s multiple comparison test. Finally, for comparison of two groups (CoQ and Ceramides levels in mice) we use Student’s <italic>t</italic>-test. Significant effects were defined as p&lt;0.05 by these tests as reported in the Figures.</p>
</sec>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><label>1</label><mixed-citation publication-type="journal"><string-name><surname>Hill</surname> <given-names>MM</given-names></string-name>, <string-name><surname>Clark</surname> <given-names>SF</given-names></string-name>, <string-name><surname>Tucker</surname> <given-names>DF</given-names></string-name>, <string-name><surname>Birnbaum</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>James</surname> <given-names>DE</given-names></string-name>, <string-name><surname>Macaulay</surname> <given-names>SL</given-names></string-name>. <article-title>A role for protein kinase Bbeta/Akt2 in insulin-stimulated GLUT4 translocation in adipocytes</article-title>. <source>Mol Cell Biol</source> <year>1999</year>; <volume>19</volume>: <fpage>7771</fpage>–<lpage>7781</lpage>.</mixed-citation></ref>
<ref id="c2"><label>2</label><mixed-citation publication-type="journal"><string-name><surname>Cong</surname> <given-names>LN</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>H</given-names></string-name>, <string-name><surname>Li</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>L</given-names></string-name>, <string-name><surname>McGibbon</surname> <given-names>MA</given-names></string-name>, <string-name><surname>Taylor</surname> <given-names>SI</given-names></string-name> <etal>et al.</etal> <article-title>Physiological role of Akt in insulin-stimulated translocation of GLUT4 in transfected rat adipose cells</article-title>. <source>Mol Endocrinol</source> <year>1997</year>; <volume>11</volume>: <fpage>1881</fpage>–<lpage>1890</lpage>.</mixed-citation></ref>
<ref id="c3"><label>3</label><mixed-citation publication-type="journal"><string-name><surname>James</surname> <given-names>DE</given-names></string-name>, <string-name><surname>Stöckli</surname> <given-names>J</given-names></string-name>, <string-name><surname>Birnbaum</surname> <given-names>MJ</given-names></string-name>. <article-title>The aetiology and molecular landscape of insulin resistance</article-title>. <source>Nat Rev Mol Cell Biol</source> <year>2021</year>; <volume>22</volume>: <fpage>751</fpage>–<lpage>771</lpage>.</mixed-citation></ref>
<ref id="c4"><label>4</label><mixed-citation publication-type="journal"><string-name><surname>Riehle</surname> <given-names>C</given-names></string-name>, <string-name><surname>Abel</surname> <given-names>ED</given-names></string-name>. <article-title>Insulin Signaling and Heart Failure</article-title>. <source>Circ Res</source> <year>2016</year>; <volume>118</volume>: <fpage>1151</fpage>–<lpage>1169</lpage>.</mixed-citation></ref>
<ref id="c5"><label>5</label><mixed-citation publication-type="journal"><string-name><surname>Leitner</surname> <given-names>BP</given-names></string-name>, <string-name><surname>Siebel</surname> <given-names>S</given-names></string-name>, <string-name><surname>Akingbesote</surname> <given-names>ND</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>X</given-names></string-name>, <string-name><surname>Perry</surname> <given-names>RJ</given-names></string-name>. <article-title>Insulin and cancer: a tangled web</article-title>. <source>Biochem J</source> <year>2022</year>; <volume>479</volume>: <fpage>583</fpage>–<lpage>607</lpage>.</mixed-citation></ref>
<ref id="c6"><label>6</label><mixed-citation publication-type="journal"><string-name><surname>Fazakerley</surname> <given-names>DJ</given-names></string-name>, <string-name><surname>Chaudhuri</surname> <given-names>R</given-names></string-name>, <string-name><surname>Yang</surname> <given-names>P</given-names></string-name>, <string-name><surname>Maghzal</surname> <given-names>GJ</given-names></string-name>, <string-name><surname>Thomas</surname> <given-names>KC</given-names></string-name>, <string-name><surname>Krycer</surname> <given-names>JR</given-names></string-name> <etal>et al.</etal> <article-title>Mitochondrial CoQ deficiency is a common driver of mitochondrial oxidants and insulin resistance</article-title>. <source>Elife</source> <year>2018</year>; <volume>7</volume>. doi:<pub-id pub-id-type="doi">10.7554/eLife.32111</pub-id>.</mixed-citation></ref>
<ref id="c7"><label>7</label><mixed-citation publication-type="journal"><string-name><surname>Holland</surname> <given-names>WL</given-names></string-name>, <string-name><surname>Summers</surname> <given-names>SA</given-names></string-name>. <article-title>Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism</article-title>. <source>Endocr Rev</source> <year>2008</year>; <volume>29</volume>: <fpage>381</fpage>–<lpage>402</lpage>.</mixed-citation></ref>
<ref id="c8"><label>8</label><mixed-citation publication-type="journal"><string-name><surname>Anderson</surname> <given-names>EJ</given-names></string-name>, <string-name><surname>Lustig</surname> <given-names>ME</given-names></string-name>, <string-name><surname>Boyle</surname> <given-names>KE</given-names></string-name>, <string-name><surname>Woodlief</surname> <given-names>TL</given-names></string-name>, <string-name><surname>Kane</surname> <given-names>DA</given-names></string-name>, <string-name><surname>Lin</surname> <given-names>C-T</given-names></string-name> <etal>et al.</etal> <article-title>Mitochondrial H2O2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans</article-title>. <source>J Clin Invest</source> <year>2009</year>; <volume>119</volume>: <fpage>573</fpage>–<lpage>581</lpage>.</mixed-citation></ref>
<ref id="c9"><label>9</label><mixed-citation publication-type="journal"><string-name><surname>Hoehn</surname> <given-names>KL</given-names></string-name>, <string-name><surname>Salmon</surname> <given-names>AB</given-names></string-name>, <string-name><surname>Hohnen-Behrens</surname> <given-names>C</given-names></string-name>, <string-name><surname>Turner</surname> <given-names>N</given-names></string-name>, <string-name><surname>Hoy</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Maghzal</surname> <given-names>GJ</given-names></string-name> <etal>et al.</etal> <article-title>Insulin resistance is a cellular antioxidant defense mechanism</article-title>. <source>Proc Natl Acad Sci U S A</source> <year>2009</year>; <volume>106</volume>: <fpage>17787</fpage>–<lpage>17792</lpage>.</mixed-citation></ref>
<ref id="c10"><label>10</label><mixed-citation publication-type="journal"><string-name><surname>Fazakerley</surname> <given-names>DJ</given-names></string-name>, <string-name><surname>Minard</surname> <given-names>AY</given-names></string-name>, <string-name><surname>Krycer</surname> <given-names>JR</given-names></string-name>, <string-name><surname>Thomas</surname> <given-names>KC</given-names></string-name>, <string-name><surname>Stöckli</surname> <given-names>J</given-names></string-name>, <string-name><surname>Harney</surname> <given-names>DJ</given-names></string-name> <etal>et al.</etal> <article-title>Mitochondrial oxidative stress causes insulin resistance without disrupting oxidative phosphorylation</article-title>. <source>J Biol Chem</source> <year>2018</year>; <volume>293</volume>: <fpage>7315</fpage>–<lpage>7328</lpage>.</mixed-citation></ref>
<ref id="c11"><label>11</label><mixed-citation publication-type="journal"><string-name><surname>Hatefi</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Haavik</surname> <given-names>AG</given-names></string-name>, <string-name><surname>Fowler</surname> <given-names>LR</given-names></string-name>, <string-name><surname>Griffiths</surname> <given-names>DE</given-names></string-name>. <article-title>Studies on the electron transfer system. XLII. Reconstitution of the electron transfer system</article-title><source>. J Biol Chem</source> <year>1962</year>; <volume>237</volume>: <fpage>2661</fpage>–<lpage>2669</lpage>.</mixed-citation></ref>
<ref id="c12"><label>12</label><mixed-citation publication-type="journal"><string-name><surname>Frerman</surname> <given-names>FE</given-names></string-name>. <article-title>Acyl-CoA dehydrogenases, electron transfer flavoprotein and electron transfer flavoprotein dehydrogenase</article-title>. <source>Biochem Soc Trans</source> <year>1988</year>; <volume>16</volume>: <fpage>416</fpage>–<lpage>418</lpage>.</mixed-citation></ref>
<ref id="c13"><label>13</label><mixed-citation publication-type="journal"><string-name><surname>Jones</surname> <given-names>ME</given-names></string-name>. <article-title>Pyrimidine nucleotide biosynthesis in animals: genes, enzymes, and regulation of UMP biosynthesis</article-title>. <source>Annu Rev Biochem</source> <year>1980</year>; <volume>49</volume>: <fpage>253</fpage>–<lpage>279</lpage>.</mixed-citation></ref>
<ref id="c14"><label>14</label><mixed-citation publication-type="journal"><string-name><surname>Montini</surname> <given-names>G</given-names></string-name>, <string-name><surname>Malaventura</surname> <given-names>C</given-names></string-name>, <string-name><surname>Salviati</surname> <given-names>L</given-names></string-name>. <article-title>Early coenzyme Q10 supplementation in primary coenzyme Q10 deficiency</article-title>. <source>N Engl J Med</source> <year>2008</year>; <volume>358</volume>: <fpage>2849</fpage>–<lpage>2850</lpage>.</mixed-citation></ref>
<ref id="c15"><label>15</label><mixed-citation publication-type="journal"><string-name><surname>Kühl</surname> <given-names>I</given-names></string-name>, <string-name><surname>Miranda</surname> <given-names>M</given-names></string-name>, <string-name><surname>Atanassov</surname> <given-names>I</given-names></string-name>, <string-name><surname>Kuznetsova</surname> <given-names>I</given-names></string-name>, <string-name><surname>Hinze</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Mourier</surname> <given-names>A</given-names></string-name> <etal>et al.</etal> <article-title>Transcriptomic and proteomic landscape of mitochondrial dysfunction reveals secondary coenzyme Q deficiency in mammals</article-title>. <source>Elife</source> <year>2017</year>; <volume>6</volume>. doi:<pub-id pub-id-type="doi">10.7554/eLife.30952</pub-id>.</mixed-citation></ref>
<ref id="c16"><label>16</label><mixed-citation publication-type="journal"><string-name><surname>Calvo</surname> <given-names>E</given-names></string-name>, <string-name><surname>Cogliati</surname> <given-names>S</given-names></string-name>, <string-name><surname>Hernansanz-Agustín</surname> <given-names>P</given-names></string-name>, <string-name><surname>Loureiro-López</surname> <given-names>M</given-names></string-name>, <string-name><surname>Guarás</surname> <given-names>A</given-names></string-name>, <string-name><surname>Casuso</surname> <given-names>RA</given-names></string-name> <etal>et al.</etal> <article-title>Functional role of respiratory supercomplexes in mice: SCAF1 relevance and segmentation of the Qpool</article-title>. <source>Sci Adv</source> <year>2020</year>; <volume>6</volume>: <fpage>eaba7509</fpage>.</mixed-citation></ref>
<ref id="c17"><label>17</label><mixed-citation publication-type="journal"><string-name><surname>Ates</surname> <given-names>O</given-names></string-name>, <string-name><surname>Bilen</surname> <given-names>H</given-names></string-name>, <string-name><surname>Keles</surname> <given-names>S</given-names></string-name>, <string-name><surname>Alp</surname> <given-names>HH</given-names></string-name>, <string-name><surname>Keleş</surname> <given-names>MS</given-names></string-name>, <string-name><surname>Yıldırım</surname> <given-names>K</given-names></string-name> <etal>et al.</etal> <article-title>Plasma coenzyme Q10 levels in type 2 diabetic patients with retinopathy</article-title>. <source>Int J Ophthalmol</source> <year>2013</year>; <volume>6</volume>: <fpage>675</fpage>–<lpage>679</lpage>.</mixed-citation></ref>
<ref id="c18"><label>18</label><mixed-citation publication-type="journal"><string-name><surname>El-ghoroury</surname> <given-names>EA</given-names></string-name>, <string-name><surname>Raslan</surname> <given-names>HM</given-names></string-name>, <string-name><surname>Badawy</surname> <given-names>EA</given-names></string-name>, <string-name><surname>El-Saaid</surname> <given-names>GS</given-names></string-name>, <string-name><surname>Agybi</surname> <given-names>MH</given-names></string-name>, <string-name><surname>Siam</surname> <given-names>I</given-names></string-name> <etal>et al.</etal> <article-title>Malondialdehyde and coenzyme Q10 in platelets and serum in type 2 diabetes mellitus: correlation with glycemic control</article-title>. <source>Blood Coagul Fibrinolysis</source> <year>2009</year>; <volume>20</volume>: <fpage>248</fpage>–<lpage>251</lpage>.</mixed-citation></ref>
<ref id="c19"><label>19</label><mixed-citation publication-type="journal"><string-name><surname>Zozina</surname> <given-names>VI</given-names></string-name>, <string-name><surname>Covantev</surname> <given-names>S</given-names></string-name>, <string-name><surname>Goroshko</surname> <given-names>OA</given-names></string-name>, <string-name><surname>Krasnykh</surname> <given-names>LM</given-names></string-name>, <string-name><surname>Kukes</surname> <given-names>VG</given-names></string-name>. <article-title>Coenzyme Q10 in Cardiovascular and Metabolic Diseases: Current State of the Problem</article-title>. <source>Curr Cardiol Rev</source> <year>2018</year>; <volume>14</volume>: <fpage>164</fpage>–<lpage>174</lpage>.</mixed-citation></ref>
<ref id="c20"><label>20</label><mixed-citation publication-type="journal"><string-name><given-names>Barcelos IP</given-names> <surname>de</surname></string-name>, <string-name><surname>Haas</surname> <given-names>RH</given-names></string-name>. <article-title>CoQ10 and Aging</article-title>. <source>Biology</source> <year>2019</year>; <volume>8</volume>. doi:<pub-id pub-id-type="doi">10.3390/biology8020028</pub-id>.</mixed-citation></ref>
<ref id="c21"><label>21</label><mixed-citation publication-type="journal"><string-name><surname>Højlund</surname> <given-names>K</given-names></string-name>, <string-name><surname>Yi</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Lefort</surname> <given-names>N</given-names></string-name>, <string-name><surname>Langlais</surname> <given-names>P</given-names></string-name>, <string-name><surname>Bowen</surname> <given-names>B</given-names></string-name>, <string-name><surname>Levin</surname> <given-names>K</given-names></string-name> <etal>et al.</etal> <article-title>Human ATP synthase beta is phosphorylated at multiple sites and shows abnormal phosphorylation at specific sites in insulin-resistant muscle</article-title>. <source>Diabetologia</source> <year>2010</year>; <volume>53</volume>: <fpage>541</fpage>–<lpage>551</lpage>.</mixed-citation></ref>
<ref id="c22"><label>22</label><mixed-citation publication-type="journal"><string-name><surname>Diaz-Vegas</surname> <given-names>A</given-names></string-name>, <string-name><surname>Sanchez-Aguilera</surname> <given-names>P</given-names></string-name>, <string-name><surname>Krycer</surname> <given-names>JR</given-names></string-name>, <string-name><surname>Morales</surname> <given-names>PE</given-names></string-name>, <string-name><surname>Monsalves-Alvarez</surname> <given-names>M</given-names></string-name>, <string-name><surname>Cifuentes</surname> <given-names>M</given-names></string-name> <etal>et al.</etal> <article-title>Is Mitochondrial Dysfunction a Common Root of Noncommunicable Chronic Diseases?</article-title> <source>Endocr Rev</source> <year>2020</year>; <volume>41</volume>. doi:<pub-id pub-id-type="doi">10.1210/endrev/bnaa005</pub-id>.</mixed-citation></ref>
<ref id="c23"><label>23</label><mixed-citation publication-type="journal"><string-name><surname>Chaurasia</surname> <given-names>B</given-names></string-name>, <string-name><surname>Summers</surname> <given-names>SA</given-names></string-name>. <article-title>Ceramides in Metabolism: Key Lipotoxic Players</article-title>. <source>Annu Rev Physiol</source> <year>2021</year>; <volume>83</volume>: <fpage>303</fpage>–<lpage>330</lpage>.</mixed-citation></ref>
<ref id="c24"><label>24</label><mixed-citation publication-type="journal"><string-name><surname>Summers</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Garza</surname> <given-names>LA</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>H</given-names></string-name>, <string-name><surname>Birnbaum</surname> <given-names>MJ</given-names></string-name>. <article-title>Regulation of insulin-stimulated glucose transporter GLUT4 translocation and Akt kinase activity by ceramide</article-title>. <source>Mol Cell Biol</source> <year>1998</year>; <volume>18</volume>: <fpage>5457</fpage>–<lpage>5464</lpage>.</mixed-citation></ref>
<ref id="c25"><label>25</label><mixed-citation publication-type="journal"><string-name><surname>Schubert</surname> <given-names>KM</given-names></string-name>, <string-name><surname>Scheid</surname> <given-names>MP</given-names></string-name>, <string-name><surname>Duronio</surname> <given-names>V</given-names></string-name>. <article-title>Ceramide inhibits protein kinase B/Akt by promoting dephosphorylation of serine 473</article-title>. <source>J Biol Chem</source> <year>2000</year>; <volume>275</volume>: <fpage>13330</fpage>–<lpage>13335</lpage>.</mixed-citation></ref>
<ref id="c26"><label>26</label><mixed-citation publication-type="journal"><string-name><surname>Powell</surname> <given-names>DJ</given-names></string-name>, <string-name><surname>Hajduch</surname> <given-names>E</given-names></string-name>, <string-name><surname>Kular</surname> <given-names>G</given-names></string-name>, <string-name><surname>Hundal</surname> <given-names>HS</given-names></string-name>. <article-title>Ceramide disables 3-phosphoinositide binding to the pleckstrin homology domain of protein kinase B (PKB)/Akt by a PKCzeta-dependent mechanism</article-title>. <source>Mol Cell Biol</source> <year>2003</year>; <volume>23</volume>: <fpage>7794</fpage>–<lpage>7808</lpage>.</mixed-citation></ref>
<ref id="c27"><label>27</label><mixed-citation publication-type="journal"><string-name><surname>Kono</surname> <given-names>T</given-names></string-name>, <string-name><surname>Barham</surname> <given-names>FW</given-names></string-name>. <article-title>The relationship between the insulin-binding capacity of fat cells and the cellular response to insulin. Studies with intact and trypsin-treated fat cells</article-title>. <source>J Biol Chem</source> <year>1971</year>; <volume>246</volume>: <fpage>6210</fpage>–<lpage>6216</lpage>.</mixed-citation></ref>
<ref id="c28"><label>28</label><mixed-citation publication-type="journal"><string-name><surname>Hoehn</surname> <given-names>KL</given-names></string-name>, <string-name><surname>Hohnen-Behrens</surname> <given-names>C</given-names></string-name>, <string-name><surname>Cederberg</surname> <given-names>A</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>LE</given-names></string-name>, <string-name><surname>Turner</surname> <given-names>N</given-names></string-name>, <string-name><surname>Yuasa</surname> <given-names>T</given-names></string-name> <etal>et al.</etal> <article-title>IRS1-independent defects define major nodes of insulin resistance</article-title>. <source>Cell Metab</source> <year>2008</year>; <volume>7</volume>: <fpage>421</fpage>–<lpage>433</lpage>.</mixed-citation></ref>
<ref id="c29"><label>29</label><mixed-citation publication-type="journal"><string-name><surname>Di Paola</surname> <given-names>M</given-names></string-name>, <string-name><surname>Cocco</surname> <given-names>T</given-names></string-name>, <string-name><surname>Lorusso</surname> <given-names>M</given-names></string-name>. <article-title>Ceramide interaction with the respiratory chain of heart mitochondria</article-title>. <source>Biochemistry</source> <year>2000</year>; <volume>39</volume>: <fpage>6660</fpage>–<lpage>6668</lpage>.</mixed-citation></ref>
<ref id="c30"><label>30</label><mixed-citation publication-type="journal"><string-name><surname>Perreault</surname> <given-names>L</given-names></string-name>, <string-name><surname>Newsom</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Strauss</surname> <given-names>A</given-names></string-name>, <string-name><surname>Kerege</surname> <given-names>A</given-names></string-name>, <string-name><surname>Kahn</surname> <given-names>DE</given-names></string-name>, <string-name><surname>Harrison</surname> <given-names>KA</given-names></string-name> <etal>et al.</etal> <article-title>Intracellular localization of diacylglycerols and sphingolipids influences insulin sensitivity and mitochondrial function in human skeletal muscle</article-title>. <source>JCI Insight</source> <year>2018</year>; <volume>3</volume>. doi:<pub-id pub-id-type="doi">10.1172/jci.insight.96805</pub-id>.</mixed-citation></ref>
<ref id="c31"><label>31</label><mixed-citation publication-type="journal"><string-name><surname>Hammerschmidt</surname> <given-names>P</given-names></string-name>, <string-name><surname>Ostkotte</surname> <given-names>D</given-names></string-name>, <string-name><surname>Nolte</surname> <given-names>H</given-names></string-name>, <string-name><surname>Gerl</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Jais</surname> <given-names>A</given-names></string-name>, <string-name><surname>Brunner</surname> <given-names>HL</given-names></string-name> <etal>et al.</etal> <article-title>CerS6-Derived Sphingolipids Interact with Mff and Promote Mitochondrial Fragmentation in Obesity</article-title>. <source>Cell</source> <year>2019</year>; <volume>177</volume>: <fpage>1536</fpage>–<lpage>1552</lpage>.e23.</mixed-citation></ref>
<ref id="c32"><label>32</label><mixed-citation publication-type="journal"><string-name><surname>Ertunc</surname> <given-names>ME</given-names></string-name>, <string-name><surname>Hotamisligil</surname> <given-names>GS</given-names></string-name>. <article-title>Lipid signaling and lipotoxicity in metaflammation: indications for metabolic disease pathogenesis and treatment</article-title>. <source>J Lipid Res</source> <year>2016</year>; <volume>57</volume>: <fpage>2099</fpage>–<lpage>2114</lpage>.</mixed-citation></ref>
<ref id="c33"><label>33</label><mixed-citation publication-type="journal"><string-name><surname>Forsman</surname> <given-names>U</given-names></string-name>, <string-name><surname>Sjöberg</surname> <given-names>M</given-names></string-name>, <string-name><surname>Turunen</surname> <given-names>M</given-names></string-name>, <string-name><surname>Sindelar</surname> <given-names>PJ</given-names></string-name>. <article-title>4-Nitrobenzoate inhibits coenzyme Q biosynthesis in mammalian cell cultures</article-title>. <source>Nat Chem Biol</source> <year>2010</year>; <volume>6</volume>: <fpage>515</fpage>–<lpage>517</lpage>.</mixed-citation></ref>
<ref id="c34"><label>34</label><mixed-citation publication-type="journal"><string-name><surname>Fernández-Ayala</surname> <given-names>DJ</given-names></string-name>, <string-name><surname>Martín</surname> <given-names>SF</given-names></string-name>, <string-name><surname>Barroso</surname> <given-names>MP</given-names></string-name>, <string-name><surname>Gómez-Díaz</surname> <given-names>C</given-names></string-name>, <string-name><surname>Villalba</surname> <given-names>JM</given-names></string-name>, <string-name><surname>Rodríguez-Aguilera</surname> <given-names>JC</given-names></string-name> <etal>et al.</etal> <article-title>Coenzyme Q protects cells against serum withdrawal-induced apoptosis by inhibition of ceramide release and caspase-3 activation</article-title>. <source>Antioxid Redox Signal</source> <year>2000</year>; <volume>2</volume>: <fpage>263</fpage>–<lpage>275</lpage>.</mixed-citation></ref>
<ref id="c35"><label>35</label><mixed-citation publication-type="journal"><string-name><surname>Koves</surname> <given-names>TR</given-names></string-name>, <string-name><surname>Ussher</surname> <given-names>JR</given-names></string-name>, <string-name><surname>Noland</surname> <given-names>RC</given-names></string-name>, <string-name><surname>Slentz</surname> <given-names>D</given-names></string-name>, <string-name><surname>Mosedale</surname> <given-names>M</given-names></string-name>, <string-name><surname>Ilkayeva</surname> <given-names>O</given-names></string-name> <etal>et al.</etal> <article-title>Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance</article-title>. <source>Cell Metab</source> <year>2008</year>; <volume>7</volume>: <fpage>45</fpage>–<lpage>56</lpage>.</mixed-citation></ref>
<ref id="c36"><label>36</label><mixed-citation publication-type="journal"><string-name><surname>Bruce</surname> <given-names>CR</given-names></string-name>, <string-name><surname>Hoy</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Turner</surname> <given-names>N</given-names></string-name>, <string-name><surname>Watt</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Allen</surname> <given-names>TL</given-names></string-name>, <string-name><surname>Carpenter</surname> <given-names>K</given-names></string-name> <etal>et al.</etal> <article-title>Overexpression of carnitine palmitoyltransferase-1 in skeletal muscle is sufficient to enhance fatty acid oxidation and improve high-fat diet-induced insulin resistance</article-title>. <source>Diabetes</source> <year>2009</year>; <volume>58</volume>: <fpage>550</fpage>–<lpage>558</lpage>.</mixed-citation></ref>
<ref id="c37"><label>37</label><mixed-citation publication-type="journal"><string-name><surname>Sebastián</surname> <given-names>D</given-names></string-name>, <string-name><surname>Herrero</surname> <given-names>L</given-names></string-name>, <string-name><surname>Serra</surname> <given-names>D</given-names></string-name>, <string-name><surname>Asins</surname> <given-names>G</given-names></string-name>, <string-name><surname>Hegardt</surname> <given-names>FG</given-names></string-name>. <article-title>CPT I overexpression protects L6E9 muscle cells from fatty acid-induced insulin resistance</article-title>. <source>Am J Physiol Endocrinol Metab</source> <year>2007</year>; <volume>292</volume>: <fpage>E677</fpage>–<lpage>86</lpage>.</mixed-citation></ref>
<ref id="c38"><label>38</label><mixed-citation publication-type="journal"><string-name><surname>Perdomo</surname> <given-names>G</given-names></string-name>, <string-name><surname>Commerford</surname> <given-names>SR</given-names></string-name>, <string-name><surname>Richard</surname> <given-names>A-MT</given-names></string-name>, <string-name><surname>Adams</surname> <given-names>SH</given-names></string-name>, <string-name><surname>Corkey</surname> <given-names>BE</given-names></string-name>, <string-name><surname>O’Doherty</surname> <given-names>RM</given-names></string-name> <etal>et al.</etal> <article-title>Increased beta-oxidation in muscle cells enhances insulin-stimulated glucose metabolism and protects against fatty acid-induced insulin resistance despite intramyocellular lipid accumulation</article-title>. <source>J Biol Chem</source> <year>2004</year>; <volume>279</volume>: <fpage>27177</fpage>–<lpage>27186</lpage>.</mixed-citation></ref>
<ref id="c39"><label>39</label><mixed-citation publication-type="journal"><string-name><surname>Fisher-Wellman</surname> <given-names>KH</given-names></string-name>, <string-name><surname>Hagen</surname> <given-names>JT</given-names></string-name>, <string-name><surname>Neufer</surname> <given-names>PD</given-names></string-name>, <string-name><surname>Kassai</surname> <given-names>M</given-names></string-name>, <string-name><surname>Cabot</surname> <given-names>MC</given-names></string-name>. <article-title>On the nature of ceramide-mitochondria interactions - Dissection using comprehensive mitochondrial phenotyping</article-title>. <source>Cell Signal</source> <year>2021</year>; <volume>78</volume>: <fpage>109838</fpage>.</mixed-citation></ref>
<ref id="c40"><label>40</label><mixed-citation publication-type="journal"><string-name><surname>Das</surname> <given-names>AT</given-names></string-name>, <string-name><surname>Tenenbaum</surname> <given-names>L</given-names></string-name>, <string-name><surname>Berkhout</surname> <given-names>B</given-names></string-name>. <article-title>Tet-On Systems For Doxycycline-inducible Gene Expression</article-title>. <source>Curr Gene Ther</source> <year>2016</year>; <volume>16</volume>: <fpage>156</fpage>–<lpage>167</lpage>.</mixed-citation></ref>
<ref id="c41"><label>41</label><mixed-citation publication-type="journal"><string-name><surname>Wu</surname> <given-names>BX</given-names></string-name>, <string-name><surname>Rajagopalan</surname> <given-names>V</given-names></string-name>, <string-name><surname>Roddy</surname> <given-names>PL</given-names></string-name>, <string-name><surname>Clarke</surname> <given-names>CJ</given-names></string-name>, <string-name><surname>Hannun</surname> <given-names>YA</given-names></string-name>. <article-title>Identification and characterization of murine mitochondria-associated neutral sphingomyelinase (MA-nSMase), the mammalian sphingomyelin phosphodiesterase 5</article-title>. <source>J Biol Chem</source> <year>2010</year>; <volume>285</volume>: <fpage>17993</fpage>–<lpage>18002</lpage>.</mixed-citation></ref>
<ref id="c42"><label>42</label><mixed-citation publication-type="journal"><string-name><surname>Bienias</surname> <given-names>K</given-names></string-name>, <string-name><surname>Fiedorowicz</surname> <given-names>A</given-names></string-name>, <string-name><surname>Sadowska</surname> <given-names>A</given-names></string-name>, <string-name><surname>Prokopiuk</surname> <given-names>S</given-names></string-name>, <string-name><surname>Car</surname> <given-names>H</given-names></string-name>. <article-title>Regulation of sphingomyelin metabolism</article-title>. <source>Pharmacol Rep</source> <year>2016</year>; <volume>68</volume>: <fpage>570</fpage>–<lpage>581</lpage>.</mixed-citation></ref>
<ref id="c43"><label>43</label><mixed-citation publication-type="journal"><string-name><surname>Feng</surname> <given-names>S</given-names></string-name>, <string-name><surname>Harayama</surname> <given-names>T</given-names></string-name>, <string-name><surname>Montessuit</surname> <given-names>S</given-names></string-name>, <string-name><surname>David</surname> <given-names>FP</given-names></string-name>, <string-name><surname>Winssinger</surname> <given-names>N</given-names></string-name>, <string-name><surname>Martinou</surname> <given-names>J-C</given-names></string-name> <etal>et al.</etal> <article-title>Mitochondria-specific photoactivation to monitor local sphingosine metabolism and function</article-title>. <source>Elife</source> <year>2018</year>; <volume>7</volume>. doi:<pub-id pub-id-type="doi">10.7554/eLife.34555</pub-id>.</mixed-citation></ref>
<ref id="c44"><label>44</label><mixed-citation publication-type="journal"><string-name><surname>Li</surname> <given-names>CM</given-names></string-name>, <string-name><surname>Park</surname> <given-names>JH</given-names></string-name>, <string-name><surname>He</surname> <given-names>X</given-names></string-name>, <string-name><surname>Levy</surname> <given-names>B</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>F</given-names></string-name>, <string-name><surname>Arai</surname> <given-names>K</given-names></string-name> <etal>et al.</etal> <article-title>The human acid ceramidase gene (ASAH): structure, chromosomal location, mutation analysis, and expression</article-title>. <source>Genomics</source> <year>1999</year>; <volume>62</volume>: <fpage>223</fpage>–<lpage>231</lpage>.</mixed-citation></ref>
<ref id="c45"><label>45</label><mixed-citation publication-type="journal"><string-name><surname>Turner</surname> <given-names>N</given-names></string-name>, <string-name><surname>Lim</surname> <given-names>XY</given-names></string-name>, <string-name><surname>Toop</surname> <given-names>HD</given-names></string-name>, <string-name><surname>Osborne</surname> <given-names>B</given-names></string-name>, <string-name><surname>Brandon</surname> <given-names>AE</given-names></string-name>, <string-name><surname>Taylor</surname> <given-names>EN</given-names></string-name> <etal>et al.</etal> <article-title>A selective inhibitor of ceramide synthase 1 reveals a novel role in fat metabolism</article-title>. <source>Nat Commun</source> <year>2018</year>; <volume>9</volume>: <fpage>3165</fpage>.</mixed-citation></ref>
<ref id="c46"><label>46</label><mixed-citation publication-type="journal"><string-name><surname>Rath</surname> <given-names>S</given-names></string-name>, <string-name><surname>Sharma</surname> <given-names>R</given-names></string-name>, <string-name><surname>Gupta</surname> <given-names>R</given-names></string-name>, <string-name><surname>Ast</surname> <given-names>T</given-names></string-name>, <string-name><surname>Chan</surname> <given-names>C</given-names></string-name>, <string-name><surname>Durham</surname> <given-names>TJ</given-names></string-name> <etal>et al.</etal> <article-title>MitoCarta3.0: an updated mitochondrial proteome now with sub-organelle localization and pathway annotations</article-title>. <source>Nucleic Acids Res</source> <year>2021</year>; <volume>49</volume>: <fpage>D1541</fpage>–<lpage>D1547</lpage>.</mixed-citation></ref>
<ref id="c47"><label>47</label><mixed-citation publication-type="journal"><string-name><surname>Letts</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Sazanov</surname> <given-names>LA</given-names></string-name>. <article-title>Clarifying the supercomplex: the higher-order organization of the mitochondrial electron transport chain</article-title>. <source>Nat Struct Mol Biol</source> <year>2017</year>; <volume>24</volume>: <fpage>800</fpage>–<lpage>808</lpage>.</mixed-citation></ref>
<ref id="c48"><label>48</label><mixed-citation publication-type="journal"><string-name><surname>Zhu</surname> <given-names>J</given-names></string-name>, <string-name><surname>Vinothkumar</surname> <given-names>KR</given-names></string-name>, <string-name><surname>Hirst</surname> <given-names>J</given-names></string-name>. <article-title>Structure of mammalian respiratory complex I</article-title>. <source>Nature</source> <year>2016</year>; <volume>536</volume>: <fpage>354</fpage>–<lpage>358</lpage>.</mixed-citation></ref>
<ref id="c49"><label>49</label><mixed-citation publication-type="journal"><string-name><surname>Brand</surname> <given-names>MD</given-names></string-name>, <string-name><surname>Nicholls</surname> <given-names>DG</given-names></string-name>. <article-title>Assessing mitochondrial dysfunction in cells</article-title>. <source>Biochem J</source> <year>2011</year>; <volume>435</volume>: <fpage>297</fpage>–<lpage>312</lpage>.</mixed-citation></ref>
<ref id="c50"><label>50</label><mixed-citation publication-type="journal"><string-name><surname>Krycer</surname> <given-names>JR</given-names></string-name>, <string-name><surname>Elkington</surname> <given-names>SD</given-names></string-name>, <string-name><surname>Diaz-Vegas</surname> <given-names>A</given-names></string-name>, <string-name><surname>Cooke</surname> <given-names>KC</given-names></string-name>, <string-name><surname>Burchfield</surname> <given-names>JG</given-names></string-name>, <string-name><surname>Fisher-Wellman</surname> <given-names>KH</given-names></string-name> <etal>et al.</etal> <article-title>Mitochondrial oxidants, but not respiration, are sensitive to glucose in adipocytes</article-title>. <source>J Biol Chem</source> <year>2020</year>; <volume>295</volume>: <fpage>99</fpage>–<lpage>110</lpage>.</mixed-citation></ref>
<ref id="c51"><label>51</label><mixed-citation publication-type="journal"><string-name><surname>Sánchez-Aguilera</surname> <given-names>P</given-names></string-name>, <string-name><surname>Diaz-Vegas</surname> <given-names>A</given-names></string-name>, <string-name><surname>Campos</surname> <given-names>C</given-names></string-name>, <string-name><surname>Quinteros-Waltemath</surname> <given-names>O</given-names></string-name>, <string-name><surname>Cerda-Kohler</surname> <given-names>H</given-names></string-name>, <string-name><surname>Barrientos</surname> <given-names>G</given-names></string-name> <etal>et al.</etal> <article-title>Role of ABCA1 on membrane cholesterol content, insulin-dependent Akt phosphorylation and glucose uptake in adult skeletal muscle fibers from mice</article-title>. <source>Biochim Biophys Acta Mol Cell Biol Lipids</source> <year>2018</year>; <volume>1863</volume>: <fpage>1469</fpage>–<lpage>1477</lpage>.</mixed-citation></ref>
<ref id="c52"><label>52</label><mixed-citation publication-type="journal"><string-name><surname>Rosales-Soto</surname> <given-names>G</given-names></string-name>, <string-name><surname>Diaz-Vegas</surname> <given-names>A</given-names></string-name>, <string-name><surname>Casas</surname> <given-names>M</given-names></string-name>, <string-name><surname>Contreras-Ferrat</surname> <given-names>A</given-names></string-name>, <string-name><surname>Jaimovich</surname> <given-names>E</given-names></string-name>. <article-title>Fibroblast growth factor-21 potentiates glucose transport in skeletal muscle fibers</article-title>. <source>J Mol Endocrinol</source> <year>2020</year>. doi:<pub-id pub-id-type="doi">10.1530/JME-19-0210</pub-id>.</mixed-citation></ref>
<ref id="c53"><label>53</label><mixed-citation publication-type="journal"><string-name><surname>Valladares</surname> <given-names>D</given-names></string-name>, <string-name><surname>Utreras-Mendoza</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Campos</surname> <given-names>C</given-names></string-name>, <string-name><surname>Morales</surname> <given-names>C</given-names></string-name>, <string-name><surname>Diaz-Vegas</surname> <given-names>A</given-names></string-name>, <string-name><surname>Contreras-Ferrat</surname> <given-names>A</given-names></string-name> <etal>et al.</etal> <article-title>IP3 receptor blockade restores autophagy and mitochondrial function in skeletal muscle fibers of dystrophic mice</article-title>. <source>Biochim Biophys Acta Mol Basis Dis</source> <year>2018</year>; <volume>1864</volume>: <fpage>3685</fpage>–<lpage>3695</lpage>.</mixed-citation></ref>
<ref id="c54"><label>54</label><mixed-citation publication-type="journal"><string-name><surname>Chalfant</surname> <given-names>CE</given-names></string-name>, <string-name><surname>Rathman</surname> <given-names>K</given-names></string-name>, <string-name><surname>Pinkerman</surname> <given-names>RL</given-names></string-name>, <string-name><surname>Wood</surname> <given-names>RE</given-names></string-name>, <string-name><surname>Obeid</surname> <given-names>LM</given-names></string-name>, <string-name><surname>Ogretmen</surname> <given-names>B</given-names></string-name> <etal>et al.</etal> <article-title>De novo ceramide regulates the alternative splicing of caspase 9 and Bcl-x in A549 lung adenocarcinoma cells. Dependence on protein phosphatase-1</article-title>. <source>J Biol Chem</source> <year>2002</year>; <volume>277</volume>: <fpage>12587</fpage>–<lpage>12595</lpage>.</mixed-citation></ref>
<ref id="c55"><label>55</label><mixed-citation publication-type="journal"><string-name><surname>Tesfay</surname> <given-names>L</given-names></string-name>, <string-name><surname>Paul</surname> <given-names>BT</given-names></string-name>, <string-name><surname>Konstorum</surname> <given-names>A</given-names></string-name>, <string-name><surname>Deng</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Cox</surname> <given-names>AO</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>J</given-names></string-name> <etal>et al.</etal> <article-title>Stearoyl-CoA Desaturase 1 Protects Ovarian Cancer Cells from Ferroptotic Cell Death</article-title>. <source>Cancer Res</source>. <year>2019</year>; <volume>79</volume>: <fpage>5355</fpage>–<lpage>5366</lpage>.</mixed-citation></ref>
<ref id="c56"><label>56</label><mixed-citation publication-type="journal"><string-name><surname>Morad</surname> <given-names>SAF</given-names></string-name>, <string-name><surname>Levin</surname> <given-names>JC</given-names></string-name>, <string-name><surname>Shanmugavelandy</surname> <given-names>SS</given-names></string-name>, <string-name><surname>Kester</surname> <given-names>M</given-names></string-name>, <string-name><surname>Fabrias</surname> <given-names>G</given-names></string-name>, <string-name><surname>Bedia</surname> <given-names>C</given-names></string-name> <etal>et al.</etal> <article-title>Ceramide--antiestrogen nanoliposomal combinations--novel impact of hormonal therapy in hormone-insensitive breast cancer</article-title>. <source>Mol Cancer Ther</source> <year>2012</year>; <volume>11</volume>: <fpage>2352</fpage>–<lpage>2361</lpage>.</mixed-citation></ref>
<ref id="c57"><label>57</label><mixed-citation publication-type="journal"><string-name><surname>Schägger</surname> <given-names>H</given-names></string-name>, <string-name><surname>Pfeiffer</surname> <given-names>K</given-names></string-name>. <article-title>Supercomplexes in the respiratory chains of yeast and mammalian mitochondria</article-title>. <source>EMBO J</source> <year>2000</year>; <volume>19</volume>: <fpage>1777</fpage>–<lpage>1783</lpage>.</mixed-citation></ref>
<ref id="c58"><label>58</label><mixed-citation publication-type="journal"><string-name><surname>Lapuente-Brun</surname> <given-names>E</given-names></string-name>, <string-name><surname>Moreno-Loshuertos</surname> <given-names>R</given-names></string-name>, <string-name><surname>Acín-Pérez</surname> <given-names>R</given-names></string-name>, <string-name><surname>Latorre-Pellicer</surname> <given-names>A</given-names></string-name>, <string-name><surname>Colás</surname> <given-names>C</given-names></string-name>, <string-name><surname>Balsa</surname> <given-names>E</given-names></string-name> <etal>et al.</etal> <article-title>Supercomplex assembly determines electron flux in the mitochondrial electron transport chain</article-title>. <source>Science</source> <year>2013</year>; <volume>340</volume>: <fpage>1567</fpage>–<lpage>1570</lpage>.</mixed-citation></ref>
<ref id="c59"><label>59</label><mixed-citation publication-type="journal"><string-name><surname>Maranzana</surname> <given-names>E</given-names></string-name>, <string-name><surname>Barbero</surname> <given-names>G</given-names></string-name>, <string-name><surname>Falasca</surname> <given-names>AI</given-names></string-name>, <string-name><surname>Lenaz</surname> <given-names>G</given-names></string-name>, <string-name><surname>Genova</surname> <given-names>ML</given-names></string-name>. <article-title>Mitochondrial respiratory supercomplex association limits production of reactive oxygen species from complex I</article-title>. <source>Antioxid Redox Signal</source> <year>2013</year>; <volume>19</volume>: <fpage>1469</fpage>–<lpage>1480</lpage>.</mixed-citation></ref>
<ref id="c60"><label>60</label><mixed-citation publication-type="journal"><string-name><surname>Guarás</surname> <given-names>A</given-names></string-name>, <string-name><surname>Perales-Clemente</surname> <given-names>E</given-names></string-name>, <string-name><surname>Calvo</surname> <given-names>E</given-names></string-name>, <string-name><surname>Acín-Pérez</surname> <given-names>R</given-names></string-name>, <string-name><surname>Loureiro-Lopez</surname> <given-names>M</given-names></string-name>, <string-name><surname>Pujol</surname> <given-names>C</given-names></string-name> <etal>et al.</etal> <article-title>The CoQH2/CoQ Ratio Serves as a Sensor of Respiratory Chain Efficiency</article-title>. <source>Cell Rep</source> <year>2016</year>; <volume>15</volume>: <fpage>197</fpage>–<lpage>209</lpage>.</mixed-citation></ref>
<ref id="c61"><label>61</label><mixed-citation publication-type="journal"><string-name><surname>Gudz</surname> <given-names>TI</given-names></string-name>, <string-name><surname>Tserng</surname> <given-names>KY</given-names></string-name>, <string-name><surname>Hoppel</surname> <given-names>CL</given-names></string-name>. <article-title>Direct inhibition of mitochondrial respiratory chain complex III by cell-permeable ceramide</article-title>. <source>J Biol Chem</source> <year>1997</year>; <volume>272</volume>: <fpage>24154</fpage>–<lpage>24158</lpage>.</mixed-citation></ref>
<ref id="c62"><label>62</label><mixed-citation publication-type="journal"><string-name><surname>Pinto</surname> <given-names>SN</given-names></string-name>, <string-name><surname>Silva</surname> <given-names>LC</given-names></string-name>, <string-name><surname>Futerman</surname> <given-names>AH</given-names></string-name>, <string-name><surname>Prieto</surname> <given-names>M</given-names></string-name>. <article-title>Effect of ceramide structure on membrane biophysical properties: the role of acyl chain length and unsaturation</article-title>. <source>Biochim Biophys Acta</source> <year>2011</year>; <volume>1808</volume>: <fpage>2753</fpage>–<lpage>2760</lpage>.</mixed-citation></ref>
<ref id="c63"><label>63</label><mixed-citation publication-type="journal"><string-name><surname>Wu</surname> <given-names>M</given-names></string-name>, <string-name><surname>Gu</surname> <given-names>J</given-names></string-name>, <string-name><surname>Guo</surname> <given-names>R</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Yang</surname> <given-names>M</given-names></string-name>. <article-title>Structure of Mammalian Respiratory Supercomplex I1III2IV1</article-title>. <source>Cell</source> <year>2016</year>; <volume>167</volume>: <fpage>1598</fpage>–<lpage>1609</lpage>.e10.</mixed-citation></ref>
<ref id="c64"><label>64</label><mixed-citation publication-type="journal"><string-name><surname>Mileykovskaya</surname> <given-names>E</given-names></string-name>, <string-name><surname>Dowhan</surname> <given-names>W</given-names></string-name>. <article-title>Cardiolipin-dependent formation of mitochondrial respiratory supercomplexes</article-title>. <source>Chem Phys Lipids</source> <year>2014</year>; <volume>179</volume>: <fpage>42</fpage>–<lpage>48</lpage>.</mixed-citation></ref>
<ref id="c65"><label>65</label><mixed-citation publication-type="journal"><string-name><surname>Babiychuk</surname> <given-names>EB</given-names></string-name>, <string-name><surname>Atanassoff</surname> <given-names>AP</given-names></string-name>, <string-name><surname>Monastyrskaya</surname> <given-names>K</given-names></string-name>, <string-name><surname>Brandenberger</surname> <given-names>C</given-names></string-name>, <string-name><surname>Studer</surname> <given-names>D</given-names></string-name>, <string-name><surname>Allemann</surname> <given-names>C</given-names></string-name> <etal>et al.</etal> <article-title>The targeting of plasmalemmal ceramide to mitochondria during apoptosis</article-title>. <source>PLoS One</source> <year>2011</year>; <volume>6</volume>: <fpage>e23706</fpage>.</mixed-citation></ref>
<ref id="c66"><label>66</label><mixed-citation publication-type="journal"><string-name><surname>Babiychuk</surname> <given-names>EB</given-names></string-name>, <string-name><surname>Monastyrskaya</surname> <given-names>K</given-names></string-name>, <string-name><surname>Draeger</surname> <given-names>A</given-names></string-name>. <article-title>Fluorescent annexin A1 reveals dynamics of ceramide platforms in living cells</article-title>. <source>Traffic</source> <year>2008</year>; <volume>9</volume>: <fpage>1757</fpage>–<lpage>1775</lpage>.</mixed-citation></ref>
<ref id="c67"><label>67</label><mixed-citation publication-type="journal"><string-name><surname>Bionda</surname> <given-names>C</given-names></string-name>, <string-name><surname>Portoukalian</surname> <given-names>J</given-names></string-name>, <string-name><surname>Schmitt</surname> <given-names>D</given-names></string-name>, <string-name><surname>Rodriguez-Lafrasse</surname> <given-names>C</given-names></string-name>, <string-name><surname>Ardail</surname> <given-names>D</given-names></string-name>. <article-title>Subcellular compartmentalization of ceramide metabolism: MAM (mitochondria-associated membrane) and/or mitochondria?</article-title> <source>Biochem J</source> <year>2004</year>; <volume>382</volume>: <fpage>527</fpage>–<lpage>533</lpage>.</mixed-citation></ref>
<ref id="c68"><label>68</label><mixed-citation publication-type="journal"><string-name><surname>Novgorodov</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>BX</given-names></string-name>, <string-name><surname>Gudz</surname> <given-names>TI</given-names></string-name>, <string-name><surname>Bielawski</surname> <given-names>J</given-names></string-name>, <string-name><surname>Ovchinnikova</surname> <given-names>TV</given-names></string-name>, <string-name><surname>Hannun</surname> <given-names>YA</given-names></string-name> <etal>et al.</etal> <article-title>Novel pathway of ceramide production in mitochondria: thioesterase and neutral ceramidase produce ceramide from sphingosine and acyl-CoA</article-title>. <source>J Biol Chem</source> <year>2011</year>; <volume>286</volume>: <fpage>25352</fpage>–<lpage>25362</lpage>.</mixed-citation></ref>
<ref id="c69"><label>69</label><mixed-citation publication-type="journal"><string-name><surname>Birbes</surname> <given-names>H</given-names></string-name>, <string-name><surname>El Bawab</surname> <given-names>S</given-names></string-name>, <string-name><surname>Hannun</surname> <given-names>YA</given-names></string-name>, <string-name><surname>Obeid</surname> <given-names>LM</given-names></string-name>. <article-title>Selective hydrolysis of a mitochondrial pool of sphingomyelin induces apoptosis</article-title>. <source>FASEB J</source> <year>2001</year>; <volume>15</volume>: <fpage>2669</fpage>–<lpage>2679</lpage>.</mixed-citation></ref>
<ref id="c70"><label>70</label><mixed-citation publication-type="journal"><string-name><surname>Yu</surname> <given-names>J</given-names></string-name>, <string-name><surname>Novgorodov</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Chudakova</surname> <given-names>D</given-names></string-name>, <string-name><surname>Zhu</surname> <given-names>H</given-names></string-name>, <string-name><surname>Bielawska</surname> <given-names>A</given-names></string-name>, <string-name><surname>Bielawski</surname> <given-names>J</given-names></string-name> <etal>et al.</etal> <article-title>JNK3 signaling pathway activates ceramide synthase leading to mitochondrial dysfunction</article-title>. <source>J Biol Chem</source> <year>2007</year>; <volume>282</volume>: <fpage>25940</fpage>–<lpage>25949</lpage>.</mixed-citation></ref>
<ref id="c71"><label>71</label><mixed-citation publication-type="journal"><string-name><surname>García-Ruiz</surname> <given-names>C</given-names></string-name>, <string-name><surname>Colell</surname> <given-names>A</given-names></string-name>, <string-name><surname>Marí</surname> <given-names>M</given-names></string-name>, <string-name><surname>Morales</surname> <given-names>A</given-names></string-name>, <string-name><surname>Fernández-Checa</surname> <given-names>JC</given-names></string-name>. <article-title>Direct effect of ceramide on the mitochondrial electron transport chain leads to generation of reactive oxygen species. Role of mitochondrial glutathione</article-title>. <source>J Biol Chem</source> <year>1997</year>; <volume>272</volume>: <fpage>11369</fpage>–<lpage>11377</lpage>.</mixed-citation></ref>
<ref id="c72"><label>72</label><mixed-citation publication-type="journal"><string-name><surname>Turpin-Nolan</surname> <given-names>SM</given-names></string-name>, <string-name><surname>Hammerschmidt</surname> <given-names>P</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>W</given-names></string-name>, <string-name><surname>Jais</surname> <given-names>A</given-names></string-name>, <string-name><surname>Timper</surname> <given-names>K</given-names></string-name>, <string-name><surname>Awazawa</surname> <given-names>M</given-names></string-name> <etal>et al.</etal> <article-title>CerS1-Derived C18:0 Ceramide in Skeletal Muscle Promotes Obesity-Induced Insulin Resistance</article-title>. <source>Cell Rep</source> <year>2019</year>; <volume>26</volume>: <fpage>1</fpage>–<lpage>10</lpage>.e7.</mixed-citation></ref>
<ref id="c73"><label>73</label><mixed-citation publication-type="journal"><string-name><surname>Oleinik</surname> <given-names>N</given-names></string-name>, <string-name><surname>Kim</surname> <given-names>J</given-names></string-name>, <string-name><surname>Roth</surname> <given-names>BM</given-names></string-name>, <string-name><surname>Selvam</surname> <given-names>SP</given-names></string-name>, <string-name><surname>Gooz</surname> <given-names>M</given-names></string-name>, <string-name><surname>Johnson</surname> <given-names>RH</given-names></string-name> <etal>et al.</etal> <article-title>Mitochondrial protein import is regulated by p17/PERMIT to mediate lipid metabolism and cellular stress</article-title>. <source>Sci Adv</source> <year>2019</year>; <volume>5</volume>: <fpage>eaax1978</fpage>.</mixed-citation></ref>
<ref id="c74"><label>74</label><mixed-citation publication-type="journal"><string-name><surname>Bonnard</surname> <given-names>C</given-names></string-name>, <string-name><surname>Durand</surname> <given-names>A</given-names></string-name>, <string-name><surname>Peyrol</surname> <given-names>S</given-names></string-name>, <string-name><surname>Chanseaume</surname> <given-names>E</given-names></string-name>, <string-name><surname>Chauvin</surname> <given-names>M-A</given-names></string-name>, <string-name><surname>Morio</surname> <given-names>B</given-names></string-name> <etal>et al.</etal> <article-title>Mitochondrial dysfunction results from oxidative stress in the skeletal muscle of diet-induced insulin-resistant mice</article-title>. <source>J Clin Invest</source> <year>2008</year>; <volume>118</volume>: <fpage>789</fpage>–<lpage>800</lpage>.</mixed-citation></ref>
<ref id="c75"><label>75</label><mixed-citation publication-type="journal"><string-name><surname>Picard</surname> <given-names>M</given-names></string-name>, <string-name><surname>Shirihai</surname> <given-names>OS</given-names></string-name>. <article-title>Mitochondrial signal transduction</article-title>. <source>Cell Metab</source> <year>2022</year>; <volume>34</volume>: <fpage>1620</fpage>–<lpage>1653</lpage>.</mixed-citation></ref>
<ref id="c76"><label>76</label><mixed-citation publication-type="journal"><string-name><surname>Zorov</surname> <given-names>DB</given-names></string-name>, <string-name><surname>Juhaszova</surname> <given-names>M</given-names></string-name>, <string-name><surname>Sollott</surname> <given-names>SJ</given-names></string-name>. <article-title>Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release</article-title>. <source>Physiol Rev</source> <year>2014</year>; <volume>94</volume>: <fpage>909</fpage>–<lpage>950</lpage>.</mixed-citation></ref>
<ref id="c77"><label>77</label><mixed-citation publication-type="journal"><string-name><surname>Siskind</surname> <given-names>LJ</given-names></string-name>, <string-name><surname>Kolesnick</surname> <given-names>RN</given-names></string-name>, <string-name><surname>Colombini</surname> <given-names>M</given-names></string-name>. <article-title>Ceramide channels increase the permeability of the mitochondrial outer membrane to small proteins</article-title>. <source>J Biol Chem</source> <year>2002</year>; <volume>277</volume>: <fpage>26796</fpage>–<lpage>26803</lpage>.</mixed-citation></ref>
<ref id="c78"><label>78</label><mixed-citation publication-type="journal"><string-name><surname>Taddeo</surname> <given-names>EP</given-names></string-name>, <string-name><surname>Laker</surname> <given-names>RC</given-names></string-name>, <string-name><surname>Breen</surname> <given-names>DS</given-names></string-name>, <string-name><surname>Akhtar</surname> <given-names>YN</given-names></string-name>, <string-name><surname>Kenwood</surname> <given-names>BM</given-names></string-name>, <string-name><surname>Liao</surname> <given-names>JA</given-names></string-name> <etal>et al.</etal> <article-title>Opening of the mitochondrial permeability transition pore links mitochondrial dysfunction to insulin resistance in skeletal muscle</article-title>. <source>Mol Metab</source> <year>2014</year>; <volume>3</volume>: <fpage>124</fpage>–<lpage>134</lpage>.</mixed-citation></ref>
<ref id="c79"><label>79</label><mixed-citation publication-type="journal"><string-name><surname>Cho</surname> <given-names>J</given-names></string-name>, <string-name><surname>Zhang</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Park</surname> <given-names>S-Y</given-names></string-name>, <string-name><surname>Joseph</surname> <given-names>A-M</given-names></string-name>, <string-name><surname>Han</surname> <given-names>C</given-names></string-name>, <string-name><surname>Park</surname> <given-names>H-J</given-names></string-name> <etal>et al.</etal> <article-title>Mitochondrial ATP transporter depletion protects mice against liver steatosis and insulin resistance</article-title>. <source>Nat Commun</source> <year>2017</year>; <volume>8</volume>: <fpage>14477</fpage>.</mixed-citation></ref>
<ref id="c80"><label>80</label><mixed-citation publication-type="journal"><string-name><surname>Walter</surname> <given-names>L</given-names></string-name>, <string-name><surname>Nogueira</surname> <given-names>V</given-names></string-name>, <string-name><surname>Leverve</surname> <given-names>X</given-names></string-name>, <string-name><surname>Heitz</surname> <given-names>MP</given-names></string-name>, <string-name><surname>Bernardi</surname> <given-names>P</given-names></string-name>, <string-name><surname>Fontaine</surname> <given-names>E</given-names></string-name>. <article-title>Three classes of ubiquinone analogs regulate the mitochondrial permeability transition pore through a common site</article-title>. <source>J Biol Chem</source> <year>2000</year>; <volume>275</volume>: <fpage>29521</fpage>–<lpage>29527</lpage>.</mixed-citation></ref>
<ref id="c81"><label>81</label><mixed-citation publication-type="journal"><string-name><surname>Galgani</surname> <given-names>JE</given-names></string-name>, <string-name><surname>Fernández-Verdejo</surname> <given-names>R</given-names></string-name>. <article-title>Pathophysiological role of metabolic flexibility on metabolic health</article-title>. <source>Obes Rev</source> <year>2021</year>; <volume>22</volume>: <fpage>e13131</fpage>.</mixed-citation></ref>
<ref id="c82"><label>82</label><mixed-citation publication-type="journal"><string-name><surname>Hernansanz-Agustín</surname> <given-names>P</given-names></string-name>, <string-name><surname>Enríquez</surname> <given-names>JA</given-names></string-name>. <article-title>Functional segmentation of CoQ and cyt c pools by respiratory complex superassembly</article-title>. <source>Free Radic Biol Med</source> <year>2021</year>; <volume>167</volume>: <fpage>232</fpage>–<lpage>242</lpage>.</mixed-citation></ref>
<ref id="c83"><label>83</label><mixed-citation publication-type="journal"><string-name><surname>Yang</surname> <given-names>F</given-names></string-name>, <string-name><surname>Shen</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Camp</surname> <given-names>DG</given-names></string-name> <article-title>2nd, Smith RD. High-pH reversed-phase chromatography with fraction concatenation for 2D proteomic analysis</article-title>. <source>Expert Rev Proteomics</source> <year>2012</year>; <volume>9</volume>: <fpage>129</fpage>–<lpage>134</lpage>.</mixed-citation></ref>
<ref id="c84"><label>84</label><mixed-citation publication-type="journal"><string-name><surname>Smyth</surname> <given-names>GK</given-names></string-name>. <article-title>Linear models and empirical bayes methods for assessing differential expression in microarray experiments</article-title>. <source>Stat Appl Genet Mol Biol</source> <year>2004</year>; <volume>3</volume>: Article3.</mixed-citation></ref>
<ref id="c85"><label>85</label><mixed-citation publication-type="journal"><string-name><surname>Szklarczyk</surname> <given-names>D</given-names></string-name>, <string-name><surname>Gable</surname> <given-names>AL</given-names></string-name>, <string-name><surname>Lyon</surname> <given-names>D</given-names></string-name>, <string-name><surname>Junge</surname> <given-names>A</given-names></string-name>, <string-name><surname>Wyder</surname> <given-names>S</given-names></string-name>, <string-name><surname>Huerta-Cepas</surname> <given-names>J</given-names></string-name> <etal>et al.</etal> <article-title>STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets</article-title>. <source>Nucleic Acids Res</source> <year>2019</year>; <volume>47</volume>: <fpage>D607</fpage>–<lpage>D613</lpage>.</mixed-citation></ref>
<ref id="c86"><label>86</label><mixed-citation publication-type="journal"><string-name><surname>Ritchie</surname> <given-names>ME</given-names></string-name>, <string-name><surname>Phipson</surname> <given-names>B</given-names></string-name>, <string-name><surname>Wu</surname> <given-names>D</given-names></string-name>, <string-name><surname>Hu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Law</surname> <given-names>CW</given-names></string-name>, <string-name><surname>Shi</surname> <given-names>W</given-names></string-name> <etal>et al.</etal> <article-title>limma powers differential expression analyses for RNA-sequencing and microarray studies</article-title>. <source>Nucleic Acids Res</source> <year>2015</year>; <volume>43</volume>: <fpage>e47</fpage>.</mixed-citation></ref>
<ref id="c87"><label>87</label><mixed-citation publication-type="journal"><string-name><surname>Langfelder</surname> <given-names>P</given-names></string-name>, <string-name><surname>Horvath</surname> <given-names>S</given-names></string-name>. <article-title>WGCNA: an R package for weighted correlation network analysis</article-title>. <source>BMC Bioinformatics</source> <year>2008</year>; <volume>9</volume>: <fpage>559</fpage>.</mixed-citation></ref>
<ref id="c88"><label>88</label><mixed-citation publication-type="journal"><string-name><surname>Wu</surname> <given-names>T</given-names></string-name>, <string-name><surname>Hu</surname> <given-names>E</given-names></string-name>, <string-name><surname>Xu</surname> <given-names>S</given-names></string-name>, <string-name><surname>Chen</surname> <given-names>M</given-names></string-name>, <string-name><surname>Guo</surname> <given-names>P</given-names></string-name>, <string-name><surname>Dai</surname> <given-names>Z</given-names></string-name> <etal>et al.</etal> <article-title>clusterProfiler 4.0: A universal enrichment tool for interpreting omics data</article-title>. <source>Innovation (Camb</source><italic>)</italic> <year>2021</year>; <volume>2</volume>: <fpage>100141</fpage>.</mixed-citation></ref>
<ref id="c89"><label>89</label><mixed-citation publication-type="journal"><string-name><surname>Fabregat</surname> <given-names>A</given-names></string-name>, <string-name><surname>Jupe</surname> <given-names>S</given-names></string-name>, <string-name><surname>Matthews</surname> <given-names>L</given-names></string-name>, <string-name><surname>Sidiropoulos</surname> <given-names>K</given-names></string-name>, <string-name><surname>Gillespie</surname> <given-names>M</given-names></string-name>, <string-name><surname>Garapati</surname> <given-names>P</given-names></string-name> <etal>et al.</etal> <article-title>The Reactome Pathway Knowledgebase</article-title>. <source>Nucleic Acids Res</source> <year>2018</year>; <volume>46</volume>: <fpage>D649</fpage>–<lpage>D655</lpage>.</mixed-citation></ref>
<ref id="c90"><label>90</label><mixed-citation publication-type="journal"><string-name><surname>Seal</surname> <given-names>RL</given-names></string-name>, <string-name><surname>Braschi</surname> <given-names>B</given-names></string-name>, <string-name><surname>Gray</surname> <given-names>K</given-names></string-name>, <string-name><surname>Jones</surname> <given-names>TEM</given-names></string-name>, <string-name><surname>Tweedie</surname> <given-names>S</given-names></string-name>, <string-name><surname>Haim-Vilmovsky</surname> <given-names>L</given-names></string-name> <etal>et al.</etal> <article-title>Genenames.org: the HGNC resources in 2023</article-title>. <source>Nucleic Acids Res</source> <year>2023</year>; <volume>51</volume>: <fpage>D1003</fpage>–<lpage>D1009</lpage>.</mixed-citation></ref>
<ref id="c91"><label>91</label><mixed-citation publication-type="journal"><string-name><surname>Govers</surname> <given-names>R</given-names></string-name>, <string-name><surname>Coster</surname> <given-names>ACF</given-names></string-name>, <string-name><surname>James</surname> <given-names>DE</given-names></string-name>. <article-title>Insulin increases cell surface GLUT4 levels by dose dependently discharging GLUT4 into a cell surface recycling pathway</article-title>. <source>Mol Cell Biol</source> <year>2004</year>; <volume>24</volume>: <fpage>6456</fpage>–<lpage>6466</lpage>.</mixed-citation></ref>
<ref id="c92"><label>92</label><mixed-citation publication-type="journal"><string-name><surname>Zarini</surname> <given-names>S</given-names></string-name>, <string-name><surname>Brozinick</surname> <given-names>JT</given-names></string-name>, <string-name><surname>Zemski Berry</surname> <given-names>KA</given-names></string-name>, <string-name><surname>Garfield</surname> <given-names>A</given-names></string-name>, <string-name><surname>Perreault</surname> <given-names>L</given-names></string-name>, <string-name><surname>Kerege</surname> <given-names>A</given-names></string-name> <etal>et al.</etal> <article-title>Serum dihydroceramides correlate with insulin sensitivity in humans and decrease insulin sensitivity in vitro</article-title>. <source>J Lipid Res</source> <year>2022</year>; <volume>63</volume>: <fpage>100270</fpage>.</mixed-citation></ref>
<ref id="c93"><label>93</label><mixed-citation publication-type="journal"><string-name><surname>Bui</surname> <given-names>M</given-names></string-name>, <string-name><surname>Gilady</surname> <given-names>SY</given-names></string-name>, <string-name><surname>Fitzsimmons</surname> <given-names>REB</given-names></string-name>, <string-name><surname>Benson</surname> <given-names>MD</given-names></string-name>, <string-name><surname>Lynes</surname> <given-names>EM</given-names></string-name>, <string-name><surname>Gesson</surname> <given-names>K</given-names></string-name> <etal>et al.</etal> <article-title>Rab32 modulates apoptosis onset and mitochondria-associated membrane (MAM) properties</article-title>. <source>J Biol Chem</source> <year>2010</year>; <volume>285</volume>: <fpage>31590</fpage>–<lpage>31602</lpage>.</mixed-citation></ref>
<ref id="c94"><label>94</label><mixed-citation publication-type="journal"><string-name><surname>Frezza</surname> <given-names>C</given-names></string-name>, <string-name><surname>Cipolat</surname> <given-names>S</given-names></string-name>, <string-name><surname>Scorrano</surname> <given-names>L</given-names></string-name>. <article-title>Organelle isolation: functional mitochondria from mouse liver, muscle and cultured fibroblasts</article-title>. <source>Nat Protoc</source> <year>2007</year>; <volume>2</volume>: <fpage>287</fpage>–<lpage>295</lpage>.</mixed-citation></ref>
<ref id="c95"><label>95</label><mixed-citation publication-type="journal"><string-name><surname>Montgomery</surname> <given-names>MK</given-names></string-name>, <string-name><surname>Osborne</surname> <given-names>B</given-names></string-name>, <string-name><surname>Brandon</surname> <given-names>AE</given-names></string-name>, <string-name><surname>O’Reilly</surname> <given-names>L</given-names></string-name>, <string-name><surname>Fiveash</surname> <given-names>CE</given-names></string-name>, <string-name><surname>Brown</surname> <given-names>SHJ</given-names></string-name> <etal>et al.</etal> <article-title>Regulation of mitochondrial metabolism in murine skeletal muscle by the medium-chain fatty acid receptor Gpr84</article-title>. <source>FASEB J</source> <year>2019</year>; <volume>33</volume>: <fpage>12264</fpage>–<lpage>12276</lpage>.</mixed-citation></ref>
<ref id="c96"><label>96</label><mixed-citation publication-type="journal"><string-name><surname>Díaz-Vegas</surname> <given-names>AR</given-names></string-name>, <string-name><surname>Cordova</surname> <given-names>A</given-names></string-name>, <string-name><surname>Valladares</surname> <given-names>D</given-names></string-name>, <string-name><surname>Llanos</surname> <given-names>P</given-names></string-name>, <string-name><surname>Hidalgo</surname> <given-names>C</given-names></string-name>, <string-name><surname>Gherardi</surname> <given-names>G</given-names></string-name> <etal>et al.</etal> <article-title>Mitochondrial Calcium Increase Induced by RyR1 and IP3R Channel Activation After Membrane Depolarization Regulates Skeletal Muscle Metabolism</article-title>. <source>Front Physiol</source> <year>2018</year>; <volume>9</volume>: <fpage>791</fpage>.</mixed-citation></ref>
<ref id="c97"><label>97</label><mixed-citation publication-type="journal"><string-name><surname>Kory</surname> <given-names>N</given-names></string-name>, <string-name><given-names>Uit</given-names> <surname>de Bos J</surname></string-name>, <string-name><surname>van der Rijt</surname> <given-names>S</given-names></string-name>, <string-name><surname>Jankovic</surname> <given-names>N</given-names></string-name>, <string-name><surname>Güra</surname> <given-names>M</given-names></string-name>, <string-name><surname>Arp</surname> <given-names>N</given-names></string-name> <etal>et al.</etal> <article-title>MCART1/SLC25A51 is required for mitochondrial NAD transport</article-title>. <source>Sci Adv</source> <year>2020</year>; <volume>6</volume>. doi:<pub-id pub-id-type="doi">10.1126/sciadv.abe5310</pub-id>.</mixed-citation></ref>
</ref-list>
</back>
<sub-article id="sa0" article-type="editor-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.87340.2.sa2</article-id>
<title-group>
<article-title>eLife Assessment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Czech</surname>
<given-names>Michael</given-names>
</name>
<role specific-use="editor">Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>University of Massachusetts Medical School</institution>
</institution-wrap>
<city>Worcester</city>
<country>United States of America</country>
</aff>
</contrib>
</contrib-group>
<kwd-group kwd-group-type="evidence-strength">
<kwd>Compelling</kwd>
</kwd-group>
<kwd-group kwd-group-type="claim-importance">
<kwd>Important</kwd>
</kwd-group>
</front-stub>
<body>
<p>This <bold>important</bold> study highlights a potential connection between fatty acid intrusion into myocytes and increases in mitochondrial ceramide that cause deficits in coenzyme Q and consequent insulin resistance. The authors primarily use the L6 myocyte model, which may not fully recapitulate in vivo conditions, however, the manuscript shows <bold>compelling</bold> data in mice that substantially supports the L6 cell results. Overall, this study provides a strong framework for a <bold>compelling</bold> pathway of myocyte dysfunction and for continued efforts to test the <bold>important</bold> hypotheses that are presented.</p>
</body>
</sub-article>
<sub-article id="sa1" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.87340.2.sa1</article-id>
<title-group>
<article-title>Reviewer #1 (Public Review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Previous reports suggested an association between ceramide accumulation in skeletal muscle and disruption of insulin signaling and metabolic dysregulation. Mechanistically, however, how intracellular ceramide attenuates insulin action and reduces metabolism is not fully understood. It was suggested that insulin receptor (IR) signaling to PI3-K/AKT is inhibited by elevated intracellular ceramide. However, other studies failed to demonstrate an inhibitory effect of ceramide on PI3K/AKT. More recently, a study was published describing that intracellular localization of diacylglycerols and sphingolipids influences insulin sensitivity and mitochondrial function in human skeletal muscle (PMID: 29415895). In the present study, Diaz-Vegas and colleagues used an in vitro system to investigate this topic further and better understand how intracellular ceramide accumulation causes cellular insulin resistance and metabolic dysregulations in cultured myocytes.</p>
<p>The authors applied multiple methods to achieve this goal. Among these procedures are:</p>
<p>1. The overexpression of enzymes involved in mitochondrial ceramide synthesis and degradation;</p>
<p>
2. Treatments of myocytes with different pharmacological tools to validate their findings;</p>
<p>
3. Mitochondrial proteomics and lipidomics analyses.</p>
<p>The effects of these experimental conditions and treatment on intracellular lipids contents, mitochondrial functions, and insulin signaling in myocytes were then evaluated.</p>
<p>Findings:</p>
<p>The author's findings indicate that incubation of myocytes with palmitate increases mitochondrial ceramide and reduces the insulin-stimulated GLUT4-HA translocation to the myocyte surface without affecting AKT activation. The elevation in mitochondrial ceramide lowers the coenzyme Q levels e depletes the electron transport chain (ETC) components, impairing mitochondrial respiration. Such mitochondrial dysfunction appears to attenuate the translocation of GLUT4-HA to the plasma membrane of the L6-myotubule. Also, mitochondrial proteomic analysis revealed an association of insulin sensitivity with mitochondrial ceramide and ETC expression levels in human muscle.</p>
<p>Based on these findings, the authors propose a mechanism whereby the building up of ceramide inside mitochondria depletes CoQ and compromises mitochondrial respiratory complexes, raising ROS. The resulting mitochondrial dysfunction causes insulin resistance in cultured myocytes. They postulate that CoQ depletion links ceramides with insulin resistance and define the respirasome as a critical connection between ceramides and mitochondrial dysfunction.</p>
<p>Relevance and critiques:</p>
<p>This original study provides direct evidence that mitochondrial ceramide accumulation depletes CoQ and downregulates multiple ETC components in myocytes. Consequently, elevation in the levels of reactive oxygen species (ROS) and mitochondrial dysfunctions occur. The authors proposed that such mitochondrial dysregulation attenuates insulin-stimulated GLUT4 translocation to the plasma membrane of L6-myotubules. Moreover, mitochondrial ceramide accumulation does not affect insulin action on AKT activation.</p>
<p>Overall, this is a well-done study, showing that in obesity, elevated mitochondrial ceramide suppresses mitochondrial function and attenuates insulin action on glucose transporter GLUT4 translocation into the myocyte surface. The main conclusion is supported by the results presented. The study also applied multiple methods and described several experiments designed to test the author's central hypothesis.</p>
<p>Importantly, these new findings shed light on possible cellular mechanisms whereby ectopic fat deposition in skeletal muscle drives insulin resistance and metabolism dysregulation. The results demonstrating that alterations in mitochondrial ceramide are sufficient to attenuate insulin-stimulated GLUT4 trafficking in cultured myocytes are very interesting. Well-done.</p>
<p>Comments for further discussion and suggestions:</p>
<p>Although the author's results suggest that higher mitochondrial ceramide levels suppress cellular insulin sensitivity, they rely solely on a partial inhibition (i.e., 30%) of insulin-stimulated GLUT4-HA translocation in L6 myocytes. It would be critical to examine how much the increased mitochondrial ceramide would inhibit insulin-induced glucose uptake in myocytes using radiolabel deoxy-glucose.</p>
<p>Another important question to be addressed is whether glycogen synthesis is affected in myocytes under these experimental conditions. Results demonstrating reductions in insulin-stimulated glucose transport and glycogen synthesis in myocytes with dysfunctional mitochondria due to ceramide accumulation would further support the author's claim.</p>
<p>In addition, it would be critical to assess whether the increased mitochondrial ceramide and consequent lowering of energy levels affect all exocytic pathways in L6 myoblasts or just the GLUT4 trafficking. Is the secretory pathway also disrupted under these conditions?</p>
<p>Additional suggestions:</p>
<p>• Figure 1: How does increased mitochondrial ceramide affect fatty acid oxidation (FAO) in L6-myocytes? As the accumulation of mitochondrial ceramide inhibits respirasome and mitochondrial activity in vitro, can reduced FAO in vivo, due to high mitochondrial ceramide, accounts for ectopic lipid deposition in skeletal muscle of obese subjects?</p>
<p>• Figure 2: Although the authors show that mtSMPD5 overexpression does not affect ceramide abundance in whole cell lysate, it would be critical to examine the abundance of this lipid in other cellular membranes and organelles, particularly plasma membrane. What is the effect of mtSMPD5 overexpression on plasma membrane lipids composition? Does that affect GLUT4-containing vesicles fusion into the plasma membrane, possibly due to depletion of v-SNARE or tSNARE?</p>
<p>• Figure 4: One critical piece of information missing is the effect (if any) of mitochondrial ceramide accumulation on the mRNAs encoding the ETC components affected by this lipid. Although the ETC protein's lower stability may account for the effect of increased ceramide, transcriptional inhibition can't be ruled out without checking the mRNA expression levels for these ETC components.</p>
<p>In the revised version of their study, the authors nicely addressed all concerns previously raised. The amount of work that went into the revisions is appreciated. All weak points have been properly addressed, and the manuscript has improved substantially.</p>
</body>
</sub-article>
<sub-article id="sa2" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.87340.2.sa0</article-id>
<title-group>
<article-title>Reviewer #2 (Public Review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary</p>
<p>The findings reported by Diaz-Vegas et al. extend those described in a previous paper from the same group establishing a role for mitochondrial CoQ depletion in the development of insulin resistance in muscle and adipose tissue (Fazakerley, 2018). In this new report, investigators sought to determine whether CoQ depletion contributes to insulin resistance caused by palmitate exposure and/or intracellular ceramide accumulation. To this end, researchers employed a widely used in vitro model of insulin resistance wherein L6 myocytes develop impaired Glut4 translocation upon exposure to palmitate (in this case, 150 uM for 16 hours). This model was combined with a variety of pharmacologic and genetic manipulations aimed at augmenting or inhibiting CoQ biosynthesis and/or ceramide biosynthesis, specifically in mitochondria. This series of experiments produced a valuable and provocative body of evidence positioning CoQ depletion downstream of mitochondrial ceramide accumulation and necessary for both palmitate- and ceramide-induced insulin resistance in L6 myocytes. Investigators concluded that mitochondrial ceramides, CoQ depletion and respiratory dysfunction are part of a core pathway leading to insulin resistance.</p>
<p>Strengths</p>
<p>The study provides exciting, first-time evidence linking palmitate-induced insulin resistance to ceramide accumulation within the mitochondria and subsequent depletion of CoQ. Ceramide accumulation specifically in mitochondria was found to be necessary and sufficient to cause insulin resistance in cultured L6 myocytes.</p>
<p>The in vitro experiments featured a set of mitochondrial-targeted genetic manipulations that permitted up/down-regulation of ceramide levels specifically in the mitochondrial compartment. Genetically induced mitochondrial ceramide accumulation led to CoQ depletion, which was accompanied by increased ROS production and diminution of ETC proteins and OXPHOS capacity and impaired insulin action, thereby establishing cause/effect.</p>
<p>Analysis of mitochondria isolated from human muscle biopsies obtained from individuals with disparate metabolic phenotypes revealed a positive correlation between complex I proteins and insulin sensitivity and a negative correlation with mitochondrial ceramide content. While it is likely that many factors contribute to these correlations, the results support the possibility that the ceramide/CoQ mechanism might be relevant to glucose control in humans.</p>
<p>Investigators were responsive to the reviewers' queries and critiques and performed additional experiments to bolster the interpretations and conclusions put forth in the manuscript. These included experiments to confirm that mito-targeted SMPD5 does not cause toxicity in L6 myocytes, and further studies using targeted metabolomic and lipidomic analyses to investigate the impact of ceramide depletion on CoQ levels in mice fed a high-fat diet and treated with P053 (a selective inhibitor of CerS1). The results were consistent with the in vitro findings.</p>
<p>Overall, these important findings offer valuable new insights into mechanisms that connect ceramides to insulin resistance and mitochondrial dysfunction, and could inform new therapeutic approaches towards improved glucose control.</p>
<p>Weaknesses</p>
<p>The mechanistic aspect of the work and conclusions put forth rely heavily on studies performed in cultured myocytes, which are highly glycolytic and generally viewed as an imperfect model for studying muscle metabolism and insulin action. Nonetheless, results from the cell culture model are generally convincing and align with the descriptive data from studies in animal models. Overall, the findings provide a strong rationale for moving this line of investigation into mouse gain/loss of function models.</p>
<p>One caveat of the approach taken is that exposure of cells to palmitate alone is not reflective of in vivo physiology. It would be interesting to know if similar effects on CoQ are observed when cells are exposed to a more physiological mixture of fatty acids that includes a high ratio of palmitate, but better mimics in vivo nutrition.</p>
</body>
</sub-article>
<sub-article id="sa3" article-type="author-comment">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.87340.2.sa3</article-id>
<title-group>
<article-title>Author Response</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Diaz-Vegas</surname>
<given-names>Alexis</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Madsen</surname>
<given-names>Soren</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cooke</surname>
<given-names>Kristen C.</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Carroll</surname>
<given-names>Luke</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8600-4023</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Khor</surname>
<given-names>Jasmine X. Y.</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Turner</surname>
<given-names>Nigel</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lim</surname>
<given-names>Xin Ying</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Astore</surname>
<given-names>Miro A.</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9896-8831</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Morris</surname>
<given-names>Jonathan</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Don</surname>
<given-names>Anthony</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1655-1184</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Garfield</surname>
<given-names>Amanda</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zarini</surname>
<given-names>Simona</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zemski Berry</surname>
<given-names>Karin A.</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7089-691X</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Ryan</surname>
<given-names>Andrew</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bergman</surname>
<given-names>Bryan C.</given-names>
</name>
<role specific-use="author">Author</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Brozinick</surname>
<given-names>Joseph T.</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7946-3432</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>James</surname>
<given-names>David E.</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5946-5257</contrib-id></contrib>
<contrib contrib-type="author">
<name>
<surname>Burchfield</surname>
<given-names>James G.</given-names>
</name>
<role specific-use="author">Author</role>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6609-6151</contrib-id></contrib>
</contrib-group>
</front-stub>
<body>
<p>The following is the authors’ response to the original reviews.</p>
<disp-quote content-type="editor-comment">
<p>Assessment note: “Whereas the results and interpretations are generally solid, the mechanistic aspect of the work and conclusions put forth rely heavily on in vitro studies performed in cultured L6 myocytes, which are highly glycolytic and generally not viewed as a good model for studying muscle metabolism and insulin action.”</p>
</disp-quote>
<p>While we acknowledge that in vitro models may not fully recapitulate the complexity of in vivo systems, we believe L6 myotubes are appropriate for studying the mechanisms underlying muscle metabolism and insulin action. L6 myotubes possess many important characteristics relevant to our research, including high insulin sensitivity and a similar mitochondrial respiration sensitivity compared to primary muscle fibres. Furthermore, several studies have demonstrated the utility of L6 myotubes as a model for studying insulin sensitivity and metabolism, including our own previous work (PMID: 19805130, 31693893, 19915010) and work of others (PMID:12086937, 29486284, 15193147).</p>
<p>Importantly, our observations from the L6 myotube model are supported by in vivo data from both mice and humans. Chow (Figure 3J, K) and high-fat fed mice (new data - Supplementary Figure 4 H-I) demonstrated a reduction in mitochondrial Ceramide and an increase in CoQ9. Muscle biopsies from humans showed a strong negative correlation between mitochondrial C18:0 ceramide levels and insulin sensitivity (PMID: 29415895). Further, complex I and IV abundance was strongly correlated with both muscle insulin sensitivity and mitochondrial ceramide (CerC18:0) (Figure 6E, F). This is consistent with our observations in L6 myotubes (Figure 6H, I). These findings support the relevance of our in vitro results to in vivo muscle metabolism.</p>
<disp-quote content-type="editor-comment">
<p><bold>Points from reviewer 1</bold></p>
<p>1. Although the authors' results suggest that higher mitochondrial ceramide levels suppress cellular insulin sensitivity, they rely solely on a partial inhibition (i.e., 30%) of insulin-stimulated GLUT4-HA translocation in L6 myocytes. It would be critical to examine how much the increased mitochondrial ceramide would inhibit insulin-induced glucose uptake in myocytes using radiolabeled deoxy-glucose.
Another important question to be addressed is whether glycogen synthesis is affected in myocytes under these experimental conditions. Results demonstrating reductions in insulin-stimulated glucose transport and glycogen synthesis in myocytes with dysfunctional mitochondria due to ceramide accumulation would further support the authors' claim.</p>
</disp-quote>
<p>Response: We have now conducted additional experiments focusing on glycogen synthesis as a readout of insulin sensitivity, as it offers an orthogonal method for assessing GLUT4 translocation and glucose uptake. L6-myotubes overexpressing the mitochondrial-targeted ASAH1 construct (as described in Fig. 3) were challenged with palmitate and insulin stimulated glycogen synthesis was measured using 14C radiolabeled glucose. As shown below, palmitate suppressed insulin-induced glycogen synthesis, which was effectively prevented by overexpression of ASAH1 (N = 5, * p&lt;0.05) supporting our previous observation using GLUT4 translocation as a readout of insulin sensitivity (Fig. 3). These results provide additional evidence highlighting the role of dysfunctional mitochondria in muscle cell glucose metabolism.</p>
<p>These data have now been added to Supplementary Figure 4K and the results modified as follows:</p>
<p>“...For this reason, several in vitro models have been employed involving incubation of insulin sensitive cell types with lipids such as palmitate to mimic lipotoxicity in vivo. In this study we have used cell surface GLUT4-HA abundance as the main readout of insulin response...”</p>
<p>“Notably, mtASAH1 overexpression protected cells from palmitate-induced insulin resistance without affecting basal insulin sensitivity (Fig. 3E). Similar results were observed using insulin-induced glycogen synthesis as an orthologous technique for Glut4 translocation. These results provide additional evidence highlighting the role of dysfunctional mitochondria in muscle cell glucose metabolism (Sup. Fig. 5K). Importantly, mtASAH1 overexpression did not rescue insulin sensitivity in cells depleted…”</p>
<fig id="sa3fig1">
<label>Author response image 1.</label>
<graphic mime-subtype="jpg" xlink:href="elife-87340-sa3-fig1.jpg" mimetype="image"/>
</fig>
<p>Additionally, the following text was added to the method section:</p>
<p>“L6 myotubes overexpressing ASAH were grown and differentiated in 12-well plates, as described in the Cell lines section, and stimulated for 16 h with palmitate-BSA or EtOH-BSA, as detailed in the Induction of insulin resistance section.</p>
<p>On day seven of differentiation, myotubes were serum starved in DMEM for 3.5 h. After incubation for 1 h at 37 °C with 2 µCi/ml D-[U-14C]-glucose in the presence or absence of 100 nM insulin, glycogen synthesis assay was performed, as previously described (Zarini S. et al., J Lipid Res, 63(10): 100270, 2022).”</p>
<disp-quote content-type="editor-comment">
<p>1. In addition, it would be critical to assess whether the increased mitochondrial ceramide and consequent lowering of energy levels affect all exocytic pathways in L6 myoblasts or just the GLUT4 trafficking. Is the secretory pathway also disrupted under these conditions?</p>
</disp-quote>
<p>Response: This is an interesting point raised by the reviewer that is aimed at the next phase of this work, to identify how ceramide induced mitochondrial dysfunction drives insulin resistance. Looking at energy deficiency in more detail as well as general trafficking is part of ongoing work, but given the complexity of this question, it is beyond the scope of the current study.</p>
<disp-quote content-type="editor-comment">
<p><bold>Points from reviewer 2</bold></p>
<p>1. The mechanistic aspect of the work and conclusions put forth rely heavily on studies performed in cultured myocytes, which are highly glycolytic and generally viewed as a poor model for studying muscle metabolism and insulin action. Nonetheless, the findings provide a strong rationale for moving this line of investigation into mouse gain/loss of function models.</p>
</disp-quote>
<p>Response: We acknowledge that in vitro models may not fully mimic in vivo complexity as described above in the response to the “Assessment note”. We have now added to the Discussion:</p>
<p>“In this study, we mainly utilised L6-myotubes, which share many important characteristics with primary muscle fibres. Both types of cells exhibit high sensitivity to insulin and respond similarly to maximal doses of insulin, with GLUT4 translocation stimulated between 2 to 4 times over basal levels in response to 100 nM insulin (as shown in Fig. 1-4 and (46,47)). Additionally, mitochondrial respiration in L6-myotubes has a similar sensitivity to mitochondrial poisons, as observed in primary muscle fibres (as shown in Fig. 5 (48)). Finally, inhibiting ceramide production increases CoQ levels in both L6-myotubes and adult muscle tissue (as shown in Fig. 2-3). Therefore, L6-myotubes possess the necessary metabolic features to investigate the role of mitochondria in insulin resistance, and this relationship is likely applicable to primary muscle fibres”.</p>
<disp-quote content-type="editor-comment">
<p>1. One caveat of the approach taken is that exposure of cells to palmitate alone is not reflective of in vivo physiology. It would be interesting to know if similar effects on CoQ are observed when cells are exposed to a more physiological mixture of fatty acids that includes a high ratio of palmitate, but better mimics in vivo nutrition.</p>
</disp-quote>
<p>Response: We appreciate the reviewer's comment. Previously, we reported that mitochondrial CoQ depletion occurs in skeletal muscle after 14 and 42 days of HFHSD feeding, coinciding with the onset of insulin resistance (PMID: 29402381, see figure below).</p>
<fig id="sa3fig2">
<label>Author response image 2.</label>
<graphic mime-subtype="jpg" xlink:href="elife-87340-sa3-fig2.jpg" mimetype="image"/>
</fig>
<p>These data demonstrated that our in vitro model recapitulates the loss of CoQ in insulin resistance observed in muscle tissue in response to a more physiological mixture of fatty acids. Further, it has been reported that different fatty acids can induce insulin resistance via different mechanisms (PMID:20609972), which would complicate interpretation of the data. Saturated fatty acids such as palmitate increase ceramides in cell-lines and humans, but unsaturated FAs generally do not (PMID: 10446195,14592453,34704121). As such we conclude that palmitate is a cleaner model for studying the effects of ceramide on skeletal muscle function.</p>
<p>We have added to discussion:</p>
<p>“…These findings align with our earlier observations demonstrating that mice exposed to HFHSD exhibit mitochondrial CoQ depletion in skeletal muscle (Fazakerley et al. 2018).”</p>
<disp-quote content-type="editor-comment">
<p>1. While the utility of targeting SMPD5 to the mitochondria is appreciated, the results in Figure 5 suggest that this manoeuvre caused a rather severe form of mitochondrial dysfunction. This could be more representative of toxicity rather than pathophysiology. It would be helpful to know if these same effects are observed with other manipulations that lower CoQ to a similar degree. If not, the discrepancies should be discussed.</p>
</disp-quote>
<p>Response: As the reviewer suggests many of these lipids can cause cell death (toxicity) if the dose is too high. We have previously found that low levels (0.15 mM) of palmitate were sufficient to trigger insulin resistance without any signs of toxicity (Hoehn, K, PNAS, 19805130). Using a similar approach, we show that mitochondrial membrane potential is maintained in SMPD5 overexpressing cells (Sup. Fig. 2J - and Author response image 2). Given that toxicity is associated with a loss of mitochondrial membrane potential (eg., 50uM Saclac; RH panel), these data suggest SMPD5 overexpression is not causing overt toxicity.</p>
<fig id="sa3fig3">
<label>Author response image 3.</label>
<graphic mime-subtype="jpg" xlink:href="elife-87340-sa3-fig3.jpg" mimetype="image"/>
</fig>
<p>Furthermore, we conducted an overrepresentation analysis of molecular processes within our proteomic data from SMPD5-overexpressing cells. As depicted below, no signs of cell toxicity were observed in our model at the protein level. This data is now available in supplementary table 1.</p>
<table-wrap id="sa3table1">
<label>Author response table 1.</label>
<graphic mime-subtype="jpg" xlink:href="elife-87340-sa3-table1.jpg" mimetype="image"/>
</table-wrap>
<p>Our results are therefore consistent with a pathological condition induced by elevated levels of ceramides independently of cellular toxicity. The following text has been added to the discussion:“...downregulation   of  the respirasome induced by  ceramides   may lead    to CoQ depletion.</p>
<p>Despite the significant impact of ceramide on mitochondrial respiration, we did not observe any indications of cell damage in any of the treatments, suggesting that our models are not explained by toxicity and increased cell death (Sup. Fig. 2H &amp; J).”</p>
<disp-quote content-type="editor-comment">
<p>1. The conclusions could be strengthened by more extensive studies in mice to assess the interplay between mitochondrial ceramides, CoQ depletion and ETC/mitochondrial dysfunction in the context of a standard diet versus HF diet-induced insulin resistance. Does P053 affect mitochondrial ceramide, ETC protein abundance, mitochondrial function, and muscle insulin sensitivity in the predicted directions?</p>
</disp-quote>
<p>Response: We agree with the referee about the importance of performing in vivo studies to corroborate our in vitro data. We have now conducted extensive new studies in mice skeletal muscle using targeted metabolomic and lipidomic analyses to investigate the impact of ceramide depletion in CoQ levels in HF-fed mice. Mice were exposed to a HF-fed diet with or without the administration of P053 (selective inhibitor of CerS1) for 5 weeks. As illustrated in the figures below, the administration of P053 led to a reduction in ceramide levels (left panel), increase in CoQ levels (middle panel) and a negative correlation between these molecules (right panel), which is consistent with our in vitro findings.</p>
<fig id="sa3fig4">
<label>Author response image 4.</label>
<graphic mime-subtype="jpg" xlink:href="elife-87340-sa3-fig4.jpg" mimetype="image"/>
</fig>
<disp-quote content-type="editor-comment">
<p>Additional suggestions:</p>
<p>1. Figure 1: How does increased mitochondrial ceramide affect fatty acid oxidation (FAO) in L6-myocytes? As the accumulation of mitochondrial ceramide inhibits respirasome and mitochondrial activity in vitro, can reduce FAO in vivo, due to high mitochondrial ceramide, accounts for ectopic lipid deposition in skeletal muscle of obese subjects?</p>
</disp-quote>
<p>Response: We appreciate the reviewer for bringing up this intriguing point. We would like to emphasise that Complex II activity is vital for fatty acid oxidation. As shown in Fig. 5H, our results indicate that specifically Complex II mediated respiration was diminished in cells with SMPD5 overexpression, suggesting that ceramides hinder the mitochondria's capability to oxidise lipids. We agree that this mechanism may potentially play a role in the ectopic lipid accumulation seen in individuals with obesity.</p>
<p>We have added the following text to discussion:</p>
<p>“...the mitochondria to switch between different energy substrates depending on fuel availability, named “metabolic Inflexibility”...this mechanism may potentially play a role in the ectopic lipid accumulation seen in individuals with obesity, a condition linked with cardio-metabolic disease.”</p>
<disp-quote content-type="editor-comment">
<p>1. Figure 2: Although the authors show that mtSMPD5 overexpression does not affect ceramide abundance in whole cell lysate, it would be critical to examine the abundance of this lipid in other cellular membranes and organelles, particularly plasma membrane. What is the effect of mtSMPD5 overexpression on plasma membrane lipids composition? Does that affect GLUT4-containing vesicles fusion into the plasma membrane, possibly due to depletion of v-SNARE or tSNARE?</p>
</disp-quote>
<p>Response: While we acknowledge the importance of this point we strongly feel that measuring lipids in purified membranes has its limitations because it is impossible to purify specific membranes without contamination from other kinds of membranes. For example, we have done proteomics on purified plasma membranes from different cell types and we always observe considerable mitochondrial contamination with these membranes (e.g. PMID 21928809). This was the main factor that led us to use the mitochondrial targeting approach.</p>
<p>Nevertheless we do acknowledge that there is a possibility that ceramides that are produced in the mitochondria in SMPD5 cells could leak out of mitochondria into other membranes and this could influence other aspects of GLUT4 trafficking and insulin action. However, we believe that the studies using mito targeted ASAH mitigate against this problem. Thus, we have now included a statement in the revised manuscript as follows: “It is also possible that ceramides generated within mitochondria in SMPD5 cells leak out from the mitochondria into other membranes (e.g. PM and Glut4 vesicles) affecting other aspects of Glut4 trafficking and insulin action. However, the observation that ASAH1 overexpression reversed IR without affecting whole cell ceramides argues against this possibility.”.</p>
<disp-quote content-type="editor-comment">
<p>1. Figure 4: One critical piece of information missing is the effect (if any) of mitochondrial ceramide accumulation on the mRNAs encoding the ETC components affected by this lipid. Although the ETC protein's lower stability may account for the effect of increased ceramide, transcriptional inhibition can't be ruled out without checking the mRNA expression levels for these ETC components.</p>
</disp-quote>
<p>Response: To address this point, we have quantified the mRNA abundance of nine complex I subunits that exhibit downregulation in our proteomic dataset subsequent to mtSMPD5 overexpression (as depicted in Figure 4G).</p>
<p>Induction of mtSMPD5 expression with doxycycline (below - Left hand panel) had no effect on the mRNA levels of the Complex I subunits (below - right hand panel).. This is consistent with our initial hypothesis that the reduction in electron transport chain (ETC) components, caused by heightened ceramide levels, primarily arises from alterations in protein stability rather than gene expression. While we acknowledge the possibility that certain subunits might be regulated at the transcriptional level, the absence of mRNA downregulation across our data strongly suggests that, at the very least, a portion of the observed protein depletion is attributed to diminished protein stability. We have incorporated this dataset into Supplementary Figure 6J and added the following text to the results:</p>
<fig id="sa3fig5">
<label>Author response image 5.</label>
<graphic mime-subtype="jpg" xlink:href="elife-87340-sa3-fig5.jpg" mimetype="image"/>
</fig>
<p>“Importantly, CI downregulation was not associated with reduction in gene expression as shown in Sup. Fig. 6J.”</p>
<p>Additionally, we have added the following text to discussion:</p>
<p>“In addition, the absence of mRNA downregulation in mtSMPD5 overexpressing cells strongly suggests that at least a portion of the observed protein depletion within CI is attributed to diminished protein stability.”</p>
<disp-quote content-type="editor-comment">
<p>1. Figure 3: The authors state that neither palmitate nor mtASAH1 overexpression affected insulin-dependent Akt phosphorylation. However, the results in Figure 3F-G do not support this conclusion, as the overexpression of mtASAH1 does enhance the insulin-stimulated AKT (thr-308) phosphorylation. They need to clarify this issue.</p>
</disp-quote>
<p>Response: We have now analysed these data in a manner that preserves the control variance, consistent with the other figures in the manuscript and there is no significant change in Akt phosphorylation in ASAH over-expressing cells.</p>
<fig id="sa3fig6">
<label>Author response image 6.</label>
<graphic mime-subtype="jpg" xlink:href="elife-87340-sa3-fig6.jpg" mimetype="image"/>
</fig>
<disp-quote content-type="editor-comment">
<p>1. Figure S2: A functional assessment of mitochondrial function in HeLa cells would be helpful to validate the small effect of Saclac treatment on CI NDUFB8.</p>
</disp-quote>
<p>Response: Mitochondrial respiration was conducted in cells treated with Saclac (2 µM and 10 µM) for 24 hours. As shown below, in Hela cells, we did not detect any mitochondrial respiratory impairments at low doses, but only at high doses of Saclac. This suggests that the minor effect of Saclac on CI NDUFB8 is insufficient to alter mitochondrial function.</p>
<fig id="sa3fig7">
<label>Author response image 7.</label>
<graphic mime-subtype="jpg" xlink:href="elife-87340-sa3-fig7.jpg" mimetype="image"/>
</fig>
<disp-quote content-type="editor-comment">
<p><bold>Reviewer #2 (Recommendations For The Authors):</bold></p>
<p>Additional questions and comments for consideration:</p>
<p>1. The working model links ceramide-induced CoQ depletion to a reduction in ETC proteins and accompanying deficits in OxPhos capacity. The idea that mitochondrial dysfunction necessarily precedes and causes insulin resistance has been heavily debated for years because many animal and human studies have found no overt changes in ETC proteins and/or mitochondrial respiratory capacity during the early phases of insulin resistance. How do the investigators reconcile their work in the context of this controversy?</p>
</disp-quote>
<p>Response: We acknowledge this controversy in our revised manuscript more clearly now as follows on page 21: “We present evidence that mitochondrial dysfunction precedes insulin resistance. However, previous studies have failed to observe changes in mitochondrial morphology, respiration or ETC components during early stages of insulin resistance (72). However, in many cases such studies fail to document changes in insulin-dependent glucose metabolism in the same tissue as was used for assessment of mitochondrial function. This is crucial because we and others do not observe impaired insulin action in all muscles from high fat fed mice for example. In addition, surrogate measures such as insulin-stimulated Akt phosphorylation may not accurately reflect tissue specific insulin action as demonstrated in figure 1C. Thus, further work is required to clarify some of these inconsistencies''.</p>
<disp-quote content-type="editor-comment">
<p>1. While the utility of targeting SMPD5 to the mitochondria is appreciated, the results in Figure 5 suggest that this manoeuvre caused a rather severe form of mitochondrial dysfunction. Is this representative of pathophysiology or toxicity?</p>
</disp-quote>
<p>Response: We believe we have addressed this in point 3 above (Principal comments, reviewer 1, point 3)</p>
<disp-quote content-type="editor-comment">
<p>1. How did this affect other mitochondrial lipids (e.g. cardiolipin)?</p>
</disp-quote>
<p>Response: As shown in the supplementary figure 3, SMPD5 overexpression did not affect other lipids species such as cardiolipin (D-J). We have added to results:</p>
<p>“Importantly, mtSMPD5 overexpression did not affect ceramide abundance in the whole cell lysate nor other lipid species inside mitochondria such as cardiolipin, cholesterol and DAGs (Sup. Fig. 3 A, D-J)”</p>
<disp-quote content-type="editor-comment">
<p>1. Are these severe effects rescued by CoQ supplementation?</p>
</disp-quote>
<p>Response: We have performed additional experiments to address this point. As shown below, mitochondrial ceramide accumulation induced by palmitate was not reversed by CoQ supplementation, as demonstrated in Figure 1F. We have added to results:</p>
<p>“Addition of CoQ9 had no effect on control cells but overcame insulin resistance in palmitate treated cells (Fig. 1A). Notably, the protective effect of CoQ9 appears to be downstream of ceramide accumulation, as it had no impact on palmitate-induced ceramide accumulation (Fig. 1E-F). Strikingly, both myriocin and CoQ9…”</p>
<p>Additionally, we assessed mitochondrial respiration by using SeaHorse in cells with SMPD5 overexpression treated with or without CoQ supplementation. Our results, depicted below, indicate that CoQ supplementation reversed the ceramide-induced decrease in basal and ATP linked mitochondrial respiration. We have modified Fig.5.</p>
<fig id="sa3fig8">
<label>Author response image 8.</label>
<graphic mime-subtype="jpg" xlink:href="elife-87340-sa3-fig8.jpg" mimetype="image"/>
</fig>
<p>We have added to results:</p>
<p>“Respiration was assessed in intact mtSMPD5-L6 myotubes treated with CoQ9 by Seahorse extracellular flux analysis. mtSMPD5 overexpression decreased basal and ATP-linked mitochondrial respiration (Fig. 5 A, B &amp;C), as well as maximal, proton-leak and non-mitochondrial respiration (Fig. 5 A, D, E &amp; F) suggesting that mitochondrial ceramides induce a generalised attenuation in mitochondrial function. Interestingly, CoQ9 supplementation partially recovered basal and ATP-linked mitochondrial respiration, suggesting that part of the mitochondrial defects are induced by CoQ9 depletion. The attenuation in mitochondrial respiration is consistent with a depletion of the ETC subunits observed in our proteomic dataset (Fig. 4)...”</p>
<disp-quote content-type="editor-comment">
<p>1. Are these same effects observed with other manipulations that lower CoQ to a similar degree?</p>
</disp-quote>
<p>Response: As mentioned in point 5 (additional suggestions from Reviewer 1), we conducted mitochondrial respiration measurements on HeLa cells treated with Saclac (2 µM and 10 µM) for 24 hours. Our findings showed no signs of mitochondrial respiratory impairments at low doses of Saclac in HeLa cells, despite observing CoQ depletion at this dose (Fig. Sup. 2C). We believe that this variation could be due to the varying sensitivity of mitochondrial respiration/ETC abundance to ceramide-induced CoQ depletion in different cell lines. Alternatively, it is possible that reduced mitochondrial respiration is a secondary event to other mitochondrial/cellular defects such as mitochondrial fragmentation or deficient nutrient transport inside mitochondria.</p>
<fig id="sa3fig9">
<label>Author response image 9.</label>
<graphic mime-subtype="jpg" xlink:href="elife-87340-sa3-fig9.jpg" mimetype="image"/>
</fig>
<disp-quote content-type="editor-comment">
<p>1. The mitochondrial concentrations of CoQ required to maintain insulin sensitivity in L6 myocytes seem to vary from experiment to experiment. Is it the absolute concentration that matters and/or the change relative to a baseline condition?</p>
</disp-quote>
<p>Response: This is an excellent observation. The findings indicate that the absolute concentration of CoQ is the determining factor for insulin sensitivity, rather than the relative depletion of CoQ compared to basal conditions. We have added to discussion:
“Finally, mtASAH1 overexpression increased CoQ levels. In both control and mtASAH1 cells, palmitate induced a depletion of CoQ, however the levels in palmitate treated mtASAH1 cells remained similar to control untreated cells (Fig. 3I). This suggests that the absolute concentration of CoQ is crucial for insulin sensitivity, rather than the relative depletion compared to basal conditions, thus supporting the causal role of mitochondrial ceramide accumulation in reducing CoQ levels in insulin resistance”</p>
<disp-quote content-type="editor-comment">
<p>1. Considering that CoQ has been shown to have antioxidant properties, does the rescue observed after a 16 h treatment require the prolonged exposure, or alternatively, are similar effects observed during short-term exposures (~1-2 h), which might imply a different or additional mechanism.</p>
</disp-quote>
<p>Response: This is an excellent point that we have long considered. The problem is how to address the question in a way that will be definitive and we are concerned that the experiment suggested by the referee will not generate definitive data. A major issue is that CoQ has low solubility and needs to reach the right compartment. As such if short term treatment (as suggested) does not rescue, it would be difficult to make any definite conclusions as this might just be because insufficient CoQ is delivered to mitochondria. Conversely, if short term treatment does rescue this could be either because CoQ does get into mitochondria and regulate ETC or because of its general antioxidant function. So, even if we observe a rescue after 1 hour of incubation with CoQ, it will not clarify whether this is due to the antioxidant effect or simply because 1 hour is adequate to boost mitoCoQ levels. Thus, in our view this experiment might not get us any closer to the answer. Nevertheless, we do feel this is an important point and we have added the following statement to our revised manuscript to acknowledge this: “Because CoQ can accumulate in various intracellular compartments, it's important to consider that its impact on insulin resistance might be due to its overall antioxidant properties rather than being limited to a mitochondrial effect”</p>
<disp-quote content-type="editor-comment">
<p>1. In Figure 1, CoQ depletion due to 4NB treatment resulted in increased ceramide levels. Could this be due to impaired palmitate oxidation leading to rerouting of intracellular palmitate to the ceramide pathway? This could be tested using stable isotope tracers.</p>
</disp-quote>
<p>Response: We have added the statement below to the manuscript to address this point. We feel that while an interesting experiment to perform it is somewhat outside of the major focus of this study.</p>
<p>“One possibility is that CoQ directly controls ceramide turnover (35). An alternate possibility is that CoQ inside mitochondria is necessary for fatty acid oxidation (12) and CoQ depletion triggers lipid overload in the cytoplasm promoting ceramide production (36). Future studies are required to determine how CoQ depletion promotes Cer accumulation. Regardless, these data indicate that ceramide and CoQ have a central role in regulating cellular insulin sensitivity.”</p>
<disp-quote content-type="editor-comment">
<p>1. To a similar point, it would be helpful to know if the C2 ceramide analog is sufficient to cause elevated mito-ceramide and/or CoQ depletion. If not, the results might imply mitochondrial uptake of palmitate is required.</p>
</disp-quote>
<p>Response: We feel this point is analogous to Point 7 above in that this experiment is not definitive enough to make any clear conclusions as it may or may not work for many different reasons. For example, C2 ceramide may not work simply because it has the wrong chain length.</p>
<p>Moreover, it is clear that C2 ceramide has effects that clearly differ from those observed with palmitate most notably the inhibitory effect on Akt signalling. For these reasons we do not agree with the logic of this experiment.</p>
<p>We have mentioned in the results section:</p>
<p>“Based on these data we surmise that C2-ceramide does not faithfully recapitulate physiological insulin resistance, in contrast to that seen with incubation with palmitate”.</p>
<disp-quote content-type="editor-comment">
<p>1. Likewise, does inhibition of CPT1 ameliorate or exacerbate palmitate-induced insulin resistance?</p>
</disp-quote>
<p>Response: This experiment has been performed by a number of different labs. For instance, muscle specific CPT1 overexpression is protective against high fat diet induced insulin resistance in mice (Bruce C, PMID19073774), CPT1 overexpression protects L6E9 muscle cells from fatty acid-induced insulin resistance (Sebastian D, PMID17062841) and increased beta-oxidation in muscle cells enhances insulin stimulated glucose metabolism and is protective against lipid induced insulin resistance (Perdomo G, PMID15105415). We have now cited all of these studies in our revised manuscript in the discussion: “In fact, increased fatty acid oxidation is protective against insulin resistance in several model organisms (37–39)”</p>
<disp-quote content-type="editor-comment">
<p>1. Does the addition of palmitate to the cells treated with mtSMPD5 further reduce CoQ9 (Figure 2I and 2J)?</p>
</disp-quote>
<p>Response: This intriguing observation, as highlighted by the referee, has prompted us to conduct additional experiments to investigate the effects of palmitate and SMPD5 overexpression on Coenzyme Q (CoQ) levels in L6 myotubes. As demonstrated in the figures presented below, both palmitate and SMPD5 overexpression independently resulted in the depletion of CoQ9, with no observed additive effects suggesting that they shared a common pathway driving CoQ9 deficiency. One plausible hypothesis is that ceramides may trigger the depletion of a specific CoQ9 pool localised within the inner mitochondrial membrane, likely the pool associated with Complex I (CI) in the Electron Transport Chain (ETC). This hypothesis is supported by previous studies indicating that approximately ~25 - 35 % of CoQ binds to CI (PMID: 33722627) and our data demonstrating that ceramide induces a selective depletion of CI in L6 myotubes (Fig. 4).</p>
<p>We have added this result to Fig. 2I in the main section.</p>
<fig id="sa3fig10">
<label>Author response image 10.</label>
<graphic mime-subtype="jpg" xlink:href="elife-87340-sa3-fig10.jpg" mimetype="image"/>
</fig>
<p>We have added to the result section:</p>
<p>“Mitochondrial CoQ levels were depleted in both palmitate-treated and mtSMPD5-overexpressing cells without any additive effects. This suggests that these strategies to increase ceramides share a common mechanism for inducing CoQ depletion in L6 myotubes (Fig. 2I).”</p>
<p>We have added to the discussion section:</p>
<p>“...These are known to form supercomplexes or respirasomes where ~25 - 35 % of CoQ is localised in mammals (58,16).…The observation that both palmitate and SMPD5 overexpression trigger CoQ depletion without additive effects support the notion that ceramides may trigger the depletion of a specific CoQ9 pool localised within the inner mitochondrial membrane.”</p>
<disp-quote content-type="editor-comment">
<p>1. Some of the cell-based experiments appear to be underpowered and therefore confidence in the interpretations might benefit from additional repeats. For example, in Figure 3i, it appears that palmitate still causes a substantial reduction of CoQ in the cells treated with mtASAH1, even though mito-ceramide levels are restored to baseline. Please specify if these and other results are representative of multiple cell culture experiments or a single experiment.</p>
</disp-quote>
<p>Response: All data were derived from a minimum of 3-4 independent experiments from at least two separate cultures of L6 cells. Separate batches of drug treatments were prepared for each experiment. We have previously compared metabolic parameters between batches of cells differentiated at different times (i.e. at least weeks apart) in a previous study (Krycer PMID 31744882) and found variations of &lt;20% for insulin-stimulated glucose oxidation. With an expected variance of 20% and a type I error rate of 0.05, this is sufficient to detect a 40% difference with a power of 0.8. As the reviewer has indicated this is likely underpowered in situations where variance is unexpectedly high or if a small difference needs to be detected.</p>
<p>In terms of Fig3, the reviewer raises an interesting point. As discussed in point 6, the fact that palmitate still appears to cause a depletion of CoQ in mtASAH1 cells likely indicates that the absolute concentration of CoQ is the determining factor for insulin sensitivity, rather than the relative depletion of CoQ compared to basal conditions. We have added to the discussion:</p>
<p>“Finally, mtASAH1 overexpression increased CoQ levels. In both control and mtASAH1 cells, palmitate induced a depletion of CoQ, but this effect was less pronounced in the mtASAH1 cell line (Fig. 3I). Our results suggest that the absolute concentration of CoQ is crucial for insulin sensitivity, rather than the relative depletion compared to basal conditions, thus supporting the causal role of mitochondrial ceramide accumulation in reducing CoQ levels in insulin resistance”</p>
<disp-quote content-type="editor-comment">
<p>1. The color scheme of 2E is inconsistent with other panels in the figure.</p>
</disp-quote>
<p>Response: Corrected</p>
<disp-quote content-type="editor-comment">
<p>1. It would be helpful if the axis labels for CoQ graphs were labeled as &quot;Mito-CoQ&quot; for clarity.</p>
</disp-quote>
<p>Response: Corrected</p>
</body>
</sub-article>
</article>